Subcutaneous Biologics, Technologies and Drug Delivery Systems Market (4th Edition) by Type of Biologic (Antibodies, Nucleotides, Proteins, Vaccines, Other Biologics), Type of Therapy (Monotherapies and Combination Therapies), Therapeutic Area (Autoimmune Disorders, Blood Disorders, Bone Disorders, Genetic Disorders, Hormonal Disorders, Infectious Disorders, Inflammatory Disorders, Kidney Disorders, Metabolic Disorders, Neurological Disorders, Oncological Disorders, Respiratory Disorders and Other Disorders), Type of Payment (Milestone Payments and Upfront Payments), Type of Drug Delivery System (Large Volume Wearable Injectors, Autoinjectors, Prefilled Syringes, Needle-Free Injection Systems and Novel Drug Reconstitution Systems) and Key Geographical Regions (North America, Europe, Asia, Middle East and North Africa, Latin America and Rest of the World), Industry Trends and Global Forecasts, 2022-2035

  • Lowest Price Guaranteed From USD 5,899

  • Published
    March 2022

  • Pages
    997

  • View Count
    18326

Example Insights

Subcutaneous-Biologics-Systems-Market-Context-thumb Subcutaneous-Biologics-Systems-Market-delivery-systems-thumb Subcutaneous-Biologics-Systems-Market-Drugs-thumb Subcutaneous-Biologics-Systems-Market-Biologics-thumb
Subcutaneous-Biologics-Systems-Market-Candidates-thumb Subcutaneous-Biologics-Systems-Market-Development-thumb Subcutaneous-Biologics-Systems-Market-Technologies-thumb Subcutaneous-Biologics-Systems-Market-platforms-thumb
Subcutaneous-Biologics-Systems-Market-Providers-thumb Subcutaneous-Biologics-Systems-Market-Collaborations-thumb Subcutaneous-Biologics-Systems-Market-Systems-thumb Subcutaneous-Biologics-Systems-Market-Injectors-thumb
Subcutaneous-Biologics-Systems-Market-Protocol-Analysis-thumb Subcutaneous-Biologics-Systems-Market-Scenarios-thumb Subcutaneous-Biologics-Systems-Market-Therapy-thumb Subcutaneous-Biologics-Systems-Market-Usability-thumb

Overview

Currently, biologics represent one of the fastest growing classes of the pharmaceutical industry. In fact, the US Food and Drug Administration (USFDA) has approved more than 630 biologic products till date, while over 8,000 such drug candidates are being evaluated in clinical studies. Primarily, biologic candidates are being designed for delivery via the parenteral route. However, this route is associated with the need for frequent medication, administered by a professional, in clinics or hospitals. Such visits pose an additional financial burden and are also very time consuming, thereby, negatively impacting the medical adherence. Further, low adherence to prescribed medications is reported to result in a loss of approximately USD 188 billion per year, in the US alone. A number of the aforementioned challenges can be mitigated by delivering drugs via the subcutaneous route, as it enables self-medication by patients. Other benefits associated with the subcutaneous administration include highly effective delivery of biologics (including vaccines, growth hormones and insulin) and substantial cost saving opportunities. Considering the various advantages offered by the subcutaneous route for the delivery of biologics, a shift in the preference towards this route has been observed in the pharmaceutical industry.

Presently, more than 330 subcutaneous biologics formulations are being evaluated in different clinical stages. In addition, several approved intravenous therapeutics are being reformulated and evaluated for delivery via the subcutaneous route of administration. However, there are certain concerns associated with the subcutaneous route. For instance, most protein-based therapeutics, such as monoclonal antibodies, need to be administered in large quantities and have been demonstrated to form highly viscous formulations when reformulated for subcutaneous delivery. In order to overcome this challenge, companies have developed / are developing a number of novel technology platforms, intended to facilitate the delivery of viscous drug formulations. Such innovations are gradually facilitating a shift towards subcutaneous delivery of biologics, primarily driven by the rising demand for self-administrable therapeutics. In fact, several subcutaneous self-administration drug delivery solutions, equipped with a variety of user-friendly features, are already available in the market; examples include prefilled syringes, pen injectors, autoinjectors, needle-free injectors and large volume wearable injectors. Over the past few years, the aforementioned drug-device combination products have witnessed a high adoption, as they enable substantial reductions in healthcare expenses (incurred by patients) and demonstrate improved therapy adherence. Therefore, considering the rising prevalence of chronic diseases and the ongoing efforts of therapy / device developers engaged in this field, the subcutaneous biologics market is anticipated to grow at a steady pace in the foreseen future.

Scope of the Report

The ‘Subcutaneous Biologics, Technologies and Drug Delivery Systems (4th Edition) Market by Type of Biologic (Antibodies, Nucleotides, Proteins, Vaccines, Other Biologics), Type of Therapy (Monotherapies and Combination Therapies and Both (Monotherapies and Combination Therapies)), Therapeutic Area (Autoimmune Disorders, Blood Disorders, Bone Disorders, Cardiovascular Disorders, Genetic Disorders, Hormonal Disorders, Infectious Disorders, Inflammatory Disorders, Metabolic Disorders, Neurological Disorders, Oncological Disorders, Respiratory Disorders, Women’s Health Disorders and Other Disorders), Type of Payment (Milestone Payments and Upfront Payments), Type of Drug Delivery System (Large Volume Wearable Injectors, Autoinjectors, Prefilled Syringes, Needle-Free Injection Systems and Novel Drug Reconstitution Systems) and Key Geographical Regions (North America, Europe, Asia, Middle East and North Africa, Latin America and Rest of the World), Industry Trends and Global Forecasts, 2022-2035’ report provides a detailed study on the current market landscape and future potential of biologics designed for subcutaneous administration. In addition, the study provides an in-depth analysis of the formulation technologies and drug delivery systems (focusing on large volume wearable injectors, autoinjectors, pen injectors, needle-free injectors, drug reconstitution systems, prefilled syringes and implants) that enable subcutaneous delivery of the biologic drugs. Amongst other elements, the report features the following:

  • A detailed assessment of the current market landscape of commercially available biologics that are designed for delivery via the subcutaneous route, based on several relevant parameters, such as approval year, type of molecule (antibody, nucleotide, protein, vaccine and others), type of therapy (monotherapy and combination therapy), route of administration (subcutaneous, intravenous and intramuscular), method of administration (infusion and injection), dosing frequency, dose concentration (in mg / ml), target disease indication(s) (anemia, arthritis, asthma, diabetes, growth failure, growth hormone deficiency, idiopathic short stature, immunodeficiency, infertility, multiple sclerosis, neutropenia, osteoporosis, psoriasis, rheumatoid arthritis and turner syndrome), therapeutic area (autoimmune disorders, blood disorders, bone disorders, genetic disorders, hormonal disorders, infectious disorders, inflammatory disorders, kidney disorders, metabolic disorders, neurological disorders, oncological disorders, respiratory disorders and other disorders) and type of available formulation (vial, cartridge, prefilled syringe, pen-injector, auto-injector and other devices). In addition, it provides details on the companies offering these approved subcutaneous biologics, along with information on their year of establishment, company size, geographical location and leading developers (in terms of number of approved subcutaneous biologics). 
  • A detailed assessment of the current market landscape of clinical-stage biologics that are designed for delivery via the subcutaneous route, based on several relevant parameters, such as phase of development (phase I, phase II, Phase III, and FDA registration), mechanism of action (inhibition, modulation, stimulation and others), type of molecule (antibody, antisense oligonucleotides, protein, small interfering RNA, vaccine and others), type of therapy (monotherapy and combination therapy), dosing frequency, target disease indication(s) (asthma, atopic dermatitis, breast cancer, Crohn’s disease, lung cancer, myasthenia gravis, non-alcoholic steatohepatitis, prostate cancer, psoriasis, rheumatoid arthritis, systemic lupus erythematosus, type I diabetes, type II diabetes and ulcerative colitis), therapeutic area (autoimmune disorders, bone disorders, cardiovascular disorders, dermatological disorders, genetic disorders, hematological disorders, hormonal disorders, infectious disorders, inflammatory disorders, kidney disorders, metabolic disorders, neurological disorders, oncological disorders, respiratory disorders and other disorders) and special designation(s) awarded (if any). In addition, it provides details on the companies engaged in the development of clinical-stage subcutaneous biologics, based on year of establishment, company size, location of headquarters and leading players (in terms of number of clinical-stage drugs).
  • An insightful success protocol analysis of leading subcutaneous biologics (in terms of value creation), taking into consideration several relevant parameters, such as approved subcutaneous biologics, dosing frequency, drug efficacy, existing competition, geographical reach, prevalence, and therapy price.
  • A detailed assessment of the current market landscape of various subcutaneous formulation technologies, based on several relevant parameters, such as fundamental principle of technology, type of molecule (biologics and small molecule), route of administration, therapeutic area and primary advantage(s) offered. In addition, it provides details on the subcutaneous formulation technologies providers, along with information on their year of establishment, company size and location of headquarters. 
  • An in-depth company competitiveness analysis of subcutaneous formulation technology providers, based on several relevant parameters, such as the company’s technology strength (taking into consideration years of experience, type of molecule, route of administration, therapeutic area and advantage(s) offered), and partnership strength (in terms of the number of partnerships inked and type of agreement).
  • Elaborate profiles of key subcutaneous technology providers, featuring a brief overview of the company, details related to its financial information (if available), technology portfolio, drug portfolio, recent developments and an informed future outlook.
  • An analysis of several partnerships and collaborations inked by subcutaneous formulation technology providers, during the period pre-2016 – 2021, based on several relevant parameters, such as year of partnership, type of partnership, type of partner, therapeutic area, focus area and country wise distribution.
  • An in-depth review of the most advanced and popular subcutaneous drug delivery systems, including large volume wearable injectors, drug device combination products, autoinjectors, pen injectors, needle-free injectors, novel drug reconstitution systems, prefilled syringes and implants, providing information on their developer(s) and device specific features. Details of specific parameters captured for different device categories are mentioned as follows:
  • Large volume wearable injectors: These devices have been analyzed based on their phase of development, type of device, actuation mechanism, technology used, route of administration, method of administration, therapeutic area, type of dose, storage volume / capacity, usability, availability of prefilled drug reservoir, availability of connectivity, drug compatibility, type of drug container, combination insulin, non-interoperable devices, availability of continuous glucose monitoring / blood glucose monitoring systems, availability of automated delivery feature, availability of automatic insulin delivery / artificial pancreas, and device control features
  • Autoinjectors: These devices have been analyzed based on their actuation mechanism, route of administration, type of dose, storage volume / capacity, usability, type of primary container and type of feedback mechanism.
  • Pen injectors: These devices have been analyzed based on their type of dose, storage volume / capacity and usability.
  • Needle-free injection systems:  These devices have been analyzed based on their phase of development, actuation mechanism, therapeutic area and usability
  • Drug reconstitution systems: These devices have been analyzed based on their storage volume / capacity, usability, type of device, type of chamber, physical state of drugs and container fabrication material
  • Prefilled syringes: These devices have been analyzed based on their storage volume / capacity, barrel fabrication material, number of barrel chambers and type of needle system
  • Implants: These devices have been analyzed based on their phase of development, therapeutic area, implant material, treatment duration and type of delivery system
  • An elaborate product competitiveness analysis of subcutaneous drug delivery systems, such as large volume wearable injectors, autoinjectors, needle-free injectors and pre-filled syringes, taking into consideration the supplier power and product specific information.
  • A discussion on affiliated trends, key drivers and challenges, which are likely to impact the industry evolution, under an elaborate SWOT framework; it also includes a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall subcutaneous products market. 

One of the key objectives of this study was to understand the primary growth drivers and estimate the existing market size and the future growth potential associated with subcutaneous biologics, technologies and drug delivery systems. Based on historical trends and sales related information for subcutaneous biologics, we have provided an informed estimate of the likely evolution of the market in the short to mid-term and long term. 
The report also provides details on the likely distribution of the current and forecasted opportunity for [A] Approved Subcutaneous Biologics across following segments:

  • Type of Biologic (antibodies, nucleotides, proteins, vaccines and other biologics)
  • Type of Therapy (monotherapy, combination therapy and both (monotherapies and combination therapies)
  • Therapeutic Area (autoimmune disorders, blood disorders, bone disorders, genetic disorders, hormonal disorders, infectious disorders, inflammatory disorders, kidney disorders, metabolic disorders, neurological disorders, oncological disorders, respiratory disorders, and other disorders)
  • Geographical Region (North America, Europe, Asia, Middle East and North Africa, Latin America and rest of the world)

Further, we have forecasted the revenues generated by approved subcutaneous biologics; for this, we have included information from yearly company biologics sales, biologics peak sales and patents. 

[B] Subcutaneous Formulation Technology Providers across following segments:

  • Type of Payment (milestone payments and upfront payments)
  • Fundamental Principle (amino acid interaction principles, complex formation principles, encapsulation principles and other fundamental principles)
  • End-User (biopharmaceutical companies, contract development and manufacturing organizations, educational institutes, investors, pharmaceutical companies, research institutes and other end users)
  • Therapeutic Area (autoimmune disorders, genetic disorders, infectious disorders, metabolic disorders, oncological disorders, ophthalmic disorders and other disorders) and 
  • Geographical Region (North America, Europe and Asia)

 [C] Subcutaneous Biologics Drug Delivery Systems across following segments:

  • Type of Drug Delivery Systems (large volume wearable injectors, autoinjectors, prefilled syringes, needle-free injection systems and novel drug reconstitution systems). The opportunity has been segmented 
  • Type of Large Volume Wearable Injectors (infusion pumps and patch pumps)
  • Usability of Large Volume Wearable Injectors (disposable and reusable)
  • Therapeutic Area of Large Volume Wearable Injectors (cardiovascular disorders, infectious diseases, neurological disorders oncological disorders and others)
  • Type of Autoinjector (disposable and reusable)
  • Therapeutic Indication of Autoinjector (anaphylaxis, multiple sclerosis, rheumatoid arthritis, migraine, diabetes, and others)
  • Type of Syringe Barrel Material for Prefilled Syringes (glass and plastic)
  • Type of Chamber System for Prefilled Syringes (single chamber and dual chamber)
  • Therapeutic Area for Prefilled Syringes (autoimmune disorders, infectious diseases, neurological disorders, blood disorders, oncological disorders, psychiatric disorders, respiratory disorders, cardiovascular disorders, metabolic disorders, ophthalmic diseases, orthopedic disorders and others)
  • Type of Needle-Free Injection Systems (disposable and re-usable)
  • Types of Actuation Mechanisms for Needle-Free Injection Systems (spring-based, gas powered and others)
  • Therapeutic Area for Needle-Free Injection System (infectious diseases, diabetes and others)
  • Type of Container Novel Drug Reconstitution System (cartridge, infusion bag and prefilled syringe)
  • Type of Fabrication Material Used for Novel Drug Reconstitution System (glass and plastic)
  • Physical State of Drug in Syringe and Cartridge for Novel Drug Reconstitution System (liquid / powder, liquid / liquid)
  • Physical State of Drug in Infusion Bag for Novel Drug Reconstitution System (liquid mixture, frozen mixture)
  • Volume of Novel Drug Reconstitution System (<1 ml, 1-2.5 ml, 2.5-5 ml, >5 ml for prefilled syringe and cartridge; <250 ml, 250-500 ml, 500-1,000 ml, >1,000 ml for infusion bag) and 
  • Key Geographical Regions for Drug Delivery Systems (North America, Europe, Asia-Pacific, Latin America, Middle East and North Africa, and rest of the world).  

Finally, in order to account for future uncertainties and add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

The opinions and insights presented in the report were influenced by discussions held with several senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry stakeholders: 

  • Steve Prestrelski (Chief Scientific Officer and Founder, Xeris Pharmaceuticals), Hong Qi (Vice President, Product Development, Xeris Pharmaceuticals) and Scott Coleman (Former Sr. Scientist Formulation, Xeris Pharmaceuticals)
  • Patrick Anquetil (Chief Executive Officer, Portal Instruments)
  • Deborah Bitterfield (Chief Executive Officer and Founder, Lindy Biosciences)
  • David Daily (Chief Executive Officer and Co-Founder, DALI Medical Devices)
  • Poonam R Velagaleti (Co-Founder, i-novion)
  • Frederic Ors (Former Chief Executive Officer, Immunovaccine Technologies)
  • David Heuzé (Communication Leader, MedinCell)
  • Menachem Zucker (Vice President and Chief Scientist, Elcam Medical)
  • Tiffany H. Burke (Director, Global Communications, West Pharmaceutical Services) and Graham Reynolds (Vice President and General Manager, Global Biologics, West Pharmaceutical Services)
  • Michael Reilly (Chief Executive Officer and Co-Founder, Excelse Bio)
  • Michael Hooven (Chief Executive Officer, Enable Injections)
  • Matthew Young (Founder and Chief Technology Officer, Oval Medical Technologies)

All actual figures have been sourced and analyzed from publicly available information forums and secondary sources. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered

  • Who are the key players that have marketed their proprietary subcutaneous biologics?
  • Who are the leading players currently engaged in the development of clinical-stage subcutaneous biologics?
  • Which popular therapeutic areas are being targeted by clinical-stage subcutaneous biologics?
  • What are the crucial factors that impact the sales of a subcutaneous biologic product?
  • Who are the leading players involved in the development of subcutaneous formulation technologies?
  • What type of drug delivery systems are being most commonly used for the delivery of subcutaneous biologics?
  • What type of partnership models are most commonly adopted by stakeholders engaged in this industry?
  • How is the current and future market opportunity likely to be distributed across key market segments?

Contents

Chapter Outlines

Chapter 2 is an executive summary of key insights captured during our research. It offers a high-level view on the likely evolution of subcutaneous biologics, formulation technologies and drug delivery systems market, in the short to mid and long term.

Chapter 3 provides a general introduction on different types of therapeutic molecules (biologics and small molecules) comparing their characteristics, such as molecular size, molecular weight, molecular structure, immunogenicity, stability and manufacturing. The chapter also highlights different types of biologically derived products that are currently being developed by several players in the industry. Additionally, it includes information on the various challenges associated with the parenteral route of drug delivery, specifically those related to the traditional intravenous (infusion) route. Further, this chapter discusses about subcutaneous formulations, which includes different approaches of delivery of such biologics, method of administration, advantages and limitations associated with this route, along with the relevant regulatory guidelines.

Chapter 4 includes information on around 120 subcutaneous biologic drug candidates that are currently approved. The chapter features an elaborate analysis of marketed biologics based on several relevant parameters, such as approval year, type of molecule (antibody, nucleotide, protein, vaccine and others), type of therapy (monotherapy and combination therapy), route of administration (subcutaneous, intravenous and intramuscular), method of administration (infusion and injection), dosing frequency, dose concentration (in mg/ml), target disease indication(s) (anemia, arthritis, asthma, diabetes, growth failure, growth hormone deficiency, idiopathic short stature, immunodeficiency, infertility, multiple sclerosis, neutropenia, osteoporosis, psoriasis, rheumatoid arthritis and turner syndrome), therapeutic area (autoimmune disorders, blood disorders, bone disorders, genetic disorders, hormonal disorders, infectious disorders, inflammatory disorders, kidney disorders, metabolic disorders, neurological disorders, oncological disorders, respiratory disorders and other disorders) and type of drug delivery device (vial, cartridge, prefilled syringe, pen-injector, auto-injector and other devices). In addition, it provides details on the companies offering these approved subcutaneous biologics, along with information on their year of establishment, company size, geographical location and leading developers (in terms of number of approved subcutaneous biologics). 

Chapter 5 includes information of over 340 subcutaneous biologics that are currently in clinical stage of development. The chapter features an elaborate analysis of clinical-stage biologics based on several relevant parameters, such as phase of development (phase I, phase II, Phase III, and FDA registration), mechanism of action (inhibition, modulation, stimulation and others), type of molecule (antibody, antisense oligonucleotides, protein, small interfering RNA, vaccine and others), type of therapy (monotherapy and combination therapy), dosing frequency, target disease indication(s) (asthma, atopic dermatitis, breast cancer, Crohn’s disease, lung cancer, myasthenia gravis, non-alcoholic steatohepatitis, prostate cancer, psoriasis, rheumatoid arthritis, systemic lupus erythematosus, type I diabetes, type II diabetes and ulcerative colitis ), therapeutic area (autoimmune disorders, bone disorders, cardiovascular disorders, dermatological disorders, genetic disorders, hematological disorders, hormonal disorders, infectious disorders, inflammatory disorders, kidney disorders, metabolic disorders, neurological disorders, oncological disorders, respiratory disorders and other disorders)and special designation(s) awarded (if any). In addition, it provides details on the several companies engaged in the development of clinical-stage subcutaneous biologics, based on the year of establishment, company size, location of headquarters and leading players (in terms of number of clinical-stage drugs).

Chapter 6 is an insightful success protocol analysis of the leading subcutaneous biologics, biologics (in terms of value creation), taking into consideration several relevant parameters, such as drug efficacy / success rate, target disease indication burden, global competition (with respect to industry players), therapy price, geographical reach and disease prevalence.

Chapter 7 includes information on over 30 subcutaneous formulation technologies. It features an elaborate analysis of clinical-stage biologics based on several relevant parameters, such as fundamental principle of technology (amino acid interaction, complex formation, encapsulation and others), type of molecule (biologics and small molecule), route of administration (intramuscular, intraocular, intravenous, local (unspecified), oral, pulmonary, subcutaneous and others), therapeutic area (autoimmune disorders, genetic disorders,  isank-deficiency disorders, infectious disorders, inflammatory disorders, metabolic disorders, neurological disorders, oncological disorders, other disorders) and primary advantage(s) offered. In addition, it provides details on the subcutaneous formulation technologies providers along with information on their year of establishment, company size and location of headquarters. 

Chapter 8 features an insightful company competitiveness analysis of the subcutaneous formulation technology developers, based on several relevant parameters, such as the company’s technology strength (taking into consideration years of experience, type of molecule, route of administration, therapeutic area and advantage(s) offered), and partnership strength (in terms of the number of partnerships inked and type of agreement).

Chapter 9 provides detailed profiles of key subcutaneous formulation technology providers engaged in this domain. Each profile features a brief overview of the company (including information on the year of establishment, number of employees, location of headquarters and key executives), details related to its financial information (if available), list of drug candidates developed using the formulation technology, details related to its recent developments, and an informed future outlook.

Chapter 10 features an analysis of recent partnerships and collaborations that have been inked by several stakeholders engaged in this domain, pre-2016-2021. The chapter includes a brief description of the partnership models (including licensing agreement, formulation development agreement, product development agreement, R&D agreement, manufacturing and supply agreement, product development and commercialization agreement, joint venture and other related agreements). Additionally, it comprises of analysis based on the year of partnership, type of partnership, type of partner, therapeutics area and focus area. Further, it consists of a schematic representation showcasing the players that have forged the maximum number of alliances. Furthermore, we have provided a world map representation of the deals inked in this field, highlighting those that have been established within and across different continents.

Chapter 11 features an elaborate discussion on subcutaneous delivery systems with special focus on large volume wearable injectors, autoinjectors, pen injectors, needle-free injectors, novel drug reconstitution systems, prefilled syringes and implants. The chapter includes a detailed analysis based on specific parameters for each device category, namely [A] large volume wearable non-insulin biologics injectors based on their phase of development, type of device, actuation mechanism, technology used, route of administration, method of administration, therapeutic area, type of dose, storage volume / capacity, usability, availability of prefilled drug reservoir, availability of connectivity, drug compatibility, availability of drug containers and key players, [B] large volume wearable insulin biologics injectors based on their phase of development, type of device, type of dose, storage volume / capacity, usability, combination insulin, non-interoperable devices, availability of prefilled drug reservoir, availability of continuous glucose monitoring (CGM) / blood glucose meters (BGM) system, availability of automated insulin delivery (AID) feature, automatic insulin delivery (AID) / artificial pancreas, availability of connectivity, availability of device control features and key players, [C] drug device combination products based on their phase of development, type device, mechanisms of action, technology used, route of administration, method of administration, therapeutics area, type of dose, storage volume/ capacity, usability, drug compatibility, drug container and key players, [D] autoinjector, by actuation mechanism, route of administration, type of dose, storage volume / capacity, usability, type of primary container, type of feedback mechanisms, and key players [E] pen-injectors based on their type of dose, storage volume / capacity, usability, and key player, [F] needle-free injection systems based on their phase of development, actuation mechanisms, therapeutic area, usability and key players  [G] novel drug reconstitution systems based on their volume of container, usability, type of device, type of chambers, physical state of drugs, container fabrication material and key player, [I] prefilled syringes based on their storage volume / capacity, barrel fabrication material, number of barrel chamber, type of needle system and key players and [J] implants based on their phase of development, therapeutic area, implant material, treatment duration, type of delivery system and key players.

Chapter 12 features an insightful product competitiveness analysis of the subcutaneous delivery system, such as large volume wearable injectors, autoinjectors, needle-free injectors and pre-filled syringes, taking into consideration the supplier power and product specific information.

Chapter 13 presents an elaborate market forecast analysis, highlighting the future potential of the approved subcutaneous biologics market till 2035. Additionally, the chapter includes future sales projections of various approved subcutaneous biologic drug candidates. The chapter presents a detailed market segmentation on the basis of type of biologic (antibodies, nucleotides, proteins, vaccines and other biologics), [B] type of therapy (monotherapy, combination therapy, and both (monotherapies and combination therapies)), [C] therapeutic area (autoimmune disorders, blood disorders, bone disorders, cardiovascular disorders, genetic disorders, hormonal disorders, infectious disorders, inflammatory disorders, metabolic disorders, neurological disorders, oncological disorders, respiratory disorders, women’s health  disorders, and other disorders) and  [D] geographical regions (North America, Europe, Asia, Middle East and North Africa, Latin America and Rest of the World).

Chapter 14 presents an elaborate market forecast analysis, highlighting the future potential of the subcutaneous formulation technology market till the year 2035. The chapter presents a detailed market segmentation on the basis of [A] type of payment (milestone payments and upfront payments),  [B] fundamental principle (amino acid interaction, complex formation, encapsulation and other fundamental principles), [C] end user (biopharmaceutical companies, biotechnology companies, contract development and manufacturing organizations, educational institutes, investors and other end users), [D] therapeutic area (autoimmune disorders, genetic disorders, infectious disorders, metabolic disorders, oncological disorders, ophthalmic disorders and other disorders) and [E] geographical regions (North America, Europe and Asia).

Chapter 15 presents an elaborate market forecast analysis, highlighting the future potential of the approved subcutaneous biologics market till the year 2035. In addition, it provides a 14-year forecast of subcutaneous delivery systems, including large volume wearable injectors, autoinjectors, prefilled syringes, needle-free injection systems and novel drug reconstitution systems.

Chapter 16 provides a detailed analysis capturing the key parameters and trends that are likely to impact the industry’s evolution, under an elaborate SWOT framework; it also includes a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall subcutaneous biologics market. 

Chapter 17 is a summary of the overall report. In this chapter, we have provided a list of the key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 18 is a collection of interview transcripts of discussions held with key stakeholders in this market. In this chapter, we have presented the details of our conversations with Deborah Bitterfield (Chief Executive Officer and Founder, Lindy Biosciences), Matthew Young (Founder and Chief Technology Officer, Oval Medical Technologies), Steve Prestrelski (Chief Scientific Officer and Founder, Xeris Pharmaceuticals), Hong Qi (Vice President, Product Development, Xeris Pharmaceuticals), Scott Coleman (Former Sr. Scientist Formulation, Xeris Pharmaceuticals), David Daily (Chief Executive Officer and Co-Founder, DALI Medical Devices), Michael Reilly (Chief Executive Officer and Co-Founder, Excelse Bio), Poonam R Velagaleti (Co-Founder, i-novion), Michael Hooven (Chief Executive Officer, Enable Injections), Frederic Ors (Former Chief Executive Officer, Immunovaccine Technologies), Patrick Anquetil (Chief Executive Officer, Portal Instruments), Menachem Zucker (Vice President and Chief Scientist, Elcam Medical), Tiffany H Burke (Director, Global Communications, West Pharmaceutical Services), Graham Reynolds (Vice President and General Manager, Global Biologics, West Pharmaceutical Services) and David Heuzé (Communication Leader, MedinCell).

Chapter 19 is an appendix, which provides tabulated data and numbers for all the figures provided in the report. 

Chapter 20 is an appendix, which provides the list of companies and organizations mentioned in the report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Different Types of Therapeutics Molecules
3.3. Biologically Derived Therapeutics
3.3.1. Types of Products
3.3.2. Routes of Administration and Formulations

3.3.3. Subcutaneous Administration
3.3.3.1. Approaches in Subcutaneous Delivery of Biologics
3.3.3.1.1. Reformulation
3.3.3.1.2. Differing Potencies
3.3.3.1.3. Novel Technologies

3.3.3.2. Methods of Subcutaneous Administration
3.3.3.3. Advantages of Subcutaneous Administration
3.3.3.4. Limitations of Subcutaneous Administration

3.4. Regulatory Considerations
3.4.1. Guidelines for Medical Devices
3.4.2. Guidelines for Drug Device Combination Products

3.5. Future Perspectives

4. APPROVED SUBCUTANEOUS BIOLOGICS: MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Approved Subcutaneous Biologics: List of Drugs
4.2.1. Analysis by Approval Year
4.2.2. Analysis by Type of Molecule
4.2.3. Analysis by Type of Therapy
4.2.4. Analysis by Route of Administration
4.2.5. Analysis by Method of Administration
4.2.6. Analysis by Dosing Frequency
4.2.7. Analysis by Dose Concentration
4.2.8. Analysis by Target Disease Indication(s)
4.2.9. Analysis by Therapeutic Area
4.2.10. Analysis by Type of Available Formulation

4.3. Approved Subcutaneous Biologics: List of Developers
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Location of Headquarters
4.3.4. Leading Developers: Analysis by Number of Approved Subcutaneous Biologics

5. CLINICAL SUBCUTANEOUS BIOLOGICS: MARKET LANDSCAPE
5.1. Chapter Overview
5.2. Clinical-Stage Subcutaneous Biologics: List of Drugs
5.2.1. Analysis by Phase of Development
5.2.2. Analysis by Mechanism of Action
5.2.3. Analysis by Type of Molecule
5.2.4. Analysis by Type of Therapy
5.2.5. Analysis by Dosing Frequency
5.2.6. Analysis by Target Disease Indication(s)
5.2.7. Analysis by Therapeutic Area
5.2.8. Analysis by Special Drug Designation(s) Awarded

5.3. Clinical-Stage Subcutaneous Biologics: List of Developers
5.3.1. Analysis by Year of Establishment
5.3.2. Analysis by Company Size
5.3.3. Analysis by Geographical Location
5.3.4. Leading Developers: Analysis by Number of Clinical-Stage Subcutaneous Biologics

6. APPROVED SUBCUTANEOUS BIOLOGICS: SUCCESS PROTOCOL ANALYSIS
6.1. Chapter Overview
6.2. Methodology
6.3. Success Protocol Analysis of Top Ten Approved Subcutaneous Biologics
6.3.1. BENLYSTA (Human Genome Sciences)
6.3.1.1. Overview
6.3.1.2. Development History
6.3.1.3. Phase of Development, Route of Administration, and Target Disease Indication(s)
6.3.1.4. Success Protocol Analysis

6.3.2. BESREMi (PharmaEssentia)
6.3.2.1. Overview
6.3.2.2. Development History
6.3.2.3. Phase of Development, Route of Administration, and Target Disease Indication(s)
6.3.2.4. Success Protocol Analysis

6.3.3. COSENTYX (Novartis)
6.3.3.1. Overview
6.3.3.2. Development History
6.3.3.3. Phase of Development, Route of Administration, and Target Disease Indication(s)
6.3.3.4. Success Protocol Analysis

6.3.4. DARZALEX FASPRO (Halozyme)
6.3.4.1. Overview
6.3.4.2. Development History
6.3.4.3. Phase of Development, Route of Administration, and Target Disease Indication(s)
6.3.4.4. Success Protocol Analysis

6.3.5. DUPIXENT (Regeneron Pharmaceuticals)
6.3.5.1. Overview
6.3.5.2. Development History
6.3.5.3. Phase of Development, Route of Administration, and Target Disease Indication(s)
6.3.5.4. Success Protocol Analysis

6.3.6. Enbrel (Amgen)
6.3.6.1. Overview
6.3.6.2. Development History
6.3.6.3. Phase of Development, Route of Administration, and Target Disease Indication(s)
6.3.6.4. Success Protocol Analysis

6.3.7. HEMLIBRA (Roche)
6.3.7.1. Overview
6.3.7.2. Development History
6.3.7.3. Phase of Development, Route of Administration, and Target Disease Indication(s)
6.3.7.4. Success Protocol Analysis

6.3.8. Prolia / Pralia (Amgen)
6.3.8.1. Overview
6.3.8.2. Development History
6.3.8.3. Phase of Development, Route of Administration, and Target Disease Indication(s)
6.3.8.4. Success Protocol Analysis

6.3.9. STELARA (Janssen Biotech)
6.3.9.1. Overview
6.3.9.2. Development History
6.3.9.3. Phase of Development, Route of Administration, and Target Disease Indication(s)
6.3.9.4. Success Protocol Analysis

6.3.10. Trulicity (Eli Lilly)
6.3.10.1. Overview
6.3.10.2. Development History
6.3.10.3. Phase of Development, Route of Administration, and Target Disease Indication(s)
6.3.10.4. Success Protocol Analysis

6.4. Conclusion

7. SUBCUTANEOUS FORMULATION TECHNOLOGIES: CURRENT MARKET LANDSCAPE
7.1. Chapter Overview
7.2. Need for Subcutaneous Formulation Technologies
7.3. Subcutaneous Formulation Technologies: List of Technologies
7.3.1. Analysis by Fundamental Principle of Technology
7.3.2. Analysis by Type of Molecule
7.3.3. Analysis by Route of Administration
7.3.4. Analysis by Therapeutic Area
7.3.5. Analysis by Advantage(s) Offered

7.4. Subcutaneous Formulation Technologies: List of Developers
7.4.1. Analysis by Year of Establishment
7.4.2. Analysis by Company Size
7.4.3. Analysis by Location of Headquarters
7.4.4. Leading Subcutaneous Formulation Technology: Analysis by Number of Advantages Offered

8. SUBCUTANEOUS FORMULATION TECHNOLOGY DEVELOPERS: COMPANY COMPETITIVENESS ANALYSIS
8.1. Chapter Overview
8.2. Assumption and Key Parameters
8.3. Methodology
8.4. Benchmarking of Technology Strength
8.5. Benchmarking of Partnership Activity

8.6. Subcutaneous Formulation Technology Developers: Company Competitiveness Analysis
8.6.1. Developers based in North America
8.6.2. Developers based in Europe and Asia

9. SUBCUTANEOUS FORMULATION TECHNOLOGY DEVELOPERS:

COMPANY PROFILES
9.1. Chapter Overview
9.2. Adocia
9.2.1. Company Overview
9.2.2. Financial Performance
9.2.3. Technology Overview
9.2.3.1. Biochaperonen Technology
9.2.4. Drug Portfolio
9.2.5. Recent Developments and Future Outlook

9.3. Ajinomoto Bio-Pharma Services
9.3.1. Company Overview
9.3.2. Financial Performance
9.3.3. Technology Overview
9.3.3.1. Crystalomics Formulation Technology
9.3.4. Drug Portfolio
9.3.5. Recent Developments and Future Outlook

9.4. Alteogen
9.4.1. Company Overview
9.4.2. Financial Performance
9.4.3. Technology Overview
9.4.3.1. Hybrozyme Technology
9.4.4. Drug Portfolio
9.4.5. Recent Developments and Future Outlook

9.5. Arecor
9.5.1. Company Overview
9.5.2. Financial Performance
9.5.3. Technology Overview
9.5.3.1. Arestat Technology
9.5.4. Drug Portfolio
9.5.5. Recent Developments and Future Outlook

9.6. Ascendis Pharma
9.6.1. Company Overview
9.6.2. Financial Performance
9.6.3. Technology Overview
9.6.3.1. TransCon Technology
9.6.4. Drug Portfolio
9.6.5. Recent Developments and Future Outlook

9.7. Avadel Pharmaceuticals
9.7.1. Company Overview
9.7.2. Financial Performance
9.7.3. Technology Overview
9.7.3.1. Medusa Technology
9.7.4. Drug Portfolio
9.7.5. Recent Developments and Future Outlook

9.8. Camurus
9.8.1. Company Overview
9.8.2. Financial Performance
9.8.3. Technology Overview
9.8.3.1. FluidCrystal Injection Depot Technology
9.8.4. Drug Portfolio
9.8.5. Recent Developments and Future Outlook

9.9. Creative Biolabs
9.9.1. Company Overview
9.9.2. Financial Performance
9.9.3. Technology Overview
9.9.3.1. Long-Acting Injectable Technology
9.9.4. Drug Portfolio
9.9.5. Recent Developments and Future Outlook

9.10. Creative BioMart
9.10.1. Company Overview
9.10.2. Financial Performance
9.10.3. Technology Overview
9.10.3.1. High Concentration Formulation Technology
9.10.4. Drug Portfolio
9.10.5. Recent Developments and Future Outlook

9.11. DURECT
9.11.1. Company Overview
9.11.2. Financial Performance
9.11.3. Technology Overview
9.11.3.1. SABER Platform
9.11.3.2. CLOUD Platform
9.11.4. Drug Portfolio
9.11.5. Recent Developments and Future Outlook

9.12. Eagle Pharmaceuticals
9.12.1. Company Overview
9.12.2. Financial Performance
9.12.3. Technology Overview
9.12.3.1. Unnamed Technology
9.12.4. Drug Portfolio
9.12.5. Recent Developments and Future Outlook

9.13. Halozyme Therapeutics
9.13.1. Company Overview
9.13.2. Financial Performance
9.13.3. Technology Overview
9.13.3.1. ENHANZE Technology
9.13.4. Drug Portfolio
9.13.5. Recent Developments and Future Outlook

9.14. MedinCell
9.14.1. Company Overview
9.14.2. Financial Performance
9.14.3. Technology Overview
9.14.3.1. BEPO Technology
9.14.4. Drug Portfolio
9.14.5. Recent Developments and Future Outlook

9.15. Serina Therapeutics
9.15.1. Company Overview
9.15.2. Financial Performance
9.15.3. Technology Overview
9.15.3.1. POZ Drug Delivery Technology
9.15.4. Drug Portfolio
9.15.5. Recent Developments and Future Outlook

9.16. Xeris Pharmaceuticals
9.16.1. Company Overview
9.16.2. Financial Performance
9.16.3. Technology Overview
9.16.3.1. XeriJect Technology
9.16.3.2. XeriSol Technology
9.16.4. Drug Portfolio
9.16.5. Recent Developments and Future Outlook

10. PARTNERSHIPS AND COLLABORATIONS
10.1. Chapter Overview
10.2. Partnership Models
10.3. Subcutaneous Formulation Technology Developers: List of Partnerships
10.3.1. Analysis by Year of Partnership
10.3.2. Analysis by Type of Partnership
10.3.3. Analysis by Type of Partner
10.3.4. Analysis by Therapeutic Area
10.3.5. Analysis by Focus Area
10.3.6. Analysis by Region
10.3.6.1. Country-wise Distribution
10.3.6.2. Intercontinental and Intracontinental Distribution

10.3.7. Most Active Developers: Analysis by Number of Partnerships

11. SUBCUTANEOUS DRUG DELIVERY SYSTEMS: CURRENT MARKET LANDSCAPE
11.1. Chapter Overview
11.2. Different Types of Subcutaneous Drug Delivery Systems

11.2.1. Large Volume Wearable Injectors
11.2.1.1. Current Market Landscape of Devices for Non-insulin Drugs
11.2.1.1.1. Analysis by Phase of Development
11.2.1.1.2. Analysis by Type of Device
11.2.1.1.3. Analysis by Actuation Mechanism
11.2.1.1.4. Analysis by Technology Used
11.2.1.1.5. Analysis by Route of Administration
11.2.1.1.6. Analysis by Method of Administration
11.2.1.1.7. Analysis by Therapeutic Area
11.2.1.1.8. Analysis by Type of Dose
11.2.1.1.9. Analysis by Storage Volume / Capacity
11.2.1.1.10. Analysis by Usability
11.2.1.1.11. Analysis by Availability of Prefilled Drug Reservoir
11.2.1.1.12. Analysis by Availability of Connectivity
11.2.1.1.13. Analysis by Availability of Drug Compatibility
11.2.1.1.14. Analysis by Availability of Drug Container
11.2.1.1.15. Most Active Players: Analysis by Number of Large Volume Wearable Injectors for Non-insulin Drugs

11.2.1.2. Current Market Landscape of Devices for Insulin Drugs
11.2.1.2.1. Analysis by Phase of Development
11.2.1.2.2. Analysis by Type of Device
11.2.1.2.3. Analysis by Type of Dose
11.2.1.2.4. Analysis by Storage Volume / Capacity
11.2.1.2.5. Analysis by Usability
11.2.1.2.6. Analysis by Combination Insulin
11.2.1.2.7. Analysis by Non-Interoperable Device
11.2.1.2.8. Analysis by Availability of Prefilled Drug Reservoir
11.2.1.2.9. Analysis by Availability of Continuous Glucose Monitoring (CGM) / Blood Glucose Meters (BGM) System
11.2.1.2.10. Analysis by Availability of Automated Insulin Delivery (AID) Feature
11.2.1.2.11. Analysis by Automatic Insulin Delivery (AID) / Artificial Pancreas
11.2.1.2.12. Analysis by Availability of Connectivity
11.2.1.2.13. Analysis by Availability of Device Control Features
11.2.1.2.14. Most Active Players: Analysis by Number of Large Volume Wearable Injectors for Insulin Drugs

11.2.1.3. Current Market Landscape of Drug Device Combination Products
11.2.1.3.1. Analysis by Phase of Development
11.2.1.3.2. Analysis by Type of Device
11.2.1.3.3. Analysis by Mechanism of Action
11.2.1.3.4. Analysis by Technology Used
11.2.1.3.5. Analysis by Route of Administration
11.2.1.3.6. Analysis by Method of Administration
11.2.1.3.7. Analysis by Therapeutic Area
11.2.1.3.8. Analysis by Type of Dose
11.2.1.3.9. Analysis by Storage Volume / Capacity
11.2.1.3.10. Analysis by Usability
11.2.1.3.11. Analysis by Drug Compatibility
11.2.1.3.12. Analysis by Drug Container
11.2.1.3.13. Most Active Players: Analysis by Number of Products Manufactured

11.2.2. Autoinjectors
11.2.2.1. Current Market Landscape
11.2.2.1.1. Analysis by Actuation Mechanism
11.2.2.1.2. Analysis by Route of Administration
11.2.2.1.3. Analysis by Type of Dose
11.2.2.1.4. Analysis by Storage Volume / Capacity
11.2.2.1.5. Analysis by Usability
11.2.2.1.6. Analysis by Type of Primary Container
11.2.2.1.7. Analysis by Type of Feedback Mechanisms
11.2.2.1.8. Most Active Players: Analysis by Number of Devices

11.2.3. Pen Injectors
11.2.3.1. Current Market Landscape
11.2.3.1.1. Analysis by Type of Dose
11.2.3.1.2. Analysis by Storage Volume / Capacity
11.2.3.1.3. Analysis by Usability
11.2.3.1.4. Most Active Players: Analysis by Number of Devices
11.2.3.2. Drug Device Combination Products

11.2.4. Needle-Free Injection Systems
11.2.4.1. Current Market Landscape
11.2.4.1.1. Analysis by Phase of Development
11.2.4.1.2. Analysis by Actuation Mechanism
11.2.4.1.3. Analysis by Therapeutic Area
11.2.4.1.4. Analysis by Usability
11.2.4.1.5. Most Active Players: Analysis by Number of Devices
11.2.4.2. Drug Device Combination Products

11.2.5. Novel Drug Reconstitution Delivery Systems
11.2.5.1. Current Market Landscape
11.2.5.1.1. Analysis by Volume of Container
11.2.5.1.1. Analysis by Usability
11.2.5.1.2 Analysis by Type of Device
11.2.5.1.3. Analysis by Type of Chamber
11.2.5.1.1. Analysis by Physical State of Drugs
11.2.5.1.4. Analysis by Container Fabrication Material
11.2.5.1.7. Most Active Players: Analysis by Number of Devices

11.2.6. Prefilled Syringes
11.2.6.1. Current Market Landscape
11.2.6.1.1. Analysis by Storage Volume / Capacity
11.2.6.1.2. Analysis by Barrel Fabrication Material
11.2.6.1.3. Analysis by Number of Barrel Chambers
11.2.6.1.4. Analysis by Type of Needle System
11.2.6.1 5. Most Active Players: Analysis by Number of Devices
11.2.6.2. Drug Device Combination Products

11.2.7. Implants
11.2.7.1. Current Market Landscape
11.2.7.1.1. Analysis by Phase of Development
11.2.7.1.2. Analysis by Therapeutic Area
11.2.7.1.3. Analysis by Implant Material
11.2.7.1.4. Analysis by Treatment Duration
11.2.7.1.5. Analysis by Type of Delivery System
11.2.7.1.6. Most Active Players: Analysis by Number of Devices
11.2.7.2. Subcutaneous Implants Eluting Small Molecules

12. SUBCUTANEOUS DRUG DELIVERY SYSTEMS: PRODUCT COMPETITIVENESS
12.1. Large Volume Wearable Injectors
12.1.1. Methodology and Key Parameters
12.1.2. Product Competitiveness Analysis: Large Volume Wearable Injectors for Non-Insulin Drugs
12.1.3. Product Competitiveness Analysis: Large Volume Wearable Injectors for Insulin Drugs
12.1.4. Product Competitiveness Analysis: Drug Device Combination Products

12.2. Autoinjectors
12.2.1. Methodology and Key Parameters
12.2.1. Product Competitiveness Analysis: Disposable Autoinjectors
12.2.2. Product Competitiveness Analysis: Reusable Autoinjectors

12.3. Needle-Free Injection Systems
12.3.1. Methodology and Key Parameters
12.3.2. Product Competitiveness Analysis: Spring-Based Needle-Free Injection Systems
12.3.3. Product Competitiveness Analysis: Gas-Powered Needle-Free Injection Systems

12.4. Prefilled Syringes
12.4.1. Methodology and Key Parameters
12.4.2. Product Competitiveness Analysis: Glass Barrel Syringes
12.4.3. Product Competitiveness Analysis: Plastic Barrel Syringes

13. APPORVED SUBCUTANEOUS BIOLOGICS: MARKET FORECAST
13.1. Chapter Overview
13.2. Scope and Limitations
13.3. Forecast Methodology and Key Assumptions
13.4. Global Approved Subcutaneous Biologics Market, 2022-2035
13.4.1. Approved Subcutaneous Biologics Market: Distribution by Type of Biologic, 2022 and 2035
13.4.1.1. Approved Subcutaneous Biologics Market for Antibodies, 2022-2035
13.4.1.2. Approved Subcutaneous Biologics Market for Nucleotides, 2022-2035
13.4.1.3. Approved Subcutaneous Biologics Market for Proteins, 2022-2035
13.4.1.4. Approved Subcutaneous Biologics Market for Vaccines, 2022-2035
13.4.1.5. Approved Subcutaneous Biologics Market for Other Biologics, 2022-2035

13.4.2. Approved Subcutaneous Biologics Market: Distribution by Type of Therapy, 2022 and 2035
13.4.2.1. Approved Subcutaneous Biologics Market for Monotherapies, 2022-2035
13.4.2.2. Approved Subcutaneous Biologics Market for Combination Therapies, 2022-2035
13.4.2.3. Approved Subcutaneous Biologics Market for Monotherapies and Combination Therapies, 2022-2035

13.4.3. Approved Subcutaneous Biologics Market: Distribution by Therapeutic Area, 2022 and 2035
13.4.3.1. Approved Subcutaneous Biologics Market for Autoimmune Disorders, 2022-2035
13.4.3.2. Approved Subcutaneous Biologics Market for Blood Disorders, 2022-2035
13.4.3.3. Approved Subcutaneous Biologics Market for Bone Disorders, 2022-2035
13.4.3.4. Approved Subcutaneous Biologics Market for Cardiovascular Disorders, 2022-2035
13.4.3.5. Approved Subcutaneous Biologics Market for Genetic Disorders, 2022-2035
13.4.3.6. Approved Subcutaneous Biologics Market for Hormonal Disorders, 2022-2035
13.4.3.7. Approved Subcutaneous Biologics Market for Infectious Disorders, 2022-2035
13.4.3.8. Approved Subcutaneous Biologics Market for Inflammatory Disorders, 2022-2035
13.4.3.9. Approved Subcutaneous Biologics Market for Metabolic Disorders, 2022-2035
13.4.3.10. Approved Subcutaneous Biologics Market for Neurological Disorders, 2022-2035
13.4.3.11. Approved Subcutaneous Biologics Market for Oncological Disorders, 2022-2035
13.4.3.12. Approved Subcutaneous Biologics Market for Respiratory Disorders, 2022-2035
13.4.3.13. Approved Subcutaneous Biologics Market for Women’s Health Disorders, 2022- 2035
13.4.3.17. Approved Subcutaneous Biologics Market for Other Disorders, 2022-2035

13.4.4. Approved Subcutaneous Biologics Market: Distribution by Geographical Region, 2022 and 2035
13.4.4.1. Approved Subcutaneous Biologics Market in North America, 2022-2035
13.4.4.2. Approved Subcutaneous Biologics Market in Europe, 2022-2035
13.4.4.3. Approved Subcutaneous Biologics Market in Asia, 2022-2035
13.4.4.4. Approved Subcutaneous Biologics Market in Middle East and North Africa, 2022- 2035
13.4.4.5. Approved Subcutaneous Biologics Market in Latin America, 2022-2035
13.4.4.6. Approved Subcutaneous Biologics Market in Rest of the World, 2022-2035

13.4.5. Drug-wise Sales Forecast
13.4.5.1. AIMOVIG (erenumab-aooe), Amgen
13.4.5.1.1 Sales Forecast

13.4.5.2. AJOVY (fremanezumab-vfrm), Teva Pharmaceuticals
13.4.5.2.1 Sales Forecast

13.4.5.3. Apidra (insulin glulisine), Sanofi
13.4.5.3.1. Sales Forecast

13.4.5.4. Basaglar / Abrasia (EU) (insulin glargine injection), Eli Lilly
13.4.5.4.1. Sales Forecast

13.4.5.5. BENLYSTA (belimumab), Human Genome Sciences
13.4.5.5.1. Sales Forecast

13.4.5.6. BESREMi (ropeginterferon alfa-2b-njft), PharmaEssentia
13.4.5.6.1. Sales Forecast

13.4.5.7. BIOTHRAX (Anthrax Vaccine Adsorbed), Emergent Biosolutions
13.4.5.7.1. Sales Forecast

13.4.5.8. CABLIVI (Caplacizumab), Abylnx
13.4.5.8.1. Sales Forecast

13.4.5.9. Cegfila, Mundipharma Corporation
13.4.5.9.1. Sales Forecast

13.4.5.10. CIMZIA (certolizumab pegol), UCB
13.4.5.10.1. Sales Forecast

13.4.5.11. COSENTYX (secukinumab), Novartis
13.4.5.11.1. Sales Forecast

13.4.5.12. CRYSVITA (burosumab-twza), Ultragenyx
13.4.5.12.1. Sales Forecast

13.4.5.13. Cuvitru (immune globulin subcutaneous [human], 20% solution), Shire
13.4.5.13.1. Sales Forecast

13.4.5.14. DARZALEX FASPRO (daratumumab and hyaluronidase-fihj / DARZALEX SC, Halozyme
13.4.5.14.1. Sales Forecast

13.4.5.15. DENGVAXIA (Dengue Tetravalent Vaccine), Sanofi Pasteur
13.4.5.15.1. Sales Forecast

13.4.5.16. DUPIXENT (dupilumab), Regeneron Pharmaceuticals
13.4.5.16.1. Sales Forecast

13.4.5.17. EMGALITY (galcanezumab-gnlm), Eli Lilly
13.4.5.17.1. Sales Forecast

13.4.5.18. EMPAVELI (pegcetacoplan), Apellis Pharmaceuticals
13.4.5.18.1. Sales Forecast

13.4.5.19. Enbrel (etanercept), Amgen
13.4.5.19.1. Sales Forecast

13.4.5.20. ENSPRYNG (satralizumab), Genentech
13.4.5.20.1. Sales Forecast

13.4.5.21. EVENITY (romosozumab-aqqg), Amgen
13.4.5.21.1. Sales Forecast

13.4.5.22. FASENRA (benralizumab), AstraZeneca
13.4.5.22.1. Sales Forecast

13.4.5.23. FIASP (Insulin Aspart), Novo Nordisk
13.4.5.23.1. Sales Forecast

13.4.5.24. Fulphila (pegfilgrastim-jmdb), Mylan Pharmaceuticals
13.4.5.24.1. Sales Forecast

13.4.5.25. Gamunex-C (Immune Globulin Injection [Human], 10% Caprylate/Chromatography Purified), Grifols Therapeutics
13.4.5.25.1. Sales Forecast

13.4.5.26. GATTEX / Revestive (teduglutide [rDNA origin]), NPS Pharmaceuticals
13.4.5.26.1. Sales Forecast

13.4.5.27. GIVLAARI (givosiran), Alnylam Pharmaceuticals
13.4.5.27.1. Sales Forecast

13.4.5.28. HAEGARDA, CSL Behring
13.4.5.28.1. Sales Forecast

13.4.5.29. HEMLIBRA (emicizumab-kxwh), Roche
13.4.5.29.1. Sales Forecast

13.4.5.30. Hepcludex (Bulevirtide), Gilead Sciences
13.4.5.30.1. Sales Forecast

13.4.5.31. Hizentra (Immune Globulin Subcutaneous [Human] 20% Liquid), CSL Behring
13.4.5.31.1. Sales Forecast

13.4.5.32. HYQVIA (Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase), Baxalta
13.4.5.32.1. Sales Forecast

13.4.5.33. ILARIS (canakinumab), Novartis
13.4.5.33.1. Sales Forecast

13.4.5.34. ILUMYA (tildrakizumab-asmn) / Ilumetri, Sun Pharma
13.4.5.34.1. Sales Forecast

13.4.5.35. Kalbitor (ecallantide), Dyax
13.4.5.35.1. Sales Forecast

13.4.5.36. Kesimpta (ofatumumab), Novartis
13.4.5.36.1. Sales Forecast

13.4.5.37. KEVZARA (sarilumab), Regeneron Pharmaceuticals
13.4.5.37.1. Sales Forecast

13.4.5.38. KINERET (anakinra), Swedish Orphan Biovitrum
13.4.5.38.1. Sales Forecast

13.4.5.39. Kyntheum / SILIQ / Lumicef (brodalumab), AstraZeneca
13.4.5.39.1. Sales Forecast

13.4.5.40. Leqvio (Inclisiran), Alnylam Pharmaceuticals
13.4.5.40.1. Sales Forecast

13.4.5.41. Lonquex (lipegfilgrastim), Teva Pharmaceuticals
13.4.5.41.1. Sales Forecast

13.4.5.42. Lyumjev (insulin lispro-aabc), Eli Lilly
13.4.5.42.1. Sales Forecast

13.4.5.43. Norditropin (somatropin), Novo Nordisk
13.4.5.43.1. Sales Forecast

13.4.5.44. NPLATE (romiplostim), Amgen
13.4.5.44.1. Sales Forecast

13.4.5.45. Nucala (mepolizumab), GlaxoSmithKline
13.4.5.45.1. Sales Forecast

13.4.5.46. OXLUMO (lumasiran), Alnylam Pharmaceuticals
13.4.5.46.1. Sales Forecast

13.4.5.47. PALYNZIQ (pegvaliase-pqpz), BioMarin Pharmaceutical
13.4.5.47.1. Sales Forecast

13.4.5.48. Pergoveris (follitropin alfa / lutropin alfa), Merck
13.4.5.48.1. Sales Forecast

13.4.5.49. Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf), Roche
13.4.5.49.1. Sales Forecast

13.4.5.50. PRALUENT (alirocumab), Regeneron Pharmaceuticals
13.4.5.50.1. Sales Forecast

13.4.5.51. Prolia / Pralia (denosumab), Amgen
13.4.5.51.1. Sales Forecast

13.4.5.52. REBLOZYL (luspatercept-aamt), Acceleron Pharma
13.4.5.52.1. Sales Forecast

13.4.5.53. REKOVELLE (follitropin delta), Ferring Pharmaceuticals
13.4.5.53.1. Sales Forecast

13.4.5.54. Repatha (evolocumab), Amgen
13.4.5.54.1. Sales Forecast

13.4.5.55. RYZODEG 70/30 (insulin degludec and insulin aspart), Novo Nordisk
13.4.5.55.1. Sales Forecast

13.4.5.56. Skyrizi ( isankizumab), AbbVie
13.4.5.56.1. Sales Forecast

13.4.5.57. SKYTROFA (lonapegsomatropin-tcgd), Ascendis Pharma
13.4.5.57.1. Sales Forecast

13.4.5.58. SOLIQUA 100/33 (insulin glargine & lixisenatide injection), Sanofi
13.4.5.58.1. Sales Forecast

13.4.5.59. STELARA (ustekinumab), Janssen Biotech
13.4.5.59.1. Sales Forecast

13.4.5.60. Strensiq (asfotase alfa), Alexion Pharmaceuticals
13.4.5.60.1. Sales Forecast

13.4.5.61. TAKHZYRO (lanadelumab-flyo), Takeda Pharmaceuticals
13.4.5.61.1. Sales Forecast

13.4.5.62. Taltz (ixekizumab), Eli Lilly
13.4.5.62.1. Sales Forecast

13.4.5.63. TEGSEDI (inotersen), Ionis Pharmaceuticals
13.4.5.63.1. Sales Forecast
 
13.4.5.64. Toujeo (insulin glargine injection) U-300, Sanofi
13.4.5.64.1. Sales Forecast
 
13.4.5.65. TREMFYA (guselkumab), Janssen Biotech
13.4.5.65.1. Sales Forecast
 
13.4.5.66. TRESIBA (insulin degludec injection), Novo Nordisk
13.4.5.66.1. Sales Forecast
 
13.4.5.67. Trulicity (dulaglutide), Eli Lilly
13.4.5.67.1. Sales Forecast

13.4.5.68. TYMLOS (abaloparatide), Radius Health
13.4.5.68.1. Sales Forecast

13.4.5.69. Tysabri (Natalizumab), Biogen
13.4.5.69.1. Sales Forecast

13.4.5.70. Voxzogo (vosoritide), BioMarin Pharmaceutical
13.4.5.70.1. Sales Forecast

13.4.5.71. VYLEESI (bremelanotide injection), AMAG Pharmaceuticals
13.4.5.71.1. Sales Forecast

13.4.5.72. XEMBIFY (immune globulin subcutaneous, human – klhw), Grifols Therapeutics
13.4.5.72.1. Sales Forecast

13.4.5.73. Xgeva / RANMARK (denosumab), Amgen
13.4.5.73.1. Sales Forecast

13.4.5.74. XULTOPHY / IdegLira (insulin degludec and liraglutide injection), Novo Nordisk
13.4.5.74.1. Sales Forecast

13.4.5.75. XYOSTED (testosterone enanthate), Antares Pharma
13.4.5.75.1. Sales Forecast

13.4.5.76. ZEGALOGUE (dasiglucagon), Zealand Pharma
13.4.5.76.1. Sales Forecast

13.3.6. Conclusion

14. SUBCUTANEOUS FORMULATION TECHNOLOGIES: MARKET FORECAST
14.1. Chapter Overview
14.2. Forecast Methodology and Key Assumptions
14.3. Global Subcutaneous Formulation Technologies Market, 2022-2035
14.3.1. Subcutaneous Formulation Technologies Market: Distribution by Type of Payment, 2022 and 2035
14.3.1.1. Subcutaneous Formulation Technologies Market for Milestone Payments, 2022- 2035

14.3.1.2. Subcutaneous Formulation Technologies Market for Upfront Payments, 2022-2035

14.3.2. Subcutaneous Formulation Technologies Market: Distribution by Fundamental Principle, 2022 and 2035
14.3.2.1. Subcutaneous Formulation Technologies Market for Amino Acid Interaction Principles, 2022-2035
14.3.2.2. Subcutaneous Formulation Technologies Market for Complex Formation Principles, 2022-2035
14.3.2.3. Subcutaneous Formulation Technologies Market for Encapsulation Principles, 2022-2035
14.3.2.4. Subcutaneous Formulation Technologies Market for Other Fundamental Principles, 2022-2035

14.3.3. Subcutaneous Formulation Technologies Market: Distribution by End User, 2022 and 2035
14.3.3.1. Subcutaneous Formulation Technologies Market for Biopharmaceutical Companies, 2022-2035
14.3.3.2. Subcutaneous Formulation Technologies Market for Biotechnology Companies, 2022-2035
14.3.3.3. Subcutaneous Formulation Technologies Market for Contract Development and Manufacturing Organizations, 2022-2035
14.3.3.4. Subcutaneous Formulation Technologies Market for Educational Institutes, 2022-2035
14.3.3.5. Subcutaneous Formulation Technologies Market for Investors, 2022-2035
14.3.3.6. Subcutaneous Formulation Technologies Market for Pharmaceutical Companies, 2022-2035
14.3.3.7. Subcutaneous Formulation Technologies Market for Research Institutes, 2022-2035
14.3.3.8. Subcutaneous Formulation Technologies Market for Other End Users, 2022-2035

14.3.4. Subcutaneous Formulation Technologies Market: Distribution by Therapeutic Area, 2022 and 2035
14.3.4.1. Subcutaneous Formulation Technologies Market for Autoimmune Disorders, 2022-2035
14.3.4.2. Subcutaneous Formulation Technologies Market for Genetic Disorders, 2022-2035
14.3.4.3. Subcutaneous Formulation Technologies Market for Infectious Disorders, 2022-2035
14.3.4.4. Subcutaneous Formulation Technologies Market for Metabolic Disorders, 2022-2035
14.3.4.5. Subcutaneous Formulation Technologies Market for Oncological Disorders, 2022-2035
14.3.4.6. Subcutaneous Formulation Technologies Market for Ophthalmic Disorders, 2022-2035
14.3.4.7. Subcutaneous Formulation Technologies Market for Other Disorders, 2022-2035

14.3.5. Subcutaneous Formulation Technologies Market: Distribution by Geographical Regions, 2022 and 2035
14.3.5.1. Subcutaneous Formulation Technologies Market in North America, 2022-2035
14.3.5.2. Subcutaneous Formulation Technologies Market in Europe, 2022-2035
14.3.5.3. Subcutaneous Formulation Technologies Market in Asia, 2022-2035

14.3.6. Conclusion

15. SUBCUTANEOUS DRUG DELIVERY SYSTEMS: MARKET FORECAST
15.1. Subcutaneous Drug Delivery Systems Market
15.2. Drug Delivery System 1: Large Volume Wearable Injectors
15.2.1. Forecast Methodology and Key Assumptions
15.2.2. Global Large Volume Wearable Injectors Market for Non-Insulin Drugs, 2021-2035 (By Value)
15.2.2.1. Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Type of Device, 2021-2035 (By Value)
15.2.2.2. Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Usability, 2021-2035 (By Value)
15.2.2.3. Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Therapeutic Area, 2021-2035 (By Value)
15.2.2.4. Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America, 2021-2035 (By Value)
15.2.2.4.1. Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Type of Device, 2021-2035 (By Value)
15.2.2.4.2. Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Usability, 2021-2035 (By Value)
15.2.2.4.3. Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Therapeutic Area, 2021-2035 (By Value)

15.2.2.5. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe, 2021-2035 (By Value)
15.2.2.5.1. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe:
 Distribution by Type of Device, 2021-2035 (By Value)
15.2.2.5.2. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Usability, 2021-2035 (By Value)
15.2.2.5.3. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Therapeutic Area, 2021-2035 (By Value)

15.2.2.6. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific, 2021-2035 (By Value)
15.2.2.6.1. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Type of Device, 2021-2035 (By Value)
15.2.2.6.2. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Usability, 2021-2035 (By Value)
15.2.2.6.3. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Therapeutic Area, 2021-2035 (By Value)

15.2.2.7. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America, 2021-2035 (By Value)
15.2.2.7.1. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America: Distribution by Type of Device, 2021-2035 (By Value)

15.2.2.7.2. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America: Distribution by Usability, 2021-2035 (By Value)

15.2.2.7.3. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America:
 Distribution by Therapeutic Area, 2021-2035 (By Value)

15.2.2.8. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa, 2021-2035 (By Value)
15.2.2.8.1. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa: Distribution by Type of Device, 2021-2035 (By Value)
15.2.2.8.2. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa: Distribution by Usability, 2021-2035 (By Value)
15.2.2.8.3. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa: Distribution by Therapeutic Area, 2021-2035 (By Value)
15.2.2.8.1. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa: Distribution by Type of Device, 2021-2035 (By Value)
15.2.2.8.2. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa: Distribution by Usability, 2021-2035 (By Value)
15.2.2.8.3. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa: Distribution by Therapeutic Area, 2021-2035 (By Value)
15.2.3. Global Large Volume Wearable Injectors Market for Non-Insulin Drugs, 2021-2035 (By Volume)
15.2.3.1. Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Type of Device, 2021-2035 (By Volume)
15.2.3.2. Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Usability, 2021-2035 (By Volume)
15.2.3.3. Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Therapeutic Area, 2021-2035 (By Volume)
15.2.3.4. Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America, 2021-2035 (By Volume)
15.2.3.4.1. Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Type of Device, 2021-2035 (By Volume)
15.2.3.4.2. Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Usability, 2021-2035 (By Volume)
15.2.3.4.3. Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Therapeutic Area, 2021-2035 (By Volume)

15.2.3.5. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe, 2021-2035 (By Volume)
15.2.3.5.1. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Type of Device, 2021-2035 (By Volume)
15.2.3.5.2. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Usability, 2021-2035 (By Volume)
15.2.3.5.3. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Therapeutic Area, 2021-2035 (By Volume)

15.2.3.6. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific, 2021-2035 (By Volume)
15.2.3.6.1. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Type of Device, 2021-2035 (By Volume)
15.2.3.6.2. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Usability, 2021-2035 (By Volume)
15.2.3.6.3. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Therapeutic Area, 2021-2035 (By Volume)

15.2.3.7. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America, 2021-2035 (By Volume)
15.2.3.7.1. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America: Distribution by Type of Device, 2021-2035 (By Volume)
15.2.3.7.2. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America: Distribution by Usability, 2021-2035 (By Volume)
15.2.3.7.3. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America: Distribution by Therapeutic Area, 2021-2035 (By Volume)

15.2.3.8. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa, 2021-2035 (By Volume)
15.2.3.8.1. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa: Distribution by Type of Device, 2021-2035 (By Volume)
15.2.3.8.2. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa: Distribution by Usability, 2021-2035 (By Volume)
15.2.3.8.3. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa: Distribution by Therapeutic Area, 2021-2035 (By Volume)

15.2.4. Global Large Volume Wearable Injectors Market for Insulin, 2021-2035
15.2.4.1. Global Large Volume Wearable Injectors Market for Insulin: Distribution by Type of Device, 2021-2035
15.2.4.2. Global Large Volume Wearable Injectors Market for Insulin: Distribution by Usability, 2021-2035
15.2.4.3. Large Volume Wearable Injectors Market for Insulin in North America, 2021-2035 (By Value)
15.2.4.3.1. Large Volume Wearable Injectors Market for Insulin in North America: Distribution by Type of Device, 2021-2035
15.2.4.3.2. Large Volume Wearable Injectors Market for Insulin in North America: Distribution by Usability, 2021-2035

15.2.4.4. Large Volume Wearable Injectors Market for Insulin in Europe, 2021-2035
15.2.4.4.1. Large Volume Wearable Injectors Market for Insulin in Europe: Distribution by Type of Device, 2021-2035
15.2.4.4.2. Large Volume Wearable Injectors Market for Insulin in Europe: Distribution by Usability, 2021-2035

15.2.4.5. Large Volume Wearable Injectors Market for Insulin in Asia Pacific, 2021-2035
15.2.4.5.1. Large Volume Wearable Injectors Market for Insulin in Asia Pacific: Distribution by Type of Device, 2021-2035
15.2.4.5.2. Large Volume Wearable Injectors Market for Insulin in Asia Pacific: Distribution by Usability, 2021-2035

15.2.4.6. Large Volume Wearable Injectors Market for Insulin in Latin America, 2021-2035
15.2.4.6.1. Large Volume Wearable Injectors Market for Insulin in Latin America: Distribution by Type of Device, 2021-2035
15.2.4.6.2. Large Volume Wearable Injectors Market for Insulin in Latin America: Distribution by Usability, 2021-2035

15.2.4.7. Large Volume Wearable Injectors Market for Insulin in Middle East and North Africa, 2021-2035
15.2.4.7.1. Large Volume Wearable Injectors Market for Insulin in Middle East and North Africa: Distribution by Type of Device, 2021-2035
15.2.4.7.2. Large Volume Wearable Injectors Market for Insulin in Middle East and North Africa: Distribution by Usability, 2021-2035

15.3. Drug Delivery System 2: Autoinjectors
15.3.1. Forecast Methodology and Key Assumptions
15.3.2. Global Autoinjectors Market, 2021-2035 (By Value)
15.3.2.1. Global Autoinjectors Market for Anaphylaxis, 2021-2035 (By Value)
15.3.2.1.1. Global Autoinjectors Market for Anaphylaxis: Distribution by Usability, 2021-2035 (By Value)
15.3.2.1.1.1. Global Disposable Autoinjectors Market for Anaphylaxis, 2021-2035 (By Value)

15.3.2.1.2. Global Autoinjectors Market for Anaphylaxis: Distribution by Route of Administration, 2021-2035 (By Value)
15.3.2.1.2.1. Global Intramuscular Autoinjectors Market for Anaphylaxis, 2021-2035 (By Value)
15.3.2.1.2.2. Global Subcutaneous / Intramuscular Autoinjectors Market for Anaphylaxis, 2021- 2035 (By Value)

15.3.2.1.3. Global Autoinjectors Market for Anaphylaxis: Distribution by Type of Molecule, 2021-2035 (By Value)
15.3.2.1.3.1. Global Small Molecule-based Autoinjectors Market for Anaphylaxis, 2021-2035 (By Value)

15.3.2.1.4. Global Autoinjectors Market for Anaphylaxis: Distribution by Geography, 2021-2035 (By Value)
15.3.2.1.4.1. Autoinjectors Market for Anaphylaxis in North America, 2021-2035 (By Value)
15.3.2.1.4.2. Autoinjectors Market for Anaphylaxis in Europe, 2021-2035 (By Value)
15.3.2.1.4.3. Autoinjectors Market for Anaphylaxis in Asia-Pacific, 2021-2035 (By Value)
15.3.2.1.4.4. Autoinjectors Market for Anaphylaxis in Rest of the World, 2021-2035 (By Value)

15.3.2.2. Global Autoinjectors Market for Multiple Sclerosis, 2021-2035 (By Value)
15.3.2.2.1. Global Autoinjectors Market for Multiple Sclerosis: Distribution by Usability, 2021- 2035 (By Value)
15.3.2.2.1.1. Global Disposable Autoinjectors Market for Multiple Sclerosis, 2021-2035 (By Value)
15.3.2.2.1.2. Global Reusable Autoinjectors Market for Multiple Sclerosis, 2021-2035 (By Value)

15.3.2.2.2. Global Autoinjectors Market for Multiple Sclerosis: Distribution by Route of Administration, 2021-2035 (By Value)
15.3.2.2.2.1. Global Intramuscular Autoinjectors Market for Multiple Sclerosis, 2021-2035 (By Value)
15.3.2.2.2.2. Global Subcutaneous Autoinjectors Market for Multiple Sclerosis, 2021-2035 (By Value)

15.3.2.2.3. Global Autoinjectors Market for Multiple Sclerosis: Distribution by Type of Molecule, 2021-2035 (By Value)
15.3.2.2.3.1. Global Protein-based Autoinjectors Market for Multiple Sclerosis, 2021-2035 (By Value)
15.3.2.2.3.2. Global Peptide-based Autoinjectors Market for Multiple Sclerosis, 2021-2035 (By Value)
15.3.2.2.3.3. Global Antibody-based Autoinjectors Market for Multiple Sclerosis, 2021-2035 (By Value)

15.3.2.2.4. Global Autoinjectors Market for Multiple Sclerosis: Distribution by Geography, 2021-2035 (By Value)
15.3.2.2.4.1. Autoinjectors Market for Multiple Sclerosis in North America, 2021-2035 (By Value)
15.3.2.2.4.2. Autoinjectors Market for Multiple Sclerosis in Europe, 2021-2035 (By Value)
15.3.2.2.4.3. Autoinjectors Market for Multiple Sclerosis in Asia-Pacific, 2021-2035 (By Value)
15.3.2.2.4.4. Autoinjectors Market for Multiple Sclerosis in Rest of the World, 2021-2035 (By Value)

15.3.2.3. Global Autoinjectors Market for Migraine, 2021-2035 (By Value)
15.3.2.3.1. Global Autoinjectors Market for Migraine: Distribution by Usability, 2021-2035 (By Value)
15.3.2.3.1.1. Global Disposable Autoinjectors Market for Migraine, 2021-2035 (By Value)

15.3.2.3.2. Global Autoinjectors Market for Migraine: Distribution by Route of Administration, 2021-2035 (By Value)
15.3.2.3.2.1. Global Subcutaneous Autoinjectors Market for Migraine, 2021-2035 (By Value)

15.3.2.3.3. Global Autoinjectors Market for Migraine: Distribution by Type of Molecule, 2021-2035 (By Value)
15.3.2.3.3.1. Global Antibody-based Autoinjectors Market for Migraine, 2021-2035 (By Value)
15.3.2.3.3.2. Global Small Molecule-based Autoinjectors Market for Migraine, 2021-2035 (By Value)

15.3.2.3.4. Global Autoinjectors Market for Migraine: Distribution by Geography, 2021-2035 (By Value)
15.3.2.3.4.1. Autoinjectors Market for Migraine in North America, 2021-2035 (By Value)
15.3.2.3.4.2. Autoinjectors Market for Migraine in Europe, 2021-2035 (By Value)
15.3.2.3.4.3. Autoinjectors Market for Migraine in Asia-Pacific, 2021-2035 (By Value)
15.3.2.3.4.4. Autoinjectors Market for Migraine in Rest of the World, 2021-2035 (By Value)

15.3.2.4. Global Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, 2021-2035 (By Value)
15.3.2.4.1. Global Autoinjectors Market for Rheumatoid and Psoriatic Arthritis: Distribution by Usability, 2021-2035 (By Value)
15.3.2.4.1.1. Global Disposable Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, 2021-2035 (By Value)
15.3.2.4.1.2. Global Reusable Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, 2021-2035 (By Value)

15.3.2.4.2. Global Autoinjectors Market for Rheumatoid and Psoriatic Arthritis: Distribution by Route of Administration, 2021-2035 (By Value)
15.3.2.4.2.1. Global Subcutaneous Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, 2021-2035 (By Value)
15.3.2.4.2.2. Global Subcutaneous / Intravenous Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, 2021-2035 (By Value)

15.3.2.4.3. Global Autoinjectors Market for Rheumatoid and Psoriatic Arthritis: Distribution by Type of Molecule, 2021-2035 (By Value)
15.3.2.4.3.1. Global Antibody-based Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, 2021-2035 (By Value)
15.3.2.4.3.2. Global Protein-based Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, 2021-2035 (By Value)
15.3.2.4.3.3. Global Small Molecule-based Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, 2021-2035 (By Value)

15.3.2.4.4. Global Autoinjectors Market for Rheumatoid and Psoriatic Arthritis: Distribution by Geography, 2021-2035 (By Value)
15.3.2.4.4.1. Autoinjectors Market for Rheumatoid and Psoriatic Arthritis in North America, 2021-2035 (By Value)
15.3.2.4.4.2. Autoinjectors Market for Rheumatoid and Psoriatic Arthritis in Europe, 2021-2035 (By Value)
15.3.2.4.4.3. Autoinjectors Market for Rheumatoid and Psoriatic Arthritis in Asia-Pacific, 2021-2035 (By Value)
15.3.2.4.4.4. Autoinjectors Market for Rheumatoid and Psoriatic Arthritis in Rest of the World, 2021-2035 (By Value)

15.3.2.5. Global Autoinjectors Market for Diabetes, 2021-2035 (By Value)
15.3.2.5.1. Global Autoinjectors Market for Diabetes: Distribution by Usability, 2021-2035 (By Value)
15.3.2.5.1.1. Global Disposable Autoinjectors Market for Diabetes, 2021-2035 (By Value)

15.3.2.5.2. Global Autoinjectors Market for Diabetes: Distribution by Route of Administration, 2021-2035 (By Value)
1.3.2.5.2.1. Global Subcutaneous Autoinjectors Market for Diabetes, 2021-2035 (By Value)

15.3.2.5.3. Global Autoinjectors Market for Diabetes: Distribution by Type of Molecule, 2021-2035 (By Value)
15.3.2.5.3.1. Global Protein-based Autoinjectors Market for Diabetes, 2021-2035 (By Value)
15.3.2.5.3.2. Global Peptide-based Autoinjectors Market for Diabetes, 2021-2035 (By Value)

15.3.2.5.4. Global Autoinjectors Market for Diabetes: Distribution by Geography, 2021-2035 (By Value)
15.3.2.5.4.1. Autoinjectors Market for Diabetes in North America, 2021-2035 (By Value)
15.3.2.5.4.2. Autoinjectors Market for Diabetes in Europe, 2021-2035 (By Value)
15.3.2.5.4.3. Autoinjectors Market for Diabetes in Asia-Pacific, 2021-2035 (By Value)
15.3.2.5.4.4. Autoinjectors Market for Diabetes in Rest of the World, 2021-2035 (By Value)

15.3.2.6. Global Autoinjectors Market for Other Indications, 2021-2035 (By Value)
15.3.2.6.1. Global Autoinjectors Market for Other Indications: Distribution by Usability, 2021-2035 (By Value)
15.3.2.6.1.1. Global Disposable Autoinjectors Market for Other Indications, 2021-2035 (By Value)

15.3.2.6.2. Global Autoinjectors Market for Other Indications: Distribution by Route of Administration, 2021-2035 (By Value)
15.3.2.6.2.1. Global Subcutaneous Autoinjectors Market for Other Indications, 2021-2035 (By Value)
15.3.2.6.2.2. Global Intramuscular Autoinjectors Market for Other Indications, 2021-2035 (By Value)
15.3.2.6.2.3. Global Subcutaneous / Intramuscular Autoinjectors Market for Other Indications, 2021-2035 (By Value)

15.3.2.6.3. Global Autoinjectors Market for Other Indications: Distribution by Type of Molecule, 2021-2035 (By Value)
15.3.2.6.3.1. Global Protein-based Autoinjectors Market for Other Indications, 2021-2035 (By Value)
15.3.2.6.3.2. Global Antibody-based Autoinjectors Market for Other Indications, 2021-2035 (By Value)
15.3.2.6.3.3. Global Small Molecule-based Autoinjectors Market for Other Indications, 2021-2035 (By Value)

15.3.2.6.4. Global Autoinjectors Market for Other Indications: Distribution by Geography, 2021-2035 (By Value)
15.3.2.6.4.1. Autoinjectors Market for Other Indications in North America, 2021-2035 (By Value)
15.3.2.6.4.2. Autoinjectors Market for Other Indications in Europe, 2021-2035 (By Value)
15.3.2.6.4.3. Autoinjectors Market for Other Indications in Asia-Pacific, 2021-2035 (By Value)
15.3.2.6.4.4. Autoinjectors Market for Other Indications in Rest of the World, 2021-2035 (By Value)

15.3.3. Global Autoinjectors Market, 2021-2035 (By Volume)
15.3.3.1. Global Autoinjectors Market for Anaphylaxis, 2021-2035 (By Volume)
15.3.3.1.1. Global Autoinjectors Market for Anaphylaxis: Distribution by Usability, 2021-2035 (By Volume)
15.3.3.1.1.1. Global Disposable Autoinjectors Market for Anaphylaxis, 2021-2035 (By Volume)

15.3.3.1.2. Global Autoinjectors Market for Anaphylaxis: Distribution by Route of Administration, 2021-2035 (By Volume)
15.3.3.1.2.1. Global Intramuscular Autoinjectors Market for Anaphylaxis, 2021-2035 (By Volume)
15.3.3.1.2.2. Global Subcutaneous / Intramuscular Autoinjectors Market for Anaphylaxis, 2021-2035 (By Volume)

15.3.3.1.3. Global Autoinjectors Market for Anaphylaxis: Distribution by Type of Molecule, 2021-2035 (By Volume)
15.3.3.1.3.1. Global Small Molecule-based Autoinjectors Market for Anaphylaxis, 2021-2035 (By Volume)

15.3.3.1.4. Global Autoinjectors Market for Anaphylaxis: Distribution by Geography, 2021-2035 (By Volume)
15.3.3.1.4.1. Autoinjectors Market for Anaphylaxis in North America, 2021-2035 (By Volume)
15.3.3.1.4.2. Autoinjectors Market for Anaphylaxis in Europe, 2021-2035 (By Volume)
15.3.3.1.4.3. Autoinjectors Market for Anaphylaxis in Asia-Pacific, 2021-2035 (By Volume)
15.3.3.1.4.4. Autoinjectors Market for Anaphylaxis in Rest of the World, 2021-2035 (By Volume)

15.3.3.2. Global Autoinjectors Market for Multiple Sclerosis, 2021-2035 (By Volume)
15.3.3.2.1. Global Autoinjectors Market for Multiple Sclerosis: Distribution by Usability, 2021-2035 (By Volume)
15.3.3.2.1.1. Global Disposable Autoinjectors Market for Multiple Sclerosis, 2021-2035 (By Volume)
15.3.3.2.1.2. Global Reusable Autoinjectors Market for Multiple Sclerosis, 2021-2035 (By Volume)

15.3.3.2.2. Global Autoinjectors Market for Multiple Sclerosis: Distribution by Route of Administration, 2021-2035 (By Volume)
15.3.3.2.2.1. Global Intramuscular Autoinjectors Market for Multiple Sclerosis, 2021-2035 (By Volume)
15.3.3.2.2.2. Global Subcutaneous Autoinjectors Market for Multiple Sclerosis, 2021-2035 (By Volume)

15.3.3.2.3. Global Autoinjectors Market for Multiple Sclerosis: Distribution by Type of Molecule, 2021-2035 (By Volume)
15.3.3.2.3.1. Global Protein-based Autoinjectors Market for Multiple Sclerosis, 2021-2035 (By Volume)
15.3.3.2.3.2. Global Peptide-based Autoinjectors Market for Multiple Sclerosis, 2021-2035 (By Volume)
15.3.3.2.3.3. Global Antibody-based Autoinjectors Market for Multiple Sclerosis, 2021-2035 (By Volume)

15.3.3.2.4. Global Autoinjectors Market for Multiple Sclerosis: Distribution by Geography, 2021-2035 (By Volume)
15.3.3.2.4.1. Autoinjectors Market for Multiple Sclerosis in North America, 2021-2035 (By Volume)
15.3.3.2.4.2. Autoinjectors Market for Multiple Sclerosis in Europe, 2021-2035 (By Volume)
15.3.3.2.4.3. Autoinjectors Market for Multiple Sclerosis in Asia-Pacific, 2021-2035 (By Volume)
15.3.3.2.4.4. Autoinjectors Market for Multiple Sclerosis in Rest of the World, 2021-2035 (By Volume)

15.3.3.3. Global Autoinjectors Market for Migraine, 2021-2035 (By Volume)
15.3.3.3.1. Global Autoinjectors Market for Migraine: Distribution by Usability, 2021-2035 (By Volume)
15.3.3.3.1.1. Global Disposable Autoinjectors Market for Migraine, 2021-2035 (By Volume)

15.3.3.3.2. Global Autoinjectors Market for Migraine: Distribution by Route of Administration, 2021-2035 (By Volume)
15.3.3.3.2.1. Global Subcutaneous Autoinjectors Market for Migraine, 2021-2035 (By Volume)

15.3.3.3.3. Global Autoinjectors Market for Migraine: Distribution by Type of Molecule, 2021-2035 (By Volume)
15.3.3.3.3.1. Global Antibody-based Autoinjectors Market for Migraine, 2021-2035 (By Volume)
15.3.3.3.3.2. Global Small Molecule-based Autoinjectors Market for Migraine, 2021-2035 (By Volume)
15.3.3.3.4. Global Autoinjectors Market for Migraine: Distribution by Geography, 2021-2035 (By Volume)
15.3.3.3.4.1. Autoinjectors Market for Migraine in North America, 2021-2035 (By Volume)
15.3.3.3.4.2. Autoinjectors Market for Migraine in Europe, 2021-2035 (By Volume)
15.3.3.3.4.3. Autoinjectors Market for Migraine in Asia-Pacific, 2021-2035 (By Volume)
15.3.3.3.4.4. Autoinjectors Market for Migraine in Rest of the World, 2021-2035 (By Volume)

15.3.3.4. Global Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, 2021-2035 (By Volume)
15.3.3.4.1. Global Autoinjectors Market for Rheumatoid and Psoriatic Arthritis: Distribution by Usability, 2021-2035 (By Volume)
15.3.3.4.1.1. Global Disposable Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, 2021-2035 (By Volume)
15.3.3.4.1.2. Global Reusable Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, 2021-2035 (By Volume)

15.3.3.4.2. Global Autoinjectors Market for Rheumatoid and Psoriatic Arthritis: Distribution by Route of Administration, 2021-2035 (By Volume)
15.3.3.4.2.1. Global Subcutaneous Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, 2021-2035 (By Volume)
15.3.3.4.2.2. Global Subcutaneous / Intravenous Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, 2021-2035 (By Volume)

15.3.3.4.3. Global Autoinjectors Market for Rheumatoid and Psoriatic Arthritis: Distribution by Type of Molecule, 2021-2035 (By Volume)
15.3.3.4.3.1. Global Antibody-based Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, 2021-2035 (By Volume)
15.3.3.4.3.2. Global Protein-based Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, 2021-2035 (By Volume)
15.3.3.4.3.3. Global Small Molecule-based Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, 2021-2035 (By Volume)
15.3.3.4.4. Global Autoinjectors Market for Rheumatoid and Psoriatic Arthritis: Distribution by Geography, 2021-2035 (By Volume)
15.3.3.4.4.1. Autoinjectors Market for Rheumatoid and Psoriatic Arthritis in North America, 2021-2035 (By Volume)
15.3.3.4.4.2. Autoinjectors Market for Rheumatoid and Psoriatic Arthritis in Europe, 2021-2035 (By Volume)
15.3.3.4.4.3. Autoinjectors Market for Rheumatoid and Psoriatic Arthritis in Asia-Pacific, 2021-2035 (By Volume)
15.3.3.4.4.4. Autoinjectors Market for Rheumatoid and Psoriatic Arthritis in Rest of the World, 2021-2035 (By Volume)

15.3.3.5. Global Autoinjectors Market for Diabetes, 2021-2035 (By Volume)
15.3.3.5.1. Global Autoinjectors Market for Diabetes: Distribution by Usability, 2021-2035 (By Volume)
15.3.3.5.1.1. Global Disposable Autoinjectors Market for Diabetes, 2021-2035 (By Volume)

15.3.3.5.2. Global Autoinjectors Market for Diabetes: Distribution by Route of Administration, 2021-2035 (By Volume)
15.3.3.5.2.1. Global Subcutaneous Autoinjectors Market for Diabetes, 2021-2035 (By Volume)

15.3.3.5.3. Global Autoinjectors Market for Diabetes: Distribution by Type of Molecule, 2021-2035 (By Volume)
15.3.3.5.3.1. Global Protein-based Autoinjectors Market for Diabetes, 2021-2035 (By Volume)
15.3.3.5.3.2. Global Peptide-based Autoinjectors Market for Diabetes, 2021-2035 (By Volume)

15.3.3.5.4. Global Autoinjectors Market for Diabetes: Distribution by Geography, 2021-2035 (By Volume)
15.3.3.5.4.1. Autoinjectors Market for Diabetes in North America, 2021-2035 (By Volume)
15.3.3.5.4.2. Autoinjectors Market for Diabetes in Europe, 2021-2035 (By Volume)
15.3.3.5.4.3. Autoinjectors Market for Diabetes in Asia-Pacific, 2021-2035 (By Volume)
15.3.3.5.4.4. Autoinjectors Market for Diabetes in Rest of the World, 2021-2035 (By Volume)

15.3.3.6. Global Autoinjectors Market for Other Indications, 2021-2035 (By Volume)
15.3.3.6.1. Global Autoinjectors Market for Other Indications: Distribution by Usability, 2021-2035 (By Volume)
15.3.3.6.1.1. Global Disposable Autoinjectors Market for Other Indications, 2021-2035 (By Volume)

15.3.3.6.2. Global Autoinjectors Market for Other Indications: Distribution by Route of Administration, 2021-2035 (By Volume)
15.3.3.6.2.1. Global Subcutaneous Autoinjectors Market for Other Indications, 2021-2035 (By Volume)
15.3.3.6.2.2. Global Intramuscular Autoinjectors Market for Other Indications, 2021-2035 (By Volume)
15.3.3.6.2.3. Global Subcutaneous / Intramuscular Autoinjectors Market for Other Indications, 2021-2035 (By Volume)

15.3.3.6.3. Global Autoinjectors Market for Other Indications: Distribution by Type of Molecule, 2021-2035 (By Volume)
15.3.3.6.3.1. Global Protein-based Autoinjectors Market for Other Indications, 2021-2035 (By Volume)
15.3.3.6.3.2. Global Antibody-based Autoinjectors Market for Other Indications, 2021-2035 (By Volume)
15.3.3.6.3.3. Global Small Molecule-based Autoinjectors Market for Other Indications, 2021-2035 (By Volume)

15.3.3.6.4. Global Autoinjectors Market for Other Indications: Distribution by Geography, 2021-2035 (By Volume)
15.3.3.6.4.1. Autoinjectors Market for Other Indications in North America, 2021-2035 (By Volume)
15.3.3.6.4.2. Autoinjectors Market for Other Indications in Europe, 2021-2035 (By Volume)
15.3.3.6.4.3. Autoinjectors Market for Other Indications in Asia-Pacific, 2021-2035 (By Volume)
15.3.3.6.4.4. Autoinjectors Market for Other Indications in Rest of the World, 2021-2035 (By Volume)

15.4. Drug Delivery System 3: Prefilled Syringes
15.4.1. Forecast Methodology and Key Assumptions
15.4.2. Global Prefilled Syringes Market, 2020-2030
15.4.2.1. Global Prefilled Syringes Market: Distribution by Type of Syringe Barrel Material, 2020-2030
15.4.2.2. Global Prefilled Syringes Market: Distribution by Type of Chamber System, 2020-2030
15.4.2.3. Global Prefilled Syringes Market: Distribution by Type of Pharmacological Molecule, 2020-2030
15.4.2.4. Global Prefilled Syringes Market: Distribution by Target Therapeutic Area, 2020-2030

15.5. Drug Delivery System 4: Needle-Free Injection Systems
15.5.1. Forecast Methodology and Key Assumptions
15.5.2. Global Needle-Free Injection Systems Market, 2020-2030
15.5.2.1. Global Needle-Free Injection Systems Market: Distribution by Usability, 2020-2030
15.5.2.2. Global Needle-Free Injection Systems Market: Distribution by Actuation Mechanism, 2020-2030
15.5.2.3. Global Needle-Free Injection Systems Market: Distribution by Target Therapeutic Area, 2020-2030

15.6. Drug Delivery System 5: Novel Drug Reconstitution Systems
15.6.1. Forecast Methodology and Key Assumptions
15.6.2. Global Novel Drug Reconstitution Systems Market, 2021-2030
15.6.2.1. Global Dual Chamber Prefilled Syringes Market, 2021-2030
15.6.2.1.1. Dual Chamber Prefilled Syringes Market, 2021-2030: Distribution by Physical State of Drug
15.6.2.1.1.1. Dual Chamber Prefilled Syringes Market for Liquid / Powder Drugs, 2021-2030
15.6.2.1.1.2. Dual Chamber Prefilled Syringes Market for Liquid / Liquid Drugs, 2021-2030
15.6.2.1.2. Dual Chamber Prefilled Syringes Market, 2021-2030: Distribution by Type of Fabrication Material Used
15.6.2.1.2.1. Glass Dual Chamber Prefilled Syringes Market, 2021-2030
15.6.2.1.2.2. Plastic Dual Chamber Prefilled Syringes Market, 2021-2030

15.6.2.1.3. Dual Chamber Prefilled Syringes Market, 2021-2030: Distribution by Volume
15.6.2.1.3.1. Dual Chamber Prefilled Syringes Market for <1 mL Syringes, 2021-2030
15.6.2.1.3.2. Dual Chamber Prefilled Syringes Market for 1-2.5 mL Syringes, 2021-2030
15.6.2.1.3.3. Dual Chamber Prefilled Syringes Market for 2.6-5 mL Syringes, 2021-2030
15.6.2.1.3.4. Dual Chamber Prefilled Syringes Market for >5 mL Syringes, 2021-2030

15.6.2.1.4. Dual Chamber Prefilled Syringes Market, 2021-2030: Distribution by Geography
15.6.2.1.4.1. Dual Chamber Prefilled Syringes Market in North America, 2021-2030
15.6.2.1.4.2. Dual Chamber Prefilled Syringes Market in Europe, 2021-2030
15.6.2.1.4.3. Dual Chamber Prefilled Syringes Market in Asia-Pacific, 2021-2030
15.6.2.1.4.4. Dual Chamber Prefilled Syringes Market in Latin America, 2021-2030
15.6.2.1.4.5. Dual Chamber Prefilled Syringes Market in Middle East and Africa, 2021-2030

15.6.2.2. Global Dual Chamber Cartridges Market, 2021-2030
15.6.2.2.1. Dual Chamber Cartridges Market, 2021-2030: Distribution by Physical State of Drug
15.6.2.2.1.1. Dual Chamber Cartridges Market for Liquid / Powder Drugs, 2021-2030
15.6.2.2.1.2. Dual Chamber Cartridges Market for Liquid / Liquid Drugs, 2021-2030

15.6.2.2.2. Dual Chamber Cartridges Market, 2021-2030: Distribution by Type of Fabrication Material Used
15.6.2.2.2.1. Glass Dual Chamber Cartridges Market, 2021-2030
15.6.2.2.2.2. Plastic Dual Chamber Cartridges Market, 2021-2030

15.6.2.2.3. Dual Chamber Cartridges Market, 2021-2030: Distribution by Volume
15.6.2.2.3.1. Dual Chamber Cartridges Market for <1 mL Cartridges, 2021-2030
15.6.2.2.3.2. Dual Chamber Cartridges Market for 1-2.5 mL Cartridges, 2021-2030
15.6.2.2.3.3. Dual Chamber Cartridges Market for 2.6-5 mL Cartridges, 2021-2030
15.6.2.2.3.4. Dual Chamber Cartridges Market for >5 mL Cartridges, 2021-2030

15.6.2.2.4. Dual Chamber Cartridges Market, 2021-2030: Distribution by Geography
15.6.2.2.4.1. Dual Chamber Cartridges Market in North America, 2021-2030
15.6.2.2.4.2. Dual Chamber Cartridges Market in Europe, 2021-2030
15.6.2.2.4.3. Dual Chamber Cartridges Market in Asia-Pacific, 2021-2030
15.6.2.2.4.4. Dual Chamber Cartridges Market in Latin America, 2021-2030
15.6.2.2.4.5. Dual Chamber Cartridges Market in Middle East and Africa, 2021-2030

15.6.2.3. Global Dual / Multi Chamber Infusion Bags Market, 2021-2030
15.6.2.3.1. Dual / Multi Chamber Infusion Bags Market, 2021-2030: Distribution by Physical State of Drug
15.6.2.3.1.1. Dual / Multi Chamber Infusion Bags Market for Liquid Mixture, 2021-2030
15.6.2.3.1.2. Dual / Multi Chamber Infusion Bags Market for Frozen Mixture, 2021-2030

15.6.2.3.2. Dual / Multi Chamber Infusion Bags Market, 2021-2030: Distribution by Type of Plastic
15.6.2.3.2.1. Dual / Multi Chamber Infusion Bags Market for Ethylene Vinyl Acetate, 2021-2030
15.6.2.3.2.2. Dual / Multi Chamber Infusion Bags Market for Polypropylene, 2021-2030
15.6.2.3.2.3. Dual / Multi Chamber Infusion Bags Market for Polyvinyl Chloride, 2021-2030
15.6.2.3.2.4. Dual / Multi Chamber Infusion Bags Market for Other Plastic Materials, 2021-2030

15.6.2.3.3. Dual / Multi Chamber Infusion Bags Market, 2021-2030: Distribution by Volume
15.6.2.3.3.1. Dual / Multi Chamber Infusion Bags Market for <250 mL Infusion Bags, 2021-2030
15.6.2.3.3.2. Dual / Multi Chamber Infusion Bags Market for 250-500 mL Infusion Bags, 2021- 2030
15.6.2.3.3.3. Dual / Multi Chamber Infusion Bags Market for 501-1,000 mL Infusion Bags, 2021-2030
15.6.2.3.3.4. Dual / Multi Chamber Infusion Bags Market for >1,000 mL Infusion Bags, 2021-2030

15.6.2.3.4. Dual / Multi Chamber Infusion Bags Market, 2021-2030: Distribution by Geography
15.6.2.3.4.1. Dual / Multi Chamber Infusion Bags Market in North America, 2021-2030
15.6.2.3.4.2. Dual / Multi Chamber Infusion Bags Market in Europe, 2021-2030
15.6.2.3.4.3. Dual / Multi Chamber Infusion Bags Market in Asia-Pacific, 2021-2030
15.6.2.3.4.4. Dual / Multi Chamber Infusion Bags Market in Latin America, 2021-2030
14.6.2.3.4.5. Dual / Multi Chamber Infusion Bags Market in Middle East and Africa, 2021-2030

16. SWOT ANALYSIS
16.1. Chapter Overview
16.2. Comparison of SWOT Factors
16.2.1. Strengths
16.2.2. Weaknesses
16.2.3. Opportunities
16.2.4. Threats

17. CONCLUDING REMARKS
17.1. Chapter Overview

18. EXECUTIVE INSIGHTS
18.1. Chapter Overview

18.2. Lindy Biosciences
18.2.1. Company Snapshot
18.2.2. Interview Transcript: Deborah Bitterfield, Chief Executive Officer and Founder

18.3. Oval Medical Technologies
18.3.1. Company Snapshot
18.3.2. Interview Transcript: Matthew Young, Chief Technology Officer and Founder

18.4. Xeris Pharmaceuticals
18.4.1. Company Snapshot
18.4.2. Interview Transcript: Steve Prestrelski, Chief Scientific Officer and Founder; Hong Qi, Vice President, Product Development; and Scott Coleman, Ex Sr. Scientist Formulation)

18.5. DALI Medical Devices
18.5.1. Company Snapshot
18.5.2. Interview Transcript: David Daily, Chief Executive Officer and Co-Founder

18.6. Excelse Bio
18.6.1. Company Snapshot
18.6.2. Interview Transcript: Michael Reilly, Chief Executive Officer and Co-Founder

18.7. i-novion
18.7.1. Company Snapshot
18.7.2. Interview Transcript: Poonam R Velagaleti, Co-Founder

18.8. Enable Injections
18.8.1. Company Snapshot
18.8.2. Interview Transcript: Michael Hooven, Chief Executive Officer

18.9. Immunovaccine Technologies
18.9.1. Company Snapshot
18.9.2. Interview Transcript: Frederic Ors, Ex Chief Executive Officer

18.10. Portal Instruments
18.10.1. Company Snapshot
18.10.2. Interview Transcript: Patrick Anquetil, Chief Executive Officer

18.11. Elcam Medical
18.11.1. Company Snapshot
18.11.2. Interview Transcript: Menachem Zucker, Vice President and Chief Scientist

18.12. West Pharmaceutical Services
18.12.1. Company Snapshot
18.12.2. Interview Transcript: Tiffany H Burke, Director, Global Communications and Graham Reynolds, Vice President and General Manager, Global Biologics

18.13. MedinCell
18.13.1. Company Snapshot
18.13.2. Interview Transcript: David Heuzé, Communication Leader

19. APPENDIX 1: TABULATED DATA

20. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATION

List Of Figures

Figure 2.1 Executive Summary: Approved Subcutaneous Biologics Market Landscape
Figure 2.2 Executive Summary: Clinical-stage Subcutaneous Biologics Market Landscape
Figure 2.3 Executive Summary: Executive Summary: Subcutaneous Formulation Technologies Market Landscape
Figure 2.4 Executive Summary: Partnerships and Collaborations
Figure 2.5 Executive Summary: Approved Subcutaneous Biologics Market Forecast
Figure 2.6 Executive Summary: Subcutaneous Formulation Technologies and Drug Delivery Systems Market
Figure 2.1 Executive Summary: Approved Subcutaneous Biologics Market Landscape
Figure 3.1 Types of Biologically Derived Therapeutics
Figure 3.2 Conversion from Intravenous to Subcutaneous Formulation: Key Points for Pharma Companies
Figure 3.3 Process of Developing a Subcutaneous Formulation from Intravenous Product
Figure 3.4 Subcutaneous Drug Delivery: Possible Routes of Administration for Large-Dose Biologics
Figure 3.5 Landscape of Large Volume Subcutaneous Drug Delivery Devices
Figure 3.6 Steps Involved in Subcutaneous Drug Delivery
Figure 4.1 Approved Subcutaneous Biologics: Distribution by Approval Year
Figure 4.2 Approved Subcutaneous Biologics: Distribution by Type of Molecule
Figure 4.3 Approved Subcutaneous Biologics: Distribution by Approval Year and Type of Molecule
Figure 4.4 Approved Subcutaneous Biologics: Distribution by Type of Therapy
Figure 4.5 Approved Subcutaneous Biologics: Distribution by Route of Administration
Figure 4.6 Approved Subcutaneous Biologics: Distribution by Method of Administration
Figure 4.7 Approved Subcutaneous Biologics: Distribution by Route of Administration and Method of Administration
Figure 4.8 Approved Subcutaneous Biologics: Distribution by Dosing Frequency
Figure 4.9 Approved Subcutaneous Biologics: Distribution by Dose Concentration
Figure 4.10 Approved Subcutaneous Biologics: Distribution by Target Disease(s) Indication Figure 4.11 Approved Subcutaneous Biologics: Distribution by Therapeutic Area
Figure 4.12 Approved Subcutaneous Biologics: Distribution by Approval Year and Therapeutic Area
Figure 4.13 Approved Subcutaneous Biologics: Distribution by Type of Available Formulation
Figure 4.14 Approved Subcutaneous Biologics: Distribution by Route of Administration and Type of Available Formulation
Figure 4.15 Approved Subcutaneous Biologics Developers: Distribution by Year of Establishment
Figure 4.16 Approved Subcutaneous Biologics Developers: Distribution by Company Size
Figure 4.17 Approved Subcutaneous Biologics Developers: Distribution by Location of Headquarters
Figure 4.18 Leading Developers: Distribution by Number of Approved Subcutaneous Biologics
Figure 5.1 Clinical-Stage Subcutaneous Biologics: Distribution by Phase of Development
Figure 5.2 Clinical-Stage Subcutaneous Biologics: Distribution by Mechanism of Action
Figure 5.3 Clinical-Stage Subcutaneous Biologics: Distribution by Type of Molecule
Figure 5.4 Clinical-Stage Subcutaneous Biologics: Distribution by Phase of Development and Type of Molecule
Figure 5.5 Clinical-Stage Subcutaneous Biologics: Distribution by Type of Therapy
Figure 5.6 Clinical-Stage Subcutaneous Biologics: Distribution by Dosing Frequency
Figure 5.7 Clinical-Stage Subcutaneous Biologics: Distribution by Type of Molecule and Dosing Frequency
Figure 5.8 Clinical-Stage Subcutaneous Biologics: Distribution by Target Disease Indication(s)
Figure 5.9 Clinical-Stage Subcutaneous Biologics: Distribution by Therapeutic Area
Figure 5.10 Clinical-Stage Subcutaneous Biologics: Distribution by Phase of Development and Therapeutic Area
Figure 5.11 Clinical-Stage Subcutaneous Biologics: Distribution by Type of Molecule and Therapeutic Area
Figure 5.12 Clinical-Stage Subcutaneous Biologics: Distribution by Special Drug Designation(s) Awarded
Figure 5.13 Clinical-Stage Subcutaneous Biologics Developers: Distribution by Year of Establishment
Figure 5.14 Clinical-Stage Subcutaneous Biologics Developers: Distribution by Company Size
Figure 5.15 Clinical-Stage Subcutaneous Biologics Developers: Distribution by Location of Headquarters
Figure 5.16 Leading Developers: Distribution by Number of Clinical-Stage Subcutaneous Biologics
Figure 6.1 Leading Approved Subcutaneous Biologics: Distribution by Value Creation Sales
Figure 6.2 BENLYSTA (Roche): Approval Timeline
Figure 6.3 BENLYSTA (Roche): Success Protocol Analysis
Figure 6.4 BESREMi (PharmaEssentia): Approval Timeline
Figure 6.5 BESREMi (PharmaEssentia): Success Protocol Analysis
Figure 6.6 COSENTYX (Novartis): Approval Timeline
Figure 6.7 COSENTYX (Novartis): Success Protocol Analysis
Figure 6.8 DARZALEX FASPRO (Halozyme): Approval Timeline
Figure 6.9 DARZALEX FASPRO (Halozyme): Success Protocol Analysis
Figure 6.10 DUPIXENT (Regeneron Pharmaceuticals) : Approval Timeline
Figure 6.11 DUPIXENT (Regeneron Pharmaceuticals): Success Protocol Analysis
Figure 6.12 Enbrel (Amgen): Approval Timeline
Figure 6.13 Enbrel (Amgen) : Success Protocol Analysis
Figure 6.14 HEMLIBRA (Roche): Approval Timeline
Figure 6.15 HEMLIBRA (Roche): Success Protocol Analysis
Figure 6.16 Prolia / Pralia (Amgen): Approval Timeline
Figure 6.17 Prolia / Pralia (Amgen): Success Protocol Analysis
Figure 6.18 STELARA (Janssen Biotech): Approval Timeline
Figure 6.19 STELARA (Janssen Biotech): Success Protocol Analysis
Figure 6.20 Trulicity (Eli Lilly): Approval Timeline
Figure 6.21 Trulicity (Eli Lilly): Success Protocol Analysis
Figure 6.22 Success Protocol Analysis: Conclusion
Figure 7.1 Subcutaneous Formulation Technologies: Distribution by Fundamental Principle of Technology
Figure 7.2 Subcutaneous Formulation Technologies: Distribution by Type of Molecule
Figure 7.3 Subcutaneous Formulation Technologies: Distribution by Route of Administration
Figure 7.4 Subcutaneous Formulation Technologies: Distribution by Type of Molecule and Route of Administration
Figure 7.5 Subcutaneous Formulation Technologies: Distribution by Therapeutic Area
Figure 7.6 Subcutaneous Formulation Technologies: Distribution by Advantage(s) Offered
Figure 7.7 Subcutaneous Formulation Technology Developers: Distribution by Year of Establishment
Figure 7.8 Subcutaneous Formulation Technology Developers: Distribution by Company Size
Figure 7.9 Subcutaneous Formulation Technology Developers: Distribution by Location of Headquarters (Region-wise)
Figure 7.10 Subcutaneous Formulation Technology Developers: Distribution by Location of Headquarters (Country-wise)
Figure 7.11 Subcutaneous Formulation Technology Developers: Distribution by Company Size and Location of Headquarters (Region-wise)
Figure 7.12 Subcutaneous Formulation Technologies: Distribution by Number of Advantages Offered
Figure 8.1 Company Competitiveness Analysis: Benchmarking of Technology Strength
Figure 8.2 Company Competitiveness Analysis: Benchmarking of Partnership Activity
Figure 8.3 Company Competitiveness Analysis: Developers based in North America
Figure 8.4 Company Competitiveness Analysis: Developers based in Europe and Asia
Figure 9.1 Adocia: Annual Revenues, 2015 – H1 2021 (EUR Million)
Figure 9.2 Ajinomoto: Annual Revenues, 2016 – H1 2021 (JPY Billion)
Figure 9.3 Ajinomoto Bio-Pharma Services: Crystalomics Technology
Figure 9.4 Alteogen: Annual Revenues, 2016 – H1 2021 (USD Million)
Figure 9.5 Arecor: Annual Revenues, 2018 – H1 2021 (EUR Million)
Figure 9.6 Arecor: Arestat Technology (Advantages)
Figure 9.7 Ascendis Pharma: Annual Revenues, 2015-H1 2021 (USD Million)
Figure 9.8 Avadel Pharmaceuticals: Annual Revenues, 2015 – 2020 (USD Million)
Figure 9.9 Avadel Pharmaceuticals: Medusa Technology
Figure 9.10 Camurus: Annual Revenues, 2015- H1 2021 (SEK)
Figure 9.11 Camurus: FluidCrystal Injection Depot Technology
Figure 9.12 DURECT: Annual Revenues, 2015-H1 2021 (USD Million)
Figure 9.13 DURECT: CLOUD Platform
Figure 9.14 Eagle Pharmaceuticals: Annual Revenues, 2015–H1 202 (USD Million)
Figure 9.15 Halozyme Therapeutics: Annual Revenues, 2015 – H1 2021 (USD Million)
Figure 9.16 MedinCell: Annual Revenues, 2015 – Q3 2021 (Euro Million)
Figure 9.17 MedinCell: BEPO Technology
Figure 9.18 Xeris Pharmaceuticals: Annual Revenues, 2016 – H1 2021 (USD Million)
Figure 9.19 Xeris Pharmaceuticals: XeriJect Technology
Figure 9.20 Xeris Pharmaceuticals: XeriSol Technology
Figure 10.1 Partnerships and Collaborations: Cumulative Year-wise Trend, Pre-2016-2021
Figure 10.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 10.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 10.4 Partnerships and Collaborations: Distribution by Type of Partnership and Company Size
Figure 10.5 Partnerships and Collaborations: Distribution by Type of Partner
Figure 10.6 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Figure 10.7 Partnerships and Collaborations: Distribution by Type of Partner and Partnership
Figure 10.8 Partnerships and Collaborations: Distribution Type of Partner and Company Size
Figure 10.9 Partnerships and Collaborations: Distribution by Therapeutic Area
Figure 10.10 Partnerships and Collaborations: Focus Area (Word Cloud)
Figure 10.11 Partnerships and Collaborations: Country-wise Distribution
Figure 10.12 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements Distribution
Figure 10.13 Most Active Players: Distribution by Number of Partnerships
Figure 11.1 Different Types of Subcutaneous Drug Delivery Systems
Figure 11.2 Large Volume Wearable Injectors: Overall Market Landscape
Figure 11.3 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Phase of Development
Figure 11.4 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Type of Device
Figure 11.5 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Actuation Mechanism
Figure 11.6 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Technology Used
Figure 11.7 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Route of Administration
Figure 11.8 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Method of Administration
Figure 11.9 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Therapeutic Area
Figure 11.10 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Type of Dose
Figure 11.11 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Storage Volume / Capacity (in mL)
Figure 11.12 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Usability
Figure 11.13 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Availability of Prefilled Drug Reservoir
Figure 11.14 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Availability of Connectivity
Figure 11.15 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Availability of Drug Compatibility
Figure 11.16 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Availability of Drug Container
Figure 11.17 Most Active Players: Distribution by Number of Large Volume Wearable Injectors for Non-Insulin Drugs
Figure 11.18 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Phase of Development
Figure 11.19 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Type of Device
Figure 11.20 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Type of Dose
Figure 11.21 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Storage Volume / Capacity (in mL)
Figure 11.22 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Usability
Figure 11.23 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Combination Insulin
Figure 11.24 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Non- Interoperable Device
Figure 11.25 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Availability of Prefilled Drug Reservoir
Figure 11.26 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Availability of Continuous Glucose Monitoring (CGM) / Blood Glucose Meters (BGM) System
Figure 11.27 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Type of Automated Insulin Delivery (AID) Features
Figure 11.28 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Availability of Automatic Insulin Delivery (AID) / Artificial Pancreas
Figure 11.29 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Availability of Connectivity
Figure 11.30 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Availability of Device Control Features
Figure 11.31 Most Active Players: Distribution by Number of Large Volume Wearable Injector for Insulin Drugs
Figure 11.32 Large Volume Drug Device Combinations: Distribution by Phase of Development
Figure 11.33 Large Volume Drug Device Combinations: Distribution by Type of Device
Figure 11.34 Large Volume Drug Device Combinations: Distribution by Mechanism of Action
Figure 11.35 Large Volume Drug Device Combinations: Distribution by Technology
Figure 11.36 Large Volume Drug Device Combinations: Distribution by Route of Administration
Figure 11.37 Large Volume Drug Device Combinations: Distribution by Method of Administration
Figure 11.38 Large Volume Drug Device Combinations: Distribution by Therapeutic Area
Figure 11.39 Large Volume Drug Device Combinations: Distribution by Type of Dose
Figure 11.40 Large Volume Drug Device Combinations: Distribution by Storage Volume / Capacity (in mL)
Figure 11.41 Large Volume Drug Device Combinations: Distribution by Usability
Figure 11.42 Large Volume Drug Device Combinations: Distribution by Drug Compatibility
Figure 11.43 Large Volume Drug Device Combinations: Distribution by Drug Container
Figure 11.44 Most Active Players: Distribution by Number of Products Manufactured
Figure 11.45 Autoinjectors: Distribution by Actuation Mechanism
Figure 11.46 Autoinjectors: Distribution by Route of Administration
Figure 11.47 Autoinjectors: Distribution by Type of Dose
Figure 11.48 Autoinjectors: Distribution by Storage Volume / Capacity (in ml)
Figure 11.49 Autoinjectors: Distribution by Usability
Figure 11.50 Autoinjectors: Distribution by Type of Primary Container
Figure 11.51 Autoinjectors: Distribution by Type of Feedback Mechanism
Figure 11.52 Most Active players: Distribution by Number of Devices
Figure 11.53 Pen Injectors: Distribution by Type of Dose
Figure 11.54 Pen Injectors: Distribution by Storage Volume / Capacity (in ml)
Figure 11.55 Pen Injectors: Distribution by Usability
Figure 11.56 Most Active Players: Distribution by Number of Devices
Figure 11.57 Needle Free Injection Systems: Distribution by Phase of Development
Figure 11.58 Needle Free Injection Systems: Distribution by Actuation Mechanism
Figure 11.59 Needle Free Injection Systems: Distribution by Therapeutic Area
Figure 11.60 Needle Free Injection Systems: Distribution by Usability
Figure 11.61 Most Active Players: Distribution by Number of Devices
Figure 11.62 Novel Drug Reconstitution Systems: Distribution by Volume Storage / Capacity (mL)
Figure 11.63 Novel Drug Reconstitution Systems: Distribution by Usability
Figure 11.64 Novel Drug Reconstitution Systems: Distribution by Type of Device
Figure 11.65 Novel Drug Reconstitution Systems: Distribution by Type of Chamber
Figure 11.66 Novel Drug Reconstitution Systems: Distribution by Type of Device and Chamber
Figure 11.67 Novel Drug Reconstitution Systems: Distribution by Physical State of Drug
Figure 11.68 Novel Drug Reconstitution Systems: Distribution by Container Fabrication Material
Figure 11.69 Novel Drug Reconstitution Systems: Distribution by Container Fabrication Material and Usability
Figure 11.70 Most Active Players: Distribution by Number of Devices
Figure 11.71 Prefilled Syringes: Distribution by Storage Volume / Capacity (ml)
Figure 11.72 Prefilled Syringes: Distribution by Barrel Fabrication Material
Figure 11.73 Prefilled Syringes: Distribution by Number of Barrel Chambers
Figure 11.74 Prefilled Syringes: Distribution by Type of Needle System
Figure 11.75 Most Active Players: Distribution by Number of Devices
Figure 11.76 Implants: Distribution by Phase of Development
Figure 11.77 Implants: Distribution by Therapeutic Area
Figure 11.78 Implants: Distribution by Implant Material
Figure 11.79 Implants: Distribution by Treatment Duration
Figure 11.80 Implants: Distribution by Type of Delivery System
Figure 11.81 Most Active Players: Distribution By number of Devices
Figure 12.1 Product Competitiveness Analysis: Large Volume Wearable Injectors for Non-Insulin Drugs
Figure 12.2 Product Competitiveness Analysis: Large Volume Wearable Injectors for Insulin Drugs
Figure 12.3 Product Competitiveness Analysis: Drug Device Combinations Products
Figure 12.4 Product Competitiveness Analysis: Disposable Autoinjectors
Figure 12.5 Product Competitiveness Analysis: Reusable Autoinjectors
Figure 12.6 Product Competitiveness Analysis: Spring-based Needle-Free Injection Systems
Figure 12.7 Product Competitiveness Analysis: Compressed Gas-powered Needle-Free Injection Systems
Figure 12.8 Product Competitiveness Analysis: Glass Barrel Prefilled Syringes
Figure 12.9 Product Competitiveness Analysis: Plastic Barrel Prefilled Syringes
Figure 13.1 Global Approved Subcutaneous Biologics Market, 2022-2035
Figure 13.2 Approved Subcutaneous Biologics Market: Distribution by Type of Biologic, 2022 and 2035
Figure 13.3 Approved Subcutaneous Biologics Market for Antibodies, 2022-2035
Figure 13.4 Approved Subcutaneous Biologics Market for Nucleotides, 2022-2035
Figure 13.5 Approved Subcutaneous Biologics Market for Proteins, 2022-2035
Figure 13.6 Approved Subcutaneous Biologics Market for Vaccines, 2022-2035
Figure 13.7 Approved Subcutaneous Biologics Market for Other Biologics, 2022-2035
Figure 13.8 Approved Subcutaneous Biologics Market: Distribution by Type of Therapy, 2022 and 2035
Figure 13.9 Approved Subcutaneous Biologics Market for Monotherapies, 2022-2035
Figure 13.10 Approved Subcutaneous Biologics Market for Combination Therapies, 2022-2035
Figure 13.11 Approved Subcutaneous Biologics Market for Monotherapies and Combination Therapies, 2022-2035
Figure 13.12 Approved Subcutaneous Biologics Market: Distribution by Therapeutic Area, 2022 and 2035
Figure 13.13 Approved Subcutaneous Biologics Market for Autoimmune Disorders, 2022-2035
Figure 13.14 Approved Subcutaneous Biologics Market for Blood Disorders, 2022-2035
Figure 13.15 Approved Subcutaneous Biologics Market for Bone Disorders, 2022-2035
Figure 13.16 Approved Subcutaneous Biologics Market for Cardiovascular Disorders, 2022-2035
Figure 13.17 Approved Subcutaneous Biologics Market for Genetic Disorders, 2022-2035
Figure 13.18 Approved Subcutaneous Biologics Market for Hormonal Disorders, 2022-2035
Figure 13.19 Approved Subcutaneous Biologics Market for Infectious Disorders, 2022-2035
Figure 13.20 Approved Subcutaneous Biologics Market for Inflammatory Disorders, 2022-2035
Figure 13.21 Approved Subcutaneous Biologics Market for Metabolic Disorders, 2022-2035
Figure 13.22 Approved Subcutaneous Biologics Market for Neurological Disorders, 2022-2035
Figure 13.23 Approved Subcutaneous Biologics Market for Oncological Disorders, 2022-2035
Figure 13.24 Approved Subcutaneous Biologics Market for Respiratory Disorders, 2022-2035
Figure 13.25 Approved Subcutaneous Biologics Market for Women’s Health Disorders, 2022-2035
Figure 13.26 Approved Subcutaneous Biologics Market for Other Disorders, 2022-2035
Figure 13.27 Approved Subcutaneous Biologics Market: Distribution by Geographical Region, 2022 and 2035
Figure 13.28 Approved Subcutaneous Biologics Market in North America, 2022-2035
Figure 13.29 Approved Subcutaneous Biologics Market in Europe, 2022-2035
Figure 13.30 Approved Subcutaneous Biologics Market in Asia, 2022-2035
Figure 13.31 Approved Subcutaneous Biologics Market in Middle East and North Africa, 2022-2035
Figure 13.32 Approved Subcutaneous Biologics Market in Latin America, 2022-2035
Figure 13.33 Approved Subcutaneous Biologics Market in Rest of the World, 2022-2035
Figure 13.34 AIMOVIG Sales Forecast, 2022-2035 (USD Million)
Figure 13.35 AJOVY Sales Forecast, 2022-2035 (USD Million)
Figure 13.36 Apidra (insulin glulisine), Sales Forecast, 2022-2035 (USD Million)
Figure 13.37 Basaglar / Abrasia (EU) Sales Forecast, 2022-2035 (USD Million)
Figure 13.38 BENLYSTA(belimumab) Sales Forecast, 2022-2035 (USD Million)
Figure 13.39 BESREMi (ropeginterferon alfa-2b-njft) Sales Forecast, 2022-2035 (USD Million)
Figure 13.40 BIOTHRAX® (Anthrax Vaccine Adsorbed) Sales Forecast, 2022-2035 (USD Million)
Figure 13.41 CABLIVI (Caplacizumab) Sales Forecast, 2022-2035 (USD Million)
Figure 13.42 Cegfila Sales Forecast, 2022-2035 (USD Million)
Figure 13.43 CIMZIA (certolizumab pegol) Sales Forecast, 2022-2035 (USD Million)
Figure 13.44 COSENTYX (secukinumab) Sales Forecast, 2022-2035 (USD Million)
Figure 13.45 CRYSVITA (burosumab-twza) Sales Forecast, 2022-2035 (USD Million)
Figure 13.46 Cuvitru (immune globulin subcutaneous [human], 20% solution) Sales Forecast, 2022-2035 (USD Million)
Figure 13.47 DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj / DARZALEX SC Sales Forecast, 2022-2035 (USD Million)
Figure 13.48 DENGVAXIA (Dengue Tetravalent Vaccine) Sales Forecast, 2022-2035 (USD Million)
Figure 13.49 DUPIXENT (dupilumab) Sales Forecast, 2022-2035 (USD Million)
Figure 13.50 EMGALITY (galcanezumab-gnlm) Sales Forecast, 2022-2035 (USD Million)
Figure 13.51 EMPAVELI (pegcetacoplan) Sales Forecast, 2022-2035 (USD Million)
Figure 13.52 Enbrel (etanercept) Sales Forecast, 2022-2035 (USD Million)
Figure 13.53 ENSPRYNG (satralizumab) Sales Forecast, 2022-2035 (USD Million)
Figure 13.54 EVENITY (romosozumab-aqqg) Sales Forecast, 2022-2035 (USD Million)
Figure 13.55 FASENRA (benralizumab) Sales Forecast, 2022-2035 (USD Million)
Figure 13.56 FIASP (Insulin Aspart) Sales Forecast, 2022-2035 (USD Million)
Figure 13.57 Fulphila (pegfilgrastim-jmdb) Sales Forecast, 2022-2035 (USD Million)
Figure 13.58 Gamunex-C (Immune Globulin Injection [Human], 10% Caprylate/Chromatography Purified) Sales Forecast, 2022-2035 (USD Million)
Figure 13.59 GATTEX / Revestive (teduglutide [rDNA origin]) Sales Forecast, 2022-2035 (USD Million)
Figure 13.60 GIVLAARI (givosiran) Sales Forecast, 2022-2035 (USD Million)
Figure 13.61 HAEGARDA Sales Forecast, 2022-2035 (USD Million)
Figure 13.62 HEMLIBRA (emicizumab-kxwh) Sales Forecast, 2022-2035 (USD Million)
Figure 13.63 Hepcludex (Bulevirtide) Sales Forecast, 2022-2035 (USD Million)
Figure 13.64 Hizentra (Immune Globulin Subcutaneous [Human] 20% Liquid) Sales Forecast, 2022-2035 (USD Million)
Figure 13.65 HYQVIA (Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase) Sales Forecast, 2022-2035 (USD Million)
Figure 13.66 ILARIS (canakinumab) Sales Forecast, 2022-2035 (USD Million)
Figure 13.67 ILUMYA (tildrakizumab-asmn) / Ilumetri Sales Forecast, 2022-2035 (USD Million)
Figure 13.68 Kalbitor (ecallantide) Sales Forecast, 2022-2035 (USD Million)
Figure 13.69 Kesimpta (ofatumumab) Sales Forecast, 2022-2035 (USD Million)
Figure 13.70 KEVZARA (sarilumab) Sales Forecast, 2022-2035 (USD Million)
Figure 13.71 KINERET (anakinra) Sales Forecast, 2022-2035 (USD Million)
Figure 13.72 Kyntheum / SILIQ / Lumicef (brodalumab) Sales Forecast, 2022-2035 (USD Million)
Figure 13.73 Leqvio (Inclisiran) Sales Forecast, 2022-2035 (USD Million)
Figure 13.74 Lonquex (lipegfilgrastim) Sales Forecast, 2022-2035 (USD Million)
Figure 13.75 Lyumjev (insulin lispro-aabc) Sales Forecast, 2022-2035 (USD Million)
Figure 13.76 Norditropin (somatropin) Sales Forecast, 2022-2035 (USD Million)
Figure 13.77 NPLATE (romiplostim) Sales Forecast, 2022-2035 (USD Million)
Figure 13.78 Nucala (mepolizumab) Sales Forecast, 2022-2035 (USD Million)
Figure 13.79 OXLUMO (lumasiran) Sales Forecast, 2022-2035 (USD Million)
Figure 13.80 PALYNZIQ (pegvaliase-pqpz) Sales Forecast, 2022-2035 (USD Million)
Figure 13.81 Pergoveris (follitropin alfa / lutropin alfa) Sales Forecast, 2022-2035 (USD Million)
Figure 13.82 Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) Sales Forecast, 2022-2035 (USD Million)
Figure 13.83 Prolia / Pralia (denosumab) Sales Forecast, 2022-2035 (USD Million)
Figure 13.84 REBLOZYL (luspatercept-aamt) Sales Forecast, 2022-2035 (USD Million)
Figure 13.85 REKOVELLE (follitropin delta) Sales Forecast, 2022-2035 (USD Million)
Figure 13.86 Repatha (evolocumab) Sales Forecast, 2022-2035 (USD Million)
Figure 13.87 RYZODEG 70/30 (insulin degludec and insulin aspart) Sales Forecast, 2022-2035 (USD Million)
Figure 13.88 Skyrizi (risankizumab) Sales Forecast, 2022-2035 (USD Million)
Figure 13.89 SKYTROFA (lonapegsomatropin-tcgd) Sales Forecast, 2022-2035 (USD Million)
Figure 13.90 SOLIQUA 100/33 (insulin glargine & lixisenatide injection) Sales Forecast, 2022-2035 (USD Million)
Figure 13.91 STELARA (ustekinumab) Sales Forecast, 2022-2035 (USD Million)
Figure 13.92 Strensiq (asfotase alfa) Sales Forecast, 2022-2035 (USD Million)
Figure 13.93 TAKHZYRO (lanadelumab-flyo) Sales Forecast, 2022-2035 (USD Million)
Figure 13.94 Taltz (ixekizumab) Sales Forecast, 2022-2035 (USD Million)
Figure 13.95 TEGSEDI (inotersen) Sales Forecast, 2022-2035 (USD Million)
Figure 13.96 Toujeo (insulin glargine injection) U-300 Sales Forecast, 2022-2035 (USD Million)
Figure 13.97 TREMFYA (guselkumab) Sales Forecast, 2022-2035 (USD Million)
Figure 13.98 TRESIBA (insulin degludec injection) Sales Forecast, 2022-2035 (USD Million)
Figure 13.99 Trulicity (dulaglutide) Sales Forecast, 2022-2035 (USD Million)
Figure 13.100 TYMLOS (abaloparatide) Sales Forecast, 2022-2035 (USD Million)
Figure 13.101 Tysabri (Natalizumab) Sales Forecast, 2022-2035 (USD Million)
Figure 13.102 Voxzogo (vosoritide) Sales Forecast, 2022-2035 (USD Million)
Figure 13.103 VYLEESI (bremelanotide injection) Sales Forecast, 2022-2035 (USD Million)
Figure 13.104 XEMBIFY (immune globulin subcutaneous, human – klhw) Sales Forecast, 2022-2035 (USD Million)
Figure 13.105 Xgeva / RANMARK (denosumab) Sales Forecast, 2022-2035 (USD Million)
Figure 13.106 XULTOPHY / IDegLira (insulin degludec and liraglutide injection) Sales Forecast, 2022-2035 (USD Million)
Figure 13.107 XYOSTED (testosterone enanthate) Sales Forecast, 2022-2035 (USD Million)
Figure 13.108 ZEGALOGUE (dasiglucagon) Sales Forecast, 2022-2035 (USD Million)
Figure 14.1 Global Subcutaneous Formulation Technologies Market, 2022-2035
Figure 14.2 Subcutaneous Formulation Technologies Market: Distribution by Type of Payment, 2022 and 2035
Figure 14.3 Subcutaneous Formulation Technologies Market for Milestone Payments, 2022-2035
Figure 14.4 Subcutaneous Formulation Technologies Market for Upfront Payments, 2022-2035
Figure 14.5 Subcutaneous Formulation Technologies Market: Distribution by Fundamental Principle, 2022 and 2035
Figure 14.6 Subcutaneous Formulation Technologies Market for Amino Acid Interaction, 2022-2035
Figure 14.7 Subcutaneous Formulation Technologies Market for Complex Formation, 2022-2035
Figure 14.8 Subcutaneous Formulation Technologies Market for Encapsulation, 2022-2035
Figure 14.9 Subcutaneous Formulation Technologies Market for Other Fundamental Principles, 2022-2035
Figure 14.10 Subcutaneous Formulation Technologies Market: Distribution by End Users, 2022 and 2035
Figure 14.11 Subcutaneous Formulation Technologies Market for Biopharmaceutical Companies, 2022-2035
Figure 14.12 Subcutaneous Formulation Technologies Market for Biotechnology Companies, 2022-2035
Figure 14.13 Subcutaneous Formulation Technologies Market for Contract Development and Manufacturing Organizations, 2022-2035
Figure 14.14 Subcutaneous Formulation Technologies Market for Educational Institutes, 2022-2035
Figure 14.15 Subcutaneous Formulation Technologies Market for Investors, 2022-2035
Figure 14.16 Subcutaneous Formulation Technologies Market for Pharmaceutical Companies, 2022-2035
Figure 14.17 Subcutaneous Formulation Technologies Market for Research Institutes, 2022-2035
Figure 14.18 Subcutaneous Formulation Technologies Market for Other End Users, 2022-2035
Figure 14.19 Subcutaneous Formulation Technologies Market: Distribution by Therapeutic Area, 2022 and 2035
Figure 14.20 Subcutaneous Formulation Technologies Market for Autoimmune Disorders, 2022-2035
Figure 14.21 Subcutaneous Formulation Technologies Market for Genetic Disorders, 2022-2035
Figure 14.22 Subcutaneous Formulation Technologies Market for Infectious Disorders, 2022-2035
Figure 14.23 Subcutaneous Formulation Technologies Market for Metabolic Disorders, 2022-2035
Figure 14.24 Subcutaneous Formulation Technologies Market for Oncological Disorders, 2022-2035
Figure 14.25 Subcutaneous Formulation Technologies Market for Ophthalmic Disorders, 2022-2035
Figure 14.26 Subcutaneous Formulation Technologies Market for Other Disorders, 2022-2035
Figure 14.27 Subcutaneous Formulation Technologies Market: Distribution by Geographical Regions, 2022 and 2035
Figure 14.28 Subcutaneous Formulation Technologies Market in North America, 2022-2035
Figure 14.29 Subcutaneous Formulation Technologies Market in Europe, 2022-2035
Figure 14.30 Subcutaneous Formulation Technologies Market in Asia, 2022-2035
Figure 15.1 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs, 2021-2035 (USD Million)
Figure 15.2 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Type of Device, 2021-2035 (USD Million)
Figure 15.3 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Usability, 2021-2035 (USD Million)
Figure 15.4 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Therapeutic Area, 2021-2035 (USD Million)
Figure 15.5 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America, 2021-2035 (USD Million)
Figure 15.6 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Type of Device, 2021-2035 (USD Million)
Figure 15.7 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Usability, 2021-2035 (USD Million)
Figure 15.8 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Therapeutic Area, 2021-2035 (USD Million)
Figure 15.9 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe, 2021- 2035 (USD Million)
Figure 15.10 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Type of Device, 2021-2035 (USD Million)
Figure 15.11 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Usability, 2021-2035 (USD Million)
Figure 15.12 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Therapeutic Area, 2021-2035 (USD Million)
Figure 15.13 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific, 2021-2035 (USD Million)
Figure 15.14 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Type of Device, 2021-2035 (USD Million)
Figure 15.15 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Usability, 2021-2035 (USD Million)
Figure 15.16 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Therapeutic Area, 2021-2035 (USD Million)
Figure 15.17 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America, 2021-2035 (USD Million)
Figure 15.18 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America: Distribution by Type of Device, 2021-2035 (USD Million)
Figure 15.19 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America: Distribution by Usability, 2021-2035 (USD Million)
Figure 15.20 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America: Distribution by Therapeutic Area, 2021-2035 (USD Million)
Figure 15.21 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa, 2021-2035 (USD Million)
Figure 15.22 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa: Distribution by Type of Device, 2021-2035 (USD Million)
Figure 15.23 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa: Distribution by Usability, 2021-2035 (USD Million)
Figure 15.24 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa: Distribution by Therapeutic Area, 2021-2035 (USD Million)
Figure 15.25 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs, 2021-2035 (Million Units)
Figure 15.26 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Type of Device, 2021-2035 (Million Units)
Figure 15.27 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Usability, 2021-2035 (Million Units)
Figure 15.28 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Therapeutic Area, 2021-2035 (Million Units)
Figure 15.29 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America, 2021-2035 (Million Units)
Figure 15.30 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Type of Device, 2021-2035 (Million Units)
Figure 15.31 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Usability, 2021-2035 (Million Units)
Figure 15.32 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Therapeutic Area, 2021-2035 (Million Units)
Figure 15.33 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe, 2021- 2035 (Million Units)
Figure 15.34 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Type of Device, 2021-2035 (Million Units)
Figure 15.35 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Usability, 2021-2035 (Million Units)
Figure 15.36 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Therapeutic Area, 2021-2035 (Million Units)
Figure 15.37 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific, 2021-2035 (Million Units)
Figure 15.38 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Type of Device, 2021-2035 (Million Units)
Figure 15.39 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Usability, 2021-2035 (Million Units)
Figure 15.40 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Therapeutic Area, 2021-2035 (Million Units)
Figure 15.41 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America, 2021-2035 (Million Units)
Figure 15.42 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America: Distribution by Type of Device, 2021-2035 (Million Units)
Figure 15.43 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America: Distribution by Usability, 2021-2035 (Million Units)
Figure 15.44 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America: Distribution by Therapeutic Area, 2021-2035 (Million Units)
Figure 15.45 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa, 2021-2035 (Million Units)
Figure 15.46 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa: Distribution by Type of Device, 2021-2035 (Million Units)
Figure 15.47 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa: Distribution by Usability, 2021-2035 (Million Units)
Figure 15.48 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa: Distribution by Therapeutic Area, 2021-2035 (Million Units)
Figure 15.49 Global Large Volume Wearable Injectors Market for Insulin, 2021-2035 (USD Billion)
Figure 15.50 Global Large Volume Wearable Injectors Market for Insulin: Distribution by Type of Device, 2021-2035 (USD Million)
Figure 15.51 Global Large Volume Wearable Injectors Market for Insulin: Distribution by Usability, 2021-2035 (USD Million)
Figure 15.52 Large Volume Wearable Injectors Market for Insulin in North America, 2021-2035 (USD Million)
Figure 15.53 Large Volume Wearable Injectors Market for Insulin in North America: Distribution by Type of Device, 2021-2035 (USD Million)
Figure 15.54 Large Volume Wearable Injectors Market for Insulin in North America: Distribution by Usability, 2021-2035 (USD Million)
Figure 15.55 Large Volume Wearable Injectors Market for Insulin in Europe, 2021-2035 (USD Million)
Figure 15.56 Large Volume Wearable Injectors Market for Insulin in Europe: Distribution by Type of Device, 2021-2035 (USD Million)
Figure 15.57 Large Volume Wearable Injectors Market for Insulin in Europe: Distribution by Usability, 2021-2035 (USD Million)
Figure 15.58 Large Volume Wearable Injectors Market for Insulin in Asia Pacific, 2021-2035 (USD Million)
Figure 15.59 Large Volume Wearable Injectors Market for Insulin in Asia Pacific: Distribution by Type of Device, 2021-2035 (USD Million)
Figure 15.60 Large Volume Wearable Injectors Market for Insulin in Asia Pacific: Distribution by Usability, 2021-2035 (USD Million)
Figure 15.61 Large Volume Wearable Injectors Market for Insulin in Latin America, 2021-2035 (USD Million)
Figure 15.62 Large Volume Wearable Injectors Market for Insulin in Latin America: Distribution by Type of Device, 2021-2035 (USD Million)
Figure 15.63 Large Volume Wearable Injectors Market for Insulin in Latin America: Distribution by Usability, 2021-2035 (USD Million)
Figure 15.64 Large Volume Wearable Injectors Market for Insulin in Middle East and North Africa, 2021-2035 (USD Million)
Figure 15.65 Large Volume Wearable Injectors Market for Insulin in Middle East and North Africa: Distribution by Type of Device, 2021-2035 (USD Million)
Figure 15.66 Large Volume Wearable Injectors Market for Insulin in Middle East and North Africa: Distribution by Usability, 2021-2035 (USD Million)
Figure 15.67 Global Autoinjectors Market, 2021-2035 (USD Billion)
Figure 15.68 Global Autoinjectors Market for Anaphylaxis, 2021-2035 (USD Billion)
Figure 15.69 Global Disposable Autoinjectors Market for Anaphylaxis, 2021-2035 (USD Billion)
Figure 15.70 Global Intramuscular Autoinjectors Market for Anaphylaxis, 2021-2035 (USD Billion)
Figure 15.71 Global Subcutaneous / Intramuscular Autoinjectors Market for Anaphylaxis, 2021-2035 (USD Billion)
Figure 15.72 Global Small Molecule-based Autoinjectors Market for Anaphylaxis, 2021-2035 (USD Billion)
Figure 15.73 Autoinjectors Market for Anaphylaxis in North America, 2021-2035 (USD Billion)
Figure 15.74 Autoinjectors Market for Anaphylaxis in Europe, 2021-2035 (USD Billion)
Figure 15.75 Autoinjectors Market for Anaphylaxis in Asia-Pacific, 2021-2035 (USD Billion)
Figure 15.76 Autoinjectors Market for Anaphylaxis in Rest of the World, 2021-2035 (USD Billion)
Figure 15.77 Global Autoinjectors Market for Multiple Sclerosis, 2021-2035 (USD Billion)
Figure 15.78 Global Disposable Autoinjectors Market for Multiple Sclerosis, 2021-2035 (USD Billion)
Figure 15.79 Global Reusable Autoinjectors Market for Multiple Sclerosis, 2021-2035 (USD Billion)
Figure 15.80 Global Intramuscular Autoinjectors Market for Multiple Sclerosis, 2021-2035 (USD Billion)
Figure 15.81 Global Subcutaneous Autoinjectors Market for Multiple Sclerosis, 2021-2035 (USD Billion)
Figure 15.82 Global Protein-based Autoinjectors Market for Multiple Sclerosis, 2021-2035 (USD Billion)
Figure 15.83 Global Peptide-based Autoinjectors Market for Multiple Sclerosis, 2021-2035 (USD Billion)
Figure 15.84 Global Antibody-based Autoinjectors Market for Multiple Sclerosis, 2021-2035 (USD Billion)
Figure 15.85 Autoinjectors Market for Multiple Sclerosis in North America, 2021-2035 (USD Billion)
Figure 15.86 Autoinjectors Market for Multiple Sclerosis in Europe, 2021-2035 (USD Billion)
Figure 15.87 Autoinjectors Market for Multiple Sclerosis in Asia-Pacific, 2021-2035 (USD Billion)
Figure 15.88 Autoinjectors Market for Multiple Sclerosis in Rest of the World, 2021-2035 (USD Billion)
Figure 15.89 Global Autoinjectors Market for Migraine, 2021-2035 (USD Billion)
Figure 15.90 Global Disposable Autoinjectors Market for Migraine, 2021-2035 (USD Billion)
Figure 15.91 Global Subcutaneous Autoinjectors Market for Migraine, 2021-2035 (USD Billion)
Figure 15.92 Global Antibody-based Autoinjectors Market for Migraine, 2021-2035 (USD Billion)
Figure 15.93 Global Small Molecule-based Autoinjectors Market for Migraine, 2021-2035 (USD Billion)
Figure 15.94 Autoinjectors Market for Migraine in North America, 2021-2035 (USD Billion)
Figure 15.95 Autoinjectors Market for Migraine in Europe, 2021-2035 (USD Billion)
Figure 15.96 Autoinjectors Market for Migraine in Asia-Pacific, 2021-2035 (USD Billion)
Figure 15.97 Autoinjectors Market for Migraine in Rest of the World, 2021-2035 (USD Billion)
Figure 15.98 Global Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, 2021-2035 (USD Billion)
Figure 15.99 Global Disposable Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, 2021-2035 (USD Billion)
Figure 15.100 Global Reusable Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, 2021-2035 (USD Billion)
Figure 15.101 Global Subcutaneous Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, 2021-2035 (USD Billion)
Figure 15.102 Global Subcutaneous / Intravenous Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, 2021-2035 (USD Billion)
Figure 15.103 Global Antibody-based Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, 2021-2035 (USD Billion)
Figure 15.104 Global Protein-based Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, 2021-2035 (USD Billion)
Figure 15.105 Global Small Molecule-based Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, 2021-2035 (USD Billion)
Figure 15.106 Autoinjectors Market for Rheumatoid and Psoriatic Arthritis in North America, 2021-2035 (USD Billion)
Figure 15.107 Autoinjectors Market for Rheumatoid and Psoriatic Arthritis in Europe, 2021-2035 (USD Billion)
Figure 15.108 Autoinjectors Market for Rheumatoid and Psoriatic Arthritis in Asia-Pacific, 2021-2035 (USD Billion)
Figure 15.109 Autoinjectors Market for Rheumatoid and Psoriatic Arthritis in Rest of the World, 2021-2035 (USD Billion)
Figure 15.110 Global Autoinjectors Market for Diabetes, 2021-2035 (USD Billion)
Figure 15.111 Global Disposable Autoinjectors Market for Diabetes, 2021-2035 (USD Billion)
Figure 15.112 Global Subcutaneous Autoinjectors Market for Diabetes, 2021-2035 (USD Billion)
Figure 15.113 Global Protein-based Autoinjectors Market for Diabetes, 2021-2035 (USD Billion)
Figure 15.114 Global Peptide-based Autoinjectors Market for Diabetes, 2021-2035 (USD Billion)
Figure 15.115 Autoinjectors Market for Diabetes in North America, 2021-2035 (USD Billion)
Figure 15.116 Autoinjectors Market for Diabetes in Europe, 2021-2035 (USD Billion)
Figure 15.117 Autoinjectors Market for Diabetes in Asia-Pacific, 2021-2035 (USD Billion)
Figure 15.118 Autoinjectors Market for Diabetes in Rest of the World, 2021-2035 (USD Billion)
Figure 15.119 Global Autoinjectors Market for Other Indications, 2021-2035 (USD Billion)
Figure 15.120 Global Disposable Autoinjectors Market for Other Indications, 2021-2035 (USD Billion)
Figure 15.121 Global Subcutaneous Autoinjectors Market for Other Indications, 2021-2035 (USD Billion)
Figure 15.122 Global Intramuscular Autoinjectors Market for Other Indications, 2021-2035 (USD Billion)
Figure 15.123 Global Subcutaneous / Intramuscular Autoinjectors Market for Other Indications, 2021-2035 (USD Billion)
Figure 15.124 Global Protein-based Autoinjectors Market for Other Indications, 2021-2035 (USD Billion)
Figure 15.125 Global Antibody-based Autoinjectors Market for Other Indications, 2021-2035 (USD Billion)
Figure 15.126 Global Small Molecule-based Autoinjectors Market for Other Indications, 2021-2035 (USD Billion)
Figure 15.127 Autoinjectors Market for Other Indications in North America, 2021-2035 (USD Billion)
Figure 15.128 Autoinjectors Market for Other Indications in Europe, 2021-2035 (USD Billion)
Figure 15.129 Autoinjectors Market for Other Indications in Asia-Pacific, 2021-2035 (USD Billion)
Figure 15.130 Autoinjectors Market for Other Indications in Rest of the World, 2021-2035 (USD Billion)
Figure 15.131 Global Autoinjectors Market, 2021-2035 (Million Units)
Figure 15.132 Global Autoinjectors Market for Anaphylaxis, 2021-2035 (Million Units)
Figure 15.133 Global Disposable Autoinjectors Market for Anaphylaxis, 2021-2035 (Million Units)
Figure 15.134 Global Intramuscular Autoinjectors Market for Anaphylaxis, 2021-2035 (Million Units)
Figure 15.135 Global Subcutaneous / Intramuscular Autoinjectors Market for Anaphylaxis, 2021-2035 (Million Units)
Figure 15.136 Global Small Molecule-based Autoinjectors Market for Anaphylaxis, 2021-2035 (Million Units)
Figure 15.137 Autoinjectors Market for Anaphylaxis in North America, 2021-2035 (Million Units)
Figure 15.138 Autoinjectors Market for Anaphylaxis in Europe, 2021-2035 (Million Units)
Figure 15.139 Autoinjectors Market for Anaphylaxis in Asia-Pacific, 2021-2035 (Million Units)
Figure 15.140 Autoinjectors Market for Anaphylaxis in Rest of the World, 2021-2035 (Million Units)
Figure 15.141 Global Autoinjectors Market for Multiple Sclerosis, 2021-2035 (Million Units)
Figure 15.142 Global Disposable Autoinjectors Market for Multiple Sclerosis, 2021-2035 (Million Units)
Figure 15.143 Global Reusable Autoinjectors Market for Multiple Sclerosis, 2021-2035 (Million Units)
Figure 15.144 Global Intramuscular Autoinjectors Market for Multiple Sclerosis, 2021-2035 (USD Billion)
Figure 15.145 Global Subcutaneous Autoinjectors Market for Multiple Sclerosis, 2021-2035 (Million Units)
Figure 15.146 Global Protein-based Autoinjectors Market for Multiple Sclerosis, 2021-2035 (Million Units)
Figure 15.147 Global Peptide-based Autoinjectors Market for Multiple Sclerosis, 2021-2035 (Million Units)
Figure 15.148 Global Antibody-based Autoinjectors Market for Multiple Sclerosis, 2021-2035 (Million Units)
Figure 15.149 Autoinjectors Market for Multiple Sclerosis in North America, 2021-2035 (Million Units)
Figure 15.150 Autoinjectors Market for Multiple Sclerosis in Europe, 2021-2035 (Million Units)
Figure 15.151 Autoinjectors Market for Multiple Sclerosis in Asia-Pacific, 2021-2035 (Million Units)
Figure 15.152 Autoinjectors Market for Multiple Sclerosis in Rest of the World, 2021-2035 (Million Units)
Figure 15.153 Global Autoinjectors Market for Migraine, 2021-2035 (Million Units)
Figure 15.154 Global Disposable Autoinjectors Market for Migraine, 2021-2035 (Million Units)
Figure 15.155 Global Subcutaneous Autoinjectors Market for Migraine, 2021-2035 (Million Units)
Figure 15.156 Global Antibody-based Autoinjectors Market for Migraine, 2021-2035 (Million Units)
Figure 15.157 Global Small Molecule-based Autoinjectors Market for Migraine, 2021-2035 (Million Units)
Figure 15.158 Autoinjectors Market for Migraine in North America, 2021-2035 (Million Units)
Figure 15.159 Autoinjectors Market for Migraine in Europe, 2021-2035 (Million Units)
Figure 15.160 Autoinjectors Market for Migraine in Asia-Pacific, 2021-2035 (Million Units)
Figure 15.161 Autoinjectors Market for Migraine in Rest of the World, 2021-2035 (Million Units)
Figure 15.162 Global Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, 2021-2035 (Million Units)
Figure 15.163 Global Disposable Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, 2021-2035 (Million Units)
Figure 15.164 Global Reusable Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, 2021-2035 (Million Units)
Figure 15.165 Global Subcutaneous Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, 2021-2035 (Million Units)
Figure 15.166 Global Subcutaneous / Intravenous Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, 2021-2035 (Million Units)
Figure 15.167 Global Antibody-based Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, 2021-2035 (Million Units)
Figure 15.168 Global Protein-based Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, 2021-2035 (Million Units)
Figure 15.169 Global Small Molecule-based Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, 2021-2035 (Million Units)
Figure 15.170 Autoinjectors Market for Rheumatoid and Psoriatic Arthritis in North America, 2021-2035 (Million Units)
Figure 15.171 Autoinjectors Market for Rheumatoid and Psoriatic Arthritis in Europe, 2021-2035 (Million Units)
Figure 15.172 Autoinjectors Market for Rheumatoid and Psoriatic Arthritis in Asia-Pacific, 2021-2035 (USD Billion)
Figure 15.173 Autoinjectors Market for Rheumatoid and Psoriatic Arthritis in Rest of the World, 2021-2035 (Million Units)
Figure 15.174 Global Autoinjectors Market for Diabetes, 2021-2035 (Million Units)
Figure 15.175 Global Disposable Autoinjectors Market for Diabetes, 2021-2035 (Million Units)
Figure 15.176 Global Subcutaneous Autoinjectors Market for Diabetes, 2021-2035 (Million Units)
Figure 15.177 Global Protein-based Autoinjectors Market for Diabetes, 2021-2035 (Million Units)
Figure 15.178 Global Peptide-based Autoinjectors Market for Diabetes, 2021-2035 (Million Units)
Figure 15.179 Autoinjectors Market for Diabetes in North America, 2021-2035 (Million Units)
Figure 15.180 Autoinjectors Market for Diabetes in Europe, 2021-2035 (Million Units)
Figure 15.181 Autoinjectors Market for Diabetes in Asia-Pacific, 2021-2035 (Million Units)
Figure 15.182 Autoinjectors Market for Diabetes in Rest of the World, 2021-2035 (Million Units)
Figure 15.183 Global Autoinjectors Market for Other Indications, 2021-2035 (Million Units)
Figure 15.184 Global Disposable Autoinjectors Market for Other Indications, 2021-2035 (USD Billion)
Figure 15.185 Global Subcutaneous Autoinjectors Market for Other Indications, 2021-2035 (Million Units)
Figure 15.186 Global Intramuscular Autoinjectors Market for Other Indications, 2021-2035 (Million Units)
Figure 15.187 Global Subcutaneous / Intramuscular Autoinjectors Market for Other Indications, 2021-2035 (Million Units)
Figure 15.188 Global Protein-based Autoinjectors Market for Other Indications, 2021-2035 (Million Units)
Figure 15.189 Global Antibody-based Autoinjectors Market for Other Indications, 2021-2035 (Million Units)
Figure 15.190 Global Small Molecule-based Autoinjectors Market for Other Indications, 2021-2035 (Million Units)
Figure 15.191 Autoinjectors Market for Other Indications in North America, 2021-2035 (Million Units)
Figure 15.192 Autoinjectors Market for Other Indications in Europe, 2021-2035 (Million Units)
Figure 15.193 Autoinjectors Market for Other Indications in Asia-Pacific, 2021-2035 (Million Units)
Figure 15.194 Autoinjectors Market for Other Indications in Rest of the World, 2021-2035 (Million Units)
Figure 15.195 Prefilled Syringes Price, 2020-2030: Conservative, Base and Optimistic Scenarios (USD per unit)
Figure 15.196 Global Prefilled Syringes Market, 2020-2030 (USD Million)
Figure 15.197 Global Prefilled Syringes Market, 2020-2030 (Million, Units)
Figure 15.198 Prefilled Syringes Market: Distribution by Type of Syringe Barrel Material, 2020, 2025 and 2030 (USD Million)
Figure 15.199 Prefilled Syringes Market: Distribution by Type of Chamber System, 2020, 2025 and 2030 (USD Million)
Figure 15.200 Prefilled Syringes Market: Distribution by Type of Pharmacological Molecule, 2020, 2025 and 2030 (USD Million)
Figure 15.201 Prefilled Syringes Market: Distribution by Target Therapeutic Area, 2020-2030
Figure 15.202 Global Needle-free Injection Systems Market, 2020-2030 (USD Million)
Figure 15.203 Global Needle-free Injection Systems Market: Distribution by Product Usability, 2020-2030, (USD Million)
Figure 15.204 Global Needle-free Injection Systems Market: Distribution by Actuation Mechanism, 2020-2030 (USD Million)
Figure 15.205 Global Needle-free Injection Systems Market: Distribution by Target Therapeutic Area, 2020-2030 (USD Million)
Figure 15.206 Global Novel Drug Reconstitution Systems Market, 2021-2030 (USD Billion)
Figure 15.207 Global Dual Chamber Prefilled Syringes Market, 2021-2030 (USD Billion)
Figure 15.208 Dual Chamber Prefilled Syringes Market, 2021 and 2030: Distribution by Physical State of Drug
Figure 15.209 Dual Chamber Prefilled Syringes Market for Liquid / Powder Drugs, 2021-2030 (USD Billion)
Figure 15.210 Dual Chamber Prefilled Syringes Market for Liquid / Liquid Drugs, 2021-2030 (USD Billion)
Figure 15.211 Dual Chamber Prefilled Syringes Market, 2021 and2030: Distribution by Type of Fabrication Material Used
Figure 15.212 Glass Dual Chamber Prefilled Syringes Market, 2021-2030 (USD Billion)
Figure 15.213 Plastic Dual Chamber Prefilled Syringes Market, 2021-2030 (USD Billion)
Figure 15.214 Dual Chamber Prefilled Syringes Market, 2021-2030: Distribution by Volume
Figure 15.215 Dual Chamber Prefilled Syringes Market for <1 mL Syringes, 2021-2030 (USD Billion)
Figure 15.216 Dual Chamber Prefilled Syringes Market for 1-2.5 mL Syringes, 2021-2030 (USD Billion)
Figure 15.217 Dual Chamber Prefilled Syringes Market for 2.5-5 mL Syringes, 2021-2030 (USD Billion)
Figure 15.218 Dual Chamber Prefilled Syringes Market for >5 mL Syringes, 2021-2030 (USD Billion)
Figure 15.219 Dual Chamber Prefilled Syringes Market, 2021 and 2030: Distribution by Geography
Figure 15.220 Dual Chamber Prefilled Syringes Market in North America, 2021-2030 (USD Billion)
Figure 15.221 Dual Chamber Prefilled Syringes Market in Europe, 2021-2030 (USD Billion)
Figure 15.222 Dual Chamber Prefilled Syringes Market in Asia-Pacific, 2021-2030 (USD Billion)
Figure 15.223 Dual Chamber Prefilled Syringes Market in Latin America, 2021-2030 (USD Billion)
Figure 15.224 Dual Chamber Prefilled Syringes Market in Middle East and Africa, 2021-2030 (USD Billion)
Figure 15.225 Global Dual Chamber Cartridges Market, 2021-2030 (USD Billion)
Figure 15.226 Dual Chamber Cartridges Market, 2021 and 2030: Distribution by Physical State of Drug
Figure 15.227 Dual Chamber Cartridges Market for Liquid / Powder Drugs, 2021-2030 (USD Billion)
Figure 15.228 Dual Chamber Cartridges Market for Liquid / Liquid Drugs, 2021-2030 (USD Billion)
Figure 15.229 Dual Chamber Cartridges Market, 2021 and 2030: Distribution by Type of Fabrication Material Used
Figure 15.230 Glass Dual Chamber Cartridges Market, 2021-2030 (USD Billion)
Figure 15.231 Plastic Dual Chamber Cartridges Market, 2021-2030 (USD Billion)
Figure 15.232 Dual Chamber Cartridges Market, 2021 and 2030: Distribution by Volume
Figure 15.233 Dual Chamber Cartridges Market for <1 mL Cartridges, 2021-2030 (USD Billion)
Figure 15.234 Dual Chamber Cartridges Market for 1-2.5 mL Cartridges, 2021-2030 (USD Billion)
Figure 15.235 Dual Chamber Cartridges Market for 2.5-5 mL Cartridges, 2021-2030 (USD Billion)
Figure 15.236 Dual Chamber Cartridges Market for >5 mL Cartridges, 2021-2030 (USD Billion)
Figure 15.237 Dual Chamber Cartridges Market, 2021-2030: Distribution by Geography
Figure 15.238 Dual Chamber Cartridges Market in North America, 2021-2030 (USD Billion)
Figure 15.239 Dual Chamber Cartridges Market in Europe, 2021-2030 (USD Billion)
Figure 15.240 Dual Chamber Cartridges Market in Asia-Pacific, 2021-2030 (USD Billion)
Figure 15.241 Dual Chamber Cartridges Market in Latin America, 2021-2030 (USD Billion)
Figure 15.242 Dual Chamber Cartridges Market in Middle East and Africa, 2021-2030 (USD Billion)
Figure 15.243 Global Dual / Multi Chamber Infusion Bags Market, 2021-2030 (USD Billion)
Figure 15.244 Dual / Multi Chamber Infusion Bags Market, 2021-2030: Distribution by Physical State of Drug
Figure 15.245 Dual / Multi Chamber Infusion Bags Market for Liquid Drugs, 2021-2030 (USD Billion)
Figure 15.246 Dual / Multi Chamber Infusion Bags Market for Frozen Drugs, 2021-2030 (USD Billion)
Figure 15.247 Dual / Multi Chamber Infusion Bags Market, 2021-2030: Distribution by Type of Plastic Bags
Figure 15.248 Dual / Multi Chamber Infusion Bags Market for Ethylene Vinyl Acetate Bags, 2021-2030 (USD Billion)
Figure 15.249 Dual / Multi Chamber Infusion Bags Market for Polypropylene Bags, 2021-2030 (USD Billion)
Figure 15.250 Dual / Multi Chamber Infusion Bags Market for Polyvinyl Chloride Bags, 2021-2030 (USD Billion)
Figure 15.251 Dual / Multi Chamber Infusion Bags Market for Other Plastic Materials Bags, 2021-2030 (USD Billion)
Figure 15.252 Dual / Multi Chamber Infusion Bags Market, 2021-2030: Distribution by Volume
Figure 15.253 Dual / Multi Chamber Infusion Bags Market for <250 mL Bags, 2021-2030 (USD Billion)
Figure 15.254 Dual / Multi Chamber Infusion Bags Market for 250-500 mL Bags, 2021- 2030 (USD Billion)
Figure 15.255 Dual / Multi Chamber Infusion Bags Market for 501-1,000 mL Bags, 2021-2030 (USD Billion)
Figure 15.256 Dual / Multi Chamber Infusion Bags Market for >1,000 mL Bags, 2021- 2030 (USD Billion)
Figure 15.257 Dual / Multi Chamber Infusion Bags Market, 2021-2030: Distribution by Geography
Figure 15.258 Dual / Multi Chamber Infusion Bags Market in North America, 2021-2030 (USD Billion)
Figure 15.259 Dual / Multi Chamber Infusion Bags Market in Europe, 2021-2030 (USD Billion)
Figure 15.260 Dual / Multi Chamber Infusion Bags Market in Asia-Pacific, 2021-2030 (USD Billion)
Figure 15.261 Dual / Multi Chamber Infusion Bags Market in Latin America, 2021-2030 (USD Billion)
Figure 15.266 Dual / Multi Chamber Infusion Bags Market in Middle East and Africa, 2021-2030 (USD Billion)
Figure 16.1 Subcutaneous Biologics SWOT Analysis: Overview
Figure 16.2 SWOT Analysis: Harvey Ball Analysis
Figure 16.3 Number of Biologics Approved by the USFDA, 2011-2020
Figure 17.1 Concluding Remarks: Approve Subcutaneous Biologics Market Landscape
Figure 17.2 Concluding Remarks: Clinical-Stage Subcutaneous Biologics Market Landscape
Figure 17.3 Concluding Remarks: Success Protocol Analysis
Figure 17.4 Concluding Remarks: Formulation Technology Market Landscape
Figure 17.5 Concluding Remarks: Company Competitiveness Analysis: Providers based in North America
Figure 17.6 Concluding Remarks: Partnerships and Collaborations
Figure 17.7 Concluding Remarks: Subcutaneous Drug Delivery Systems Market Landscape
Figure 17.8 Concluding Remarks: Product Competitiveness Analysis: Subcutaneous Drug Delivery Systems
Figure 17.9 Concluding Remarks: Product Competitiveness Analysis: Subcutaneous Drug Delivery Systems
Figure 17.10 Concluding Remarks: Approved Subcutaneous Biologics Market Forecast
Figure 17.11 Concluding Remarks: Approved Subcutaneous Biologics Market Forecast

List Of Tables

Table 3.1 Comparison of Characteristics of Small Molecules and Biologics
Table 3.2 Parenteral Routes of Administration
Table 3.3 Parenteral Drug Formulations: Associated Physical and Chemical Instabilities
Table 3.4 Parenteral Drug Formulations: Key Excipients
Table 4.1 List of Approved Subcutaneous Biologics
Table 4.2 Approved Subcutaneous Biologics: Information on Targeted Indication and Therapeutic Area
Table 4.3 Approved Subcutaneous Biologics: Information on Dosing Frequency, Dose Concentration and Therapeutic Area
Table 4.4 Approved Subcutaneous Biologics: Information on Available Formulation
Table 4.5 Subcutaneous Biologics: List of Companies
Table 5.1 List of Clinical Subcutaneous Biologics
Table 5.2 Clinical Subcutaneous Biologics: Information on Type of Therapy, Dosing Frequency, Therapeutic Area, Special Drug Designation(s) Awarded
Table 5.3 Clinical Subcutaneous Biologics: List of Companies
Table 6.1 BENLYSTA (Human Genome Sciences): Information on Target Disease Indication(s), Route of Administration, and Phase of Development
Table 6.2 BESREMi (PharmaEssentia): Information on Target Disease Indication(s), Route of Administration, and Phase of Development
Table 6.3 COSENTYX (Novartis)Trulicity® (Eli Lilly): Information on Target Disease Indication(s), Route of Administration, and Phase of Development
Table 6.4 DARZALEX FASPRO (Halozyme): Information on Target Disease Indication(s), Route of Administration, and Phase of Development
Table 6.5 DUPIXENT (Regeneron Pharmaceuticals): Information on Target Disease Indication(s), Route of Administration, and Phase of Development
Table 6.6 Enbrel (Amgen): Information on Target Disease Indication(s), Route of Administration, and Phase of Development
Table 6.7 HEMLIBRA (Roche): Information on Target Disease Indication(s), Route of Administration, and Phase of Development
Table 6.8 Prolia / Pralia (Amgen): Information on Target Disease Indication(s), Route of Administration, and Phase of Development
Table 6.9 STELARA (Janssen Biotech): Information on Target Disease Indication(s), Route of Administration, and Phase of Development
Table 6.10 Trulicity (Eli Lilly): Information on Target Disease Indication(s), Route of Administration, and Phase of Development
Table 7.1 Subcutaneous Formulation Technologies: List of Technology Developers
Table 7.2 Subcutaneous Formulation Technologies: Information on Fundamental Principle and Type of Molecule
Table 7.3 Subcutaneous Formulation Technologies: Information on Route of Administration
Table 7.4 Subcutaneous Formulation Technologies: Information on Therapeutics Area and Key Characteristics
Table 8.1 Company Competitiveness Analysis: Benchmarking of Technology Strength
Table 8.2 Company Competitiveness Analysis: Benchmarking of Partnership Activity
Table 8.3 Company Competitiveness Analysis: Players Based in North America
Table 8.4 Company Competitiveness Analysis: Players Based in Europe and Asia
Table 9.1 Subcutaneous Formulation Technologies Developers: List of Companies Profiled
Table 9.2 Adocia: Company Overview
Table 9.3 Adocia: Product Portfolio
Table 9.4 Adocia: Recent Developments and Future Outlook
Table 9.5 Ajinomoto: Company Overview
Table 9.6 Ajinomoto Biopharma: Recent Developments and Future Outlook
Table 9.7 Alteogen: Company Overview
Table 9.8 Alteogen: Product Portfolio
Table 9.9 Alteogen: Recent Developments and Future Outlook
Table 9.10 Arecor: Company Overview
Table 9.11 Arecor: Product Portfolio
Table 9.12 Arecor: Recent Developments and Future Outlook.
Table 9.13 Ascendis Pharma: Company Overview
Table 9.14 Ascendis Pharma: Product Portfolio
Table 9.15 Ascendis Pharma: Recent Developments and Future Outlook.
Table 9.16 Avadel Pharmaceutical: Company Overview
Table 9.17 Avadel Pharmaceuticals: Product Portfolio
Table 9.18 Avadel Pharmaceuticals: Recent Developments and Future Outlook.
Table 9.19 Camurus: Company Overview
Table 9.20 Camurus: Product Portfolio
Table 9.21 Camurus: Recent Developments and Future Outlook
Table 9.22 Creative Biolabs: Company Overview
Table 9.23 Creative Biomart: Company Overview
Table 9.24 DURECT: Company Overview
Table 9.25 DURECT: Product Portfolio
Table 9.26 DURECT: Recent Developments and Future Outlook
Table 9.27 Eagle Pharmaceutical: Company Overview
Table 9.28 Eagle Pharmaceutical: Recent Developments and Future Outlook
Table 9.29 Halozyme Therapeutics: Company Overview
Table 9.30 Halozyme Therapeutics: Product Portfolio
Table 9.31 Halozyme Therapeutics: Recent Developments and Future Outlook
Table 9.32 Medincell: Company Overview
Table 9.33 MedinCell: Product Portfolio
Table 9.34 MedinCell: Recent Developments and Future Outlook.
Table 9.35 Serina Therapeutics: Company Overview
Table 9.36 Serina Therapeutics: Product Portfolio
Table 9.37 Serina Therapeutics: Recent Developments and Future Outlook
Table 9.38 Xeris pharmaceutical: Company Overview
Table 9.39 Xeris Pharmaceuticals: Product Portfolio
Table 9.40 Xeris Pharmaceuticals: Recent Developments and Future Outlook
Table 10.1 Subcutaneous Formulation Technologies: List of Partnerships, Pre-2016-2021
Table 10.2 Subcutaneous Formulation Technologies: Information on Type of Agreement Region-wise and Geography-wise)
Table 11.1 Large Volume Wearable Injectors for Non-Insulin Drugs: Information on Development Status and Device Features
Table 11.2 Large Volume Wearable Injectors for Non-Insulin Drugs: Information on Administration Related Parameters
Table 11.3 Large Volume Wearable Injectors for Insulin Drugs: Information on Development Status and Device Features
Table 11.4 Large Volume Wearable Injectors for Insulin Drugs: Information on Device Monitoring and Connectivity Features
Table 11.5 Large Volume Drug Device Combinations: Information on Development Status and Device Features
Table 11.6 Large Volume Drug Device Combinations: Information on Drug Administration Related Parameters
Table 11.7 Autoinjectors: Development Pipeline
Table 11.8 Autoinjectors: List of Additional Parameters of Devices
Table 11.9 Pen Injectors: Development Landscape
Table 11.10 List of Smart Pen Injectors
Table 11.11 List of Drug and Pen Injector Combination Products
Table 11.12 Needle Free Injection Systems: Development Landscape
Table 11.13 Novel Drug Reconstitution Systems: Information on Type of Product, Number of Chambers, Physical State of Drug and Product Certifications
Table 11.14 Novel Drug Reconstitution Systems: Information on Container Fabrication Material, Volume, Drug Class, Device Usability and Provisions for Self-Administration
Table 11.15 Prefilled Syringes: List of Available / Under Development Devices
Table 11.16 Drugs Approved in Prefilled Syringes, 2013-2019
Table 11.17 Other Drugs Sold in Prefilled Syringes
Table 11.18 Implants: Development Landscape
Table 11.19 Implants: Information on Material Type, Treatment Duration and Type of Delivery System
Table 11.20 Implants: Subcutaneous Implants Eluting Small Molecules
Table 19.1 Approved Subcutaneous Biologics: Distribution by Approval Year
Table 19.2 Approved Subcutaneous Biologics: Distribution by Type of Molecule
Table 19.3 Approved Subcutaneous Biologics: Distribution by Approval Year and Type of Molecule
Table 19.4 Approved Subcutaneous Biologics: Distribution by Type of Therapy
Table 19.5 Approved Subcutaneous Biologics: Distribution by Route of Administration
Table 19.6 Approved Subcutaneous Biologics: Distribution by Method of Administration
Table 19.7 Approved Subcutaneous Biologics: Distribution by Route of Administration and Method of Administration
Table 19.8 Approved Subcutaneous Biologics: Distribution by Dosing Frequency
Table 19.9 Approved Subcutaneous Biologics: Distribution by Dose Concentration
Table 19.10 Approved Subcutaneous Biologics: Distribution by Therapeutic Area
Table 19.11 Approved Subcutaneous Biologics: Distribution by Approval Year and Therapeutic Area
Table 19.12 Approved Subcutaneous Biologics: Distribution by Type of Available Formulation
Table 19.13 Approved Subcutaneous Biologics: Distribution by Route of Administration and Type of Available Formulations
Table 19.14 Approved Subcutaneous Biologics Developers: Distribution by Year of Establishment
Table 19.15 Approved Subcutaneous Biologics Developers: Distribution by Company Size
Table 19.16 Approved Subcutaneous Biologics Developers: Distribution by Location of Headquarters
Table 19.17 Leading Developers: Distribution by Number of Approved Subcutaneous Biologics
Table 19.18 Clinical-Stage Subcutaneous Biologics: Distribution by Phase of Development
Table 19.19 Clinical-Stage Subcutaneous Biologics: Distribution by Mechanism of Action
Table 19.20 Clinical-Stage Subcutaneous Biologics: Distribution by Type of Molecule
Table 19.21 Clinical-Stage Subcutaneous Biologics: Distribution by Phase of Development and Type of Molecule
Table 19.22 Clinical-Stage Subcutaneous Biologics: Distribution by Type of Therapy
Table 19.23 Clinical-Stage Subcutaneous Biologics: Distribution by Type of Molecule and Type of Therapy
Table 19.24 Clinical-Stage Subcutaneous Biologics: Distribution by Dosing Frequency
Table 19.25 Clinical-Stage Subcutaneous Biologics: Distribution by Type of Molecule and Dosing Frequency
Table 19.26 Clinical-Stage Subcutaneous Biologics: Distribution by Target Disease Indication(s)
Table 19.27 Clinical-Stage Subcutaneous Biologics: Distribution by Therapeutics Area
Table 19.28 Clinical-Stage Subcutaneous Biologics: Distribution by Phase of Development and Therapeutics Area
Table 19.29 Clinical-Stage Subcutaneous Biologics: Distribution by Type of Molecule and Therapeutics Area
Table 19.30 Clinical-Stage Subcutaneous Biologics: Distribution by Special Drug Designation(s) Awarded
Table 19.31 Clinical-Stage Subcutaneous Biologics Developers: Distribution by Year of Establishment
Table 19.32 Clinical-Stage Subcutaneous Biologics Developers: Distribution by Company Size
Table 19.33 Clinical-Stage Subcutaneous Biologics Developers: Distribution by Location of Headquarters
Table 19.34 Leading Developers: Distribution by Number of Clinical-Stage Subcutaneous Biologics
Table 19.35 Subcutaneous Formulation Technology: Distribution by Fundamental Principle of Technology
Table 19.36 Subcutaneous Formulation Technology: Distribution by Type of Molecule
Table 19.37 Subcutaneous Formulation Technologies: Distribution by Route of Administration
Table 19.38 Subcutaneous Formulation Technologies: Distribution by Type of Molecule and Route of Administration
Table 19.39 Subcutaneous Formulation Technologies: Distribution by Therapeutic Area
Table 19.40 Subcutaneous Formulation Technologies: Distribution by Advantage(s) Offered
Table 19.41 Subcutaneous Formulation Technology Developers: Distribution by Year of Establishment
Table 19.42 Subcutaneous Formulation Technology Developers: Distribution by Company Size
Table 19.43 Subcutaneous Formulation Technology Developers: Distribution by Location of Headquarters (Region Wise)
Table 19.44 Subcutaneous Formulation Technology Developers: Distribution by Location of Headquarters (Country-Wise)
Table 19.45 Subcutaneous Formulation Technology Developers: Distribution by Company Size and Location of Headquarters (Region Wise)
Table 19.46 Subcutaneous Formulation Technologies: Distribution by Number of Advantages Offered
Table 19.47 Adocia: Annual Revenues, 2015 – H1 2021 (EUR Million)
Table 19.48 Ajinomoto: Annual Revenues, 2016 – H1 2021 (JPY Billion)
Table 19.49 Alteogen : Annual Revenues, 2018 – H1 2021 (USD Million)
Table 19.50 Arecor: Annual Revenues, 2016 – H1 2021 (USD Million)
Table 19.52 Ascendis Pharma: Annual Revenues, 2015-H1 2021 (USD Million)
Table 19.53 Avadel Pharmaceuticals: Annual Revenues, 2015 – 2020 (USD Million)
Table 19.54 Camurus: Annual Revenues, 2015- H1 2021 (SEK)
Table 19.55 DURECT: Annual Revenues, 2015-H1 2021 (USD Million)
Table 19.56 Eagle Pharmaceuticals: Annual Revenues, 2015–H1 202 (USD Million)
Table 19.57 Halozyme Therapeutics: Annual Revenues, 2015 – H1 2021 (USD Million)
Table 19.58 MedinCell: Annual Revenues, 2015 – Q3 2021 (Euro Million)
Table 19.59 Xeris Pharmaceuticals: Annual Revenues, 2016 – H1 2021 (USD Million)
Table 19.60 Partnerships and Collaborations: Cumulative Year-wise Trend, Pre-2016-2021
Table 19.61 Partnerships and Collaborations: Distribution by Type of Partnership
Table 19.62 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 19.63 Partnerships and Collaborations: Distribution by Type of Partnership and Company Size
Table 19.64 Partnerships and Collaborations: Distribution by Type of Partner
Table 19.65 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Table 19.66 Partnerships and Collaborations: Distribution by Type of Partner and Partnership
Table 19.67 Partnerships and Collaborations: Distribution Type of Partner and Company Size
Table 19.68 Partnerships and Collaborations: Distribution by Therapeutic Area
Table 19.69 Partnerships and Collaborations: Country-wise Distribution
Table 19.70 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements Distribution
Table 19.71 Most Active Players: Distribution by Number of Partnerships
Table 19.72 Large Volume Wearable Injectors: Overall Market Landscape
Table 19.73 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Phase of Development
Table 19.74 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Type of Device
Table 19.75 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Actuation Mechanism
Table 19.76 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Technology Used
Table 19.77 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Route of Administration
Table 19.78 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Method of Administration
Table 19.79 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Therapeutic Area
Table 19.80 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Type of Dose
Table 19.81 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Storage Volume / Capacity (in mL)
Table 19.82 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Usability
Table 19.83 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Availability of Prefilled Drug Reservoir
Table 19.84 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Availability of Connectivity
Table 19.85 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Availability of Drug Compatibility
Table 19.86 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Availability of Drug Container
Table 19.87 Most Active Players: Distribution by Number of Large Volume Wearable Injectors for Non-Insulin Drugs
Table 19.88 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Phase of Development
Table 19.89 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Type of Device
Table 19.90 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Type of Dose
Table 19.91 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Storage Volume / Capacity (in mL)
Table 19.92 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Usability
Table 19.93 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Combination Insulin
Table 19.94 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Non- Interoperable Device
Table 19.95 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Availability of Prefilled Drug Reservoir
Table 19.96 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Availability of Continuous Glucose Monitoring (CGM) / Blood Glucose Meters (BGM) System
Table 19.97 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Type of Automated Insulin Delivery (AID) Feature
Table 19.98 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Availability of Automatic Insulin Delivery (AID) / Artificial Pancreas
Table 19.99 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Availability of Connectivity
Table 19.100 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Availability of Device Control Features
Table 19.101 Most Active Players: Distribution by Number of Large Volume Wearable Injector for Insulin Drugs
Table 19.102 Large Volume Drug Device Combinations: Distribution by Phase of Development
Table 19.103 Large Volume Drug Device Combinations: Distribution by Type of Device
Table 19.104 Large Volume Drug Device Combinations: Distribution by Mechanism of Action
Table 19.105 Large Volume Drug Device Combinations: Distribution by Technology
Table 19.106 Large Volume Drug Device Combinations: Distribution by Route of Administration
Table 19.107 Large Volume Drug Device Combinations: Distribution by Method of Administration
Table 19.108 Large Volume Drug Device Combinations: Distribution by Therapeutic Area
Table 19.109 Large Volume Drug Device Combinations: Distribution by Type of Dose
Table 19.110 Large Volume Drug Device Combinations: Distribution by Storage Volume / Capacity (in mL)
Table 19.111 Large Volume Drug Device Combinations: Distribution by Usability
Table 19.112 Large Volume Drug Device Combinations: Distribution by Drug Compatibility
Table 19.113 Large Volume Drug Device Combinations: Distribution by Drug Container
Table 19.114 Most Active Players: Distribution by Number of Products Manufactured
Table 19.115 Autoinjectors: Distribution by Actuation Mechanism
Table 19.116 Autoinjectors: Distribution by Route of Administration
Table 19.117 Autoinjectors: Distribution by Type of Dose
Table 19.118 Autoinjectors: Distribution by Storage Volume / Capacity (in mL)
Table 19.119 Autoinjectors: Distribution by Usability
Table 19.120 Autoinjectors: Distribution by Type of Primary Container
Table 19.121 Autoinjectors: Distribution by Type of Feedback Mechanism
Table 19.122 Most Active players: Distribution by Number of Devices
Table 19.123 Pen Injectors: Distribution by Type of Dose
Table 19.124 Pen Injectors: Distribution by Storage Volume / Capacity (in ml)
Table 19.125 Pen Injectors: Distribution by Usability
Table 19.126 Most Active Players: Distribution by Number of Devices
Table 19.127 Needle Free Injection Systems: Distribution by Phase of Development
Table 19.128 Needle Free Injection Systems: Distribution by Actuation Mechanism
Table 19.129 Needle Free Injection Systems: Distribution by Therapeutic Area
Table 19.130 Needle Free Injection Systems: Distribution by Usability
Table 19.131 Most Active Players: Distribution by Number of Devices
Table 19.132 Novel Drug Reconstitution Systems: Distribution by Volume Storage / Capacity (in mL)
Table 19.133 Novel Drug Reconstitution Systems: Distribution by Usability
Table 19.134 Novel Drug Reconstitution Systems: Distribution by Type of Device
Table 19.135 Novel Drug Reconstitution Systems: Distribution by Type of Chamber
Table 19.136 Novel Drug Reconstitution Systems: Distribution by Type of Device and Chamber
Table 19.137 Novel Drug Reconstitution Systems: Distribution by Physical State of Drug
Table 19.138 Novel Drug Reconstitution Systems: Distribution by Container Fabrication Material
Table 19.139 Novel Drug Reconstitution Systems: Distribution by Container Fabrication Material and Usability
Table 19.140 Most Active Players: Distribution by Number of Devices
Table 19.141 Prefilled Syringes: Distribution by Storage Volume / Capacity (in ml)
Table 19.142 Prefilled Syringes: Distribution by Barrel Fabrication Material
Table 19.143 Prefilled Syringes: Distribution by Number of Barrel Chambers
Table 19.144 Prefilled Syringes: Distribution by Type of Needle System
Table 19.145 Most Active Players: Distribution by Number of Devices
Table 19.146 Implants: Distribution by Phase of Development
Table 19.147 Implants: Distribution by Therapeutic Area
Table 19.148 Implants: Distribution by Implant Material
Table 19.149 Implants: Distribution by Treatment Duration
Table 19.150 Implants: Distribution by Type of Delivery System
Table 19.151 Most Active Players: Distribution By number of Devices
Table 19.152 Global Approved Subcutaneous Biologics Market, Conservative, Base and Optimistic Scenario (USD Million), 2022-2035
Table 19.153 Approved Subcutaneous Biologics Market: Distribution by Type of Biologic, 2022 and 2035
Table 19.154 Approved Subcutaneous Biologics Market for Antibodies, Conservative, Base and Optimistic Scenario (USD Million), 2022-2035
Table 19.155 Approved Subcutaneous Biologics Market for Nucleotides, Conservative, Base and Optimistic Scenario (USD Million), 2022-2035
Table 19.156 Approved Subcutaneous Biologics Market for Proteins, Conservative, Base and Optimistic Scenario (USD Million), 2022-2035
Table 19.157 Approved Subcutaneous Biologics Market for Vaccines, Conservative, Base and Optimistic Scenario (USD Million), 2022-2035
Table 19.158 Approved Subcutaneous Biologics Market for Other Biologics, Conservative, Base and Optimistic Scenario (USD Million), 2022-2035
Table 19.159 Approved Subcutaneous Biologics Market: Distribution by Type of Therapy, 2022 and 2035
Table 19.160 Approved Subcutaneous Biologics Market for Monotherapies, Conservative, Base and Optimistic Scenario (USD Million), 2022-2035
Table 19.161 Approved Subcutaneous Biologics Market for Combination Therapies, Conservative, Base and Optimistic Scenario (USD Million), 2022-2035
Table 19.162 Approved Subcutaneous Biologics Market for Monotherapies and Combination Therapies, Conservative, Base and Optimistic Scenario (USD Million), 2022-2035
Table 19.163 Approved Subcutaneous Biologics Market: Distribution by Therapeutic Area, 2022 and 2035
Table 19.164 Approved Subcutaneous Biologics Market for Autoimmune Disorders, Conservative, Base and Optimistic Scenario (USD Million), 2022-2035
Table 19.165 Approved Subcutaneous Biologics Market for Blood Disorders, Conservative, Base and Optimistic Scenario (USD Million), 2022-2035
Table 19.166 Approved Subcutaneous Biologics Market for Bone Disorders, Conservative, Base and Optimistic Scenario (USD Million), 2022-2035
Table 19.167 Approved Subcutaneous Biologics Market for Cardiovascular Disorders, Conservative, Base and Optimistic Scenario (USD Million), 2022-2035
Table 19.168 Approved Subcutaneous Biologics Market for Genetic Disorders, Conservative, Base and Optimistic Scenario (USD Million), 2022-2035
Table 19.169 Approved Subcutaneous Biologics Market for Hormonal Disorders, Conservative, Base and Optimistic Scenario (USD Million),2022-2035
Table 19.170 Approved Subcutaneous Biologics Market for Infectious Disorders, Conservative, Base and Optimistic Scenario (USD Million), 2022-2035
Table 19.171 Approved Subcutaneous Biologics Market for Inflammatory Disorders, Conservative, Base and Optimistic Scenario (USD Million),2022-2035
Table 19.172 Approved Subcutaneous Biologics Market for Metabolic Disorders, Conservative, Base and Optimistic Scenario (USD Million),2022-2035
Table 19.173 Approved Subcutaneous Biologics Market for Neurological Disorders, Conservative, Base and Optimistic Scenario (USD Million), 2022-2035
Table 19.174 Approved Subcutaneous Biologics Market for Oncological Disorders, Conservative, Base and Optimistic Scenario (USD Million),2022-2035
Table 19.175 Approved Subcutaneous Biologics Market for Respiratory Disorders, Conservative, Base and Optimistic Scenario (USD Million),2022-2035
Table 19.176 Approved Subcutaneous Biologics Market for Women’s Health Disorders, Conservative, Base and Optimistic Scenario (USD Million),2022-2035
Table 19.177 Approved Subcutaneous Biologics Market for Other Disorders, Conservative, Base and Optimistic Scenario (USD Million),2022-2035
Table 19.178 Approved Subcutaneous Biologics Market: Distribution by Geographical Region, 2022 and 2035
Table 19.179 Approved Subcutaneous Biologics Market in North America, Conservative, Base and Optimistic Scenario (USD Million),2022-2035
Table 19.180 Approved Subcutaneous Biologics Market in Europe, Conservative, Base and Optimistic Scenario (USD Million),2022-2035
Table 19.181 Approved Subcutaneous Biologics Market in Asia, Conservative, Base and Optimistic Scenario (USD Million),2022-2035
Table 19.182 Approved Subcutaneous Biologics Market in Middle East and North Africa, Conservative, Base and Optimistic Scenario (USD Million),2022-2035
Table 19.183 Approved Subcutaneous Biologics Market in Latin America, Conservative, Base and Optimistic Scenario (USD Million),2022-2035
Table 19.184 Approved Subcutaneous Biologics Market in Rest of the World, Conservative, Base and Optimistic Scenario (USD Million),2022-2035
Table 19.185 AIMOVIG Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.186 AJOVY Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.187 Apidra (insulin glulisine), Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.188 Basaglar / Abrasia (EU) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.189 BENLYSTA (belimumab) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.190 BESREMi (ropeginterferon alfa-2b-njft) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.191 BIOTHRAX (Anthrax Vaccine Adsorbed) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.192 CABLIVI (Caplacizumab) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.193 Cegfila Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.194 CIMZIA (certolizumab pegol) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.195 COSENTYX (secukinumab) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.196 CRYSVITA (burosumab-twza) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.197 Cuvitru (immune globulin subcutaneous [human], 20% solution) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.198 DARZALEX FASPRO (daratumumab and hyaluronidase-fihj / DARZALEX SC Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.199 DENGVAXIA (Dengue Tetravalent Vaccine) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.200 DUPIXENT (dupilumab) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.201 EMGALITY (galcanezumab-gnlm) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.202 EMPAVELI (pegcetacoplan) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.203 Enbrel (etanercept) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.204 ENSPRYNG (satralizumab) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.205 EVENITY (romosozumab-aqqg) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.206 FASENRA (benralizumab) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.207 Fertavid (follitropin beta) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.208 FIASP (Insulin Aspart) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.209 Fulphila (pegfilgrastim-jmdb) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.210 Gamunex-C (Immune Globulin Injection [Human], 10% Caprylate /Chromatography Purified) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.211 GATTEX / Revestive (teduglutide [rDNA origin]) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.212 GIVLAARI (givosiran) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.213 HAEGARDA Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.214 HEMLIBRA (emicizumab-kxwh) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.215 Hepcludex (Bulevirtide) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.216 Hizentra (Immune Globulin Subcutaneous [Human] 20% Liquid) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.217 HYQVIA (Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.218 ILARIS (canakinumab) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.219 ILUMYA (tildrakizumab-asmn) / Ilumetri Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.220 Kalbitor (ecallantide) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.221 Kesimpta (ofatumumab) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.222 KEVZARA (sarilumab) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.223 KINERET (anakinra) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.224 Kyntheum / SILIQ / Lumicef (brodalumab) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.225 Leqvio (Inclisiran) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.226 Lonquex (lipegfilgrastim) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.227 Lyumjev (insulin lispro-aabc) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.228 Norditropin (somatropin) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.229 NPLATE (romiplostim) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.230 Nucala (mepolizumab) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.231 OXLUMO (lumasiran) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.232 PALYNZIQ (pegvaliase-pqpz) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.233 Pergoveris (follitropin alfa / lutropin alfa) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.234 Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.235 PRALUENT (alirocumab) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.236 Prolia / Pralia (denosumab) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.237 REBLOZYL (luspatercept-aamt) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.238 REKOVELLE (follitropin delta) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.239 Repatha (evolocumab) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.240 RYZODEG 70/30 (insulin degludec and insulin aspart) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.241 Skyrizi (risankizumab) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.242 SKYTROFA (lonapegsomatropin-tcgd) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.243 SOLIQUA 100/33 (insulin glargine & lixisenatide injection) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.244 STELARA (ustekinumab) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.245 Strensiq (asfotase alfa) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.246 TAKHZYRO (lanadelumab-flyo) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.247 Taltz (ixekizumab) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.248 TEGSEDI (inotersen) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.249 Toujeo (insulin glargine injection) U-300 Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.250 TREMFYA (guselkumab) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.251 TRESIBA (insulin degludec injection) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.252 Trulicity (dulaglutide) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.253 TYMLOS (abaloparatide) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.254 Tysabri (Natalizumab) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.255 Voxzogo (vosoritide) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.256 VYLEESI (bremelanotide injection) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.257 XEMBIFY (immune globulin subcutaneous, human – klhw) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.258 Xgeva / RANMARK (denosumab) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.259 XULTOPHY® / IDegLira (insulin degludec and liraglutide injection) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.260 XYOSTED (testosterone enanthate) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.261 ZEGALOGUE (dasiglucagon) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.262 Global Subcutaneous Formulation Technologies Market, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.263 Subcutaneous Formulation Technologies Market: Distribution by Type of Payment, 2022-2035 (USD Million)
Table 19.264 Subcutaneous Formulation Technologies Market for Milestone Payments, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.265 Subcutaneous Formulation Technologies Market for Upfront Payments, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.266 Subcutaneous Formulation Technologies Market: Distribution by Fundamental Principle, 2022-2035 (USD Million)
Table 19.267 Subcutaneous Formulation Technologies Market for Amino Acid Interaction Principles, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.268 Subcutaneous Formulation Technologies Market for Complex Formation Principles, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.269 Subcutaneous Formulation Technologies Market for Encapsulation Principles, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.270 Subcutaneous Formulation Technologies Market for Other Fundamental Principles, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.271 Subcutaneous Formulation Technologies Market: Distribution by End Users, 2022-2035 (USD Million)
Table 19.272 Subcutaneous Formulation Technologies Market for Biopharmaceutical Companies, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.273 Subcutaneous Formulation Technologies Market for Biotechnology Companies, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.274 Subcutaneous Formulation Technologies Market for Contract Development and Manufacturing Organizations, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.275 Subcutaneous Formulation Technologies Market for Educational Institutes, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.276 Subcutaneous Formulation Technologies Market for Investors, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.277 Subcutaneous Formulation Technologies Market for Pharmaceutical Companies, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.278 Subcutaneous Formulation Technologies Market for Research Institutes, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.279 Subcutaneous Formulation Technologies Market for Other End Users, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.280 Subcutaneous Formulation Technologies Market: Distribution by Therapeutic Area, 2022 and 2035
Table 19.281 Subcutaneous Formulation Technologies Market for Autoimmune Disorders, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.282 Subcutaneous Formulation Technologies Market for Genetic Disorders, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.283 Subcutaneous Formulation Technologies Market for Infectious Disorders, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.284 Subcutaneous Formulation Technologies Market for Metabolic Disorders, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.285 Subcutaneous Formulation Technologies Market for Oncological Disorders, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.286 Subcutaneous Formulation Technologies Market for Ophthalmic Disorders, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.287 Subcutaneous Formulation Technologies Market for Other Disorders, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.288 Subcutaneous Formulation Technologies Market: Distribution by Geographical Regions, 2022 and 2035
Table 19.289 Subcutaneous Formulation Technologies Market for North America, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.290 Subcutaneous Formulation Technologies Market for Europe, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.291 Subcutaneous Formulation Technologies Market for Asia, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.292 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
Table 19.293 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Type of Device, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
Table 19.294 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Usability, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
Table 19.295 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Therapeutic Area, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
Table 19.296 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
Table 19.297 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Type of Device, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
Table 19.298 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Usability, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
Table 19.299 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Therapeutic Area, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
Table 19.300 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
Table 19.301 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Type of Device, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
Table 19.302 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Usability, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
Table 19.303 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Therapeutic Area, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
Table 19.304 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
Table 19.305 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Type of Device, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
Table 19.306 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Usability, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
Table 19.307 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Therapeutic Area, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
Table 19.308 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
Table 19.309 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America: Distribution by Type of Device, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
Table 19.310 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America: Distribution by Usability, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
Table 19.311 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America: Distribution by Therapeutic Area, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
Table 19.312 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
Table 19.313 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa: Distribution by Type of Device, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
Table 19.314 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa: Distribution by Usability, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
Table 19.315 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa: Distribution by Therapeutic Area, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
Table 19.316 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.317 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Type of Device, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.318 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Usability, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.319 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Therapeutic Area, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.320 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.321 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Type of Device, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.322 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Usability, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.323 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Therapeutic Area, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.324 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.325 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Type of Device, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.326 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Usability, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.327 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Therapeutic Area, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.328 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.329 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Type of Device, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.330 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Usability, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.331 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Therapeutic Area, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.332 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.333 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America: Distribution by Type of Device, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.334 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America: Distribution by Usability, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.335 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America: Distribution by Therapeutic Area, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.336 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.337 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa: Distribution by Type of Device, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.338 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa: Distribution by Usability, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.339 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa: Distribution by Therapeutic Area, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.340 Global Large Volume Wearable Injectors Market for Insulin, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.341 Global Large Volume Wearable Injectors Market for Insulin: Distribution by Type of Device, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
Table 19.342 Global Large Volume Wearable Injectors Market for Insulin: Distribution by Usability, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
Table 19.343 Large Volume Wearable Injectors Market for Insulin in North America, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
Table 19.344 Large Volume Wearable Injectors Market for Insulin in North America: Distribution by Type of Device, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
Table 19.345 Large Volume Wearable Injectors Market for Insulin in North America: Distribution by Usability, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
Table 19.346 Large Volume Wearable Injectors Market for Insulin in Europe, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
Table 19.347 Large Volume Wearable Injectors Market for Insulin in Europe: Distribution by Type of Device, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
Table 19.348 Large Volume Wearable Injectors Market for Insulin in Europe: Distribution by Usability, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
Table 19.349 Large Volume Wearable Injectors Market for Insulin in Asia Pacific, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
Table 19.350 Large Volume Wearable Injectors Market for Insulin in Asia Pacific: Distribution by Type of Device, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
Table 19.351 Large Volume Wearable Injectors Market for Insulin in Asia Pacific: Distribution by Usability, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
Table 19.352 Large Volume Wearable Injectors Market for Insulin in Latin America, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
Table 19.353 Large Volume Wearable Injectors Market for Insulin in Latin America: Distribution by Type of Device, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
Table 19.354 Large Volume Wearable Injectors Market for Insulin in Latin America: Distribution by Usability, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
Table 19.355 Large Volume Wearable Injectors Market for Insulin in Middle East and North Africa, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
Table 19.356 Large Volume Wearable Injectors Market for Insulin in Middle East and North Africa: Distribution by Type of Device, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
Table 19.357 Large Volume Wearable Injectors Market for Insulin in Middle East and North Africa: Distribution by Usability, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
Table 19.358 Global Autoinjectors Market, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.359 Global Autoinjectors Market for Anaphylaxis, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.360 Global Disposable Autoinjectors Market for Anaphylaxis, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.361 Global Intramuscular Autoinjectors Market for Anaphylaxis, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.362 Global Subcutaneous / Intramuscular Autoinjectors Market for Anaphylaxis, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.363 Global Small Molecule-based Autoinjectors Market for Anaphylaxis, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.364 Autoinjectors Market for Anaphylaxis in North America, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.365 Autoinjectors Market for Anaphylaxis in Europe, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.366 Autoinjectors Market for Anaphylaxis in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.367 Autoinjectors Market for Anaphylaxis in Rest of the World, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.368 Global Autoinjectors Market for Multiple Sclerosis, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.369 Global Disposable Autoinjectors Market for Multiple Sclerosis, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.370 Global Reusable Autoinjectors Market for Multiple Sclerosis, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.371 Global Intramuscular Autoinjectors Market for Multiple Sclerosis, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.372 Global Subcutaneous Autoinjectors Market for Multiple Sclerosis, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.373 Global Protein-based Autoinjectors Market for Multiple Sclerosis, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.374 Global Peptide-based Autoinjectors Market for Multiple Sclerosis, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.375 Global Antibody-based Autoinjectors Market for Multiple Sclerosis, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.376 Autoinjectors Market for Multiple Sclerosis in North America, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.377 Autoinjectors Market for Multiple Sclerosis in Europe, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.378 Autoinjectors Market for Multiple Sclerosis in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.379 Autoinjectors Market for Multiple Sclerosis in Rest of the World, 2021-2035 (USD Billion)
Table 19.380 Global Autoinjectors Market for Migraine, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.381 Global Disposable Autoinjectors Market for Migraine, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.382 Global Subcutaneous Autoinjectors Market for Migraine, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.383 Global Antibody-based Autoinjectors Market for Migraine, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.384 Global Small Molecule-based Autoinjectors Market for Migraine, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.385 Autoinjectors Market for Migraine in North America, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.386 Autoinjectors Market for Migraine in Europe, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.387 Autoinjectors Market for Migraine in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.388 Autoinjectors Market for Migraine in Rest of the World, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.389 Global Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.390 Global Disposable Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.391 Global Reusable Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.392 Global Subcutaneous Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.393 Global Subcutaneous / Intravenous Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.394 Global Antibody-based Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.395 Global Protein-based Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.396 Global Small Molecule-based Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.397 Autoinjectors Market for Rheumatoid and Psoriatic Arthritis in North America, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.398 Autoinjectors Market for Rheumatoid and Psoriatic Arthritis in Europe, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.399 Autoinjectors Market for Rheumatoid and Psoriatic Arthritis in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.400 Autoinjectors Market for Rheumatoid and Psoriatic Arthritis in Rest of the World, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.401 Global Autoinjectors Market for Diabetes, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.402 Global Disposable Autoinjectors Market for Diabetes, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.403 Global Subcutaneous Autoinjectors Market for Diabetes, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.404 Global Protein-based Autoinjectors Market for Diabetes, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.405 Global Peptide-based Autoinjectors Market for Diabetes, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.406 Autoinjectors Market for Diabetes in North America, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.407 Autoinjectors Market for Diabetes in Europe, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.408 Autoinjectors Market for Diabetes in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.409 Autoinjectors Market for Diabetes in Rest of the World, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.410 Global Autoinjectors Market for Other Indications, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.411 Global Disposable Autoinjectors Market for Other Indications, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.412 Global Subcutaneous Autoinjectors Market for Other Indications, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.413 Global Intramuscular Autoinjectors Market for Other Indications, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.414 Global Subcutaneous / Intramuscular Autoinjectors Market for Other Indications, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.415 Global Protein-based Autoinjectors Market for Other Indications, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.416 Global Antibody-based Autoinjectors Market for Other Indications, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.417 Global Small Molecule-based Autoinjectors Market for Other Indications, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.418 Autoinjectors Market for Other Indications in North America, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.419 Autoinjectors Market for Other Indications in Europe, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.420 Autoinjectors Market for Other Indications in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.421 Autoinjectors Market for Other Indications in Rest of the World, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.422 Global Autoinjectors Market, 2021-2035 (Million Units)
Table 19.423 Global Autoinjectors Market for Anaphylaxis, 2021-2035 (Million Units)
Table 19.424 Global Disposable Autoinjectors Market for Anaphylaxis, 2021-2035 (Million Units)
Table 19.425 Global Intramuscular Autoinjectors Market for Anaphylaxis, 2021-2035 (Million Units)
Table 19.426 Global Subcutaneous / Intramuscular Autoinjectors Market for Anaphylaxis, 2021-2035 (Million Units)
Table 19.427 Global Small Molecule-based Autoinjectors Market for Anaphylaxis, 2021-2035 (Million Units)
Table 19.428 Autoinjectors Market for Anaphylaxis in North America, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.429 Autoinjectors Market for Anaphylaxis in Europe, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.430 Autoinjectors Market for Anaphylaxis in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.431 Autoinjectors Market for Anaphylaxis in Rest of the World, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.432 Global Autoinjectors Market for Multiple Sclerosis, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.433 Global Disposable Autoinjectors Market for Multiple Sclerosis, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.434 Global Reusable Autoinjectors Market for Multiple Sclerosis, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.435 Global Intramuscular Autoinjectors Market for Multiple Sclerosis, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.436 Global Subcutaneous Autoinjectors Market for Multiple Sclerosis, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.437 Global Protein-based Autoinjectors Market for Multiple Sclerosis, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.438 Global Peptide-based Autoinjectors Market for Multiple Sclerosis, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.439 Global Antibody-based Autoinjectors Market for Multiple Sclerosis, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.440 Autoinjectors Market for Multiple Sclerosis in North America, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.441 Autoinjectors Market for Multiple Sclerosis in Europe, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.442 Autoinjectors Market for Multiple Sclerosis in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.443 Autoinjectors Market for Multiple Sclerosis in Rest of the World, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.444 Global Autoinjectors Market for Migraine, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.445 Global Disposable Autoinjectors Market for Migraine, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.446 Global Subcutaneous Autoinjectors Market for Migraine, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.447 Global Antibody-based Autoinjectors Market for Migraine, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.448 Global Small Molecule-based Autoinjectors Market for Migraine, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.449 Autoinjectors Market for Migraine in North America, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.450 Autoinjectors Market for Migraine in Europe, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.451 Autoinjectors Market for Migraine in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.452 Autoinjectors Market for Migraine in Rest of the World, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.453 Global Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.454 Global Disposable Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.455 Global Reusable Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.456 Global Subcutaneous Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.457 Global Subcutaneous / Intravenous Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.458 Global Antibody-based Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.459 Global Protein-based Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.460 Global Small Molecule-based Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.461 Autoinjectors Market for Rheumatoid and Psoriatic Arthritis in North America, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.462 Autoinjectors Market for Rheumatoid and Psoriatic Arthritis in Europe, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.463 Autoinjectors Market for Rheumatoid and Psoriatic Arthritis in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.464 Autoinjectors Market for Rheumatoid and Psoriatic Arthritis in Rest of the World, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.465 Global Autoinjectors Market for Diabetes, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.466 Global Disposable Autoinjectors Market for Diabetes, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.467 Global Subcutaneous Autoinjectors Market for Diabetes, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.468 Global Protein-based Autoinjectors Market for Diabetes, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.469 Global Peptide-based Autoinjectors Market for Diabetes, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.470 Autoinjectors Market for Diabetes in North America, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.471 Autoinjectors Market for Diabetes in Europe, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.472 Autoinjectors Market for Diabetes in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.473 Autoinjectors Market for Diabetes in Rest of the World, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.474 Global Autoinjectors Market for Other Indications, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.475 Global Disposable Autoinjectors Market for Other Indications, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.476 Global Subcutaneous Autoinjectors Market for Other Indications, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.477 Global Intramuscular Autoinjectors Market for Other Indications, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.478 Global Subcutaneous / Intramuscular Autoinjectors Market for Other Indications, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.479 Global Protein-based Autoinjectors Market for Other Indications, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.480 Global Antibody-based Autoinjectors Market for Other Indications, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.481 Global Small Molecule-based Autoinjectors Market for Other Indications, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.482 Autoinjectors Market for Other Indications in North America, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.483 Autoinjectors Market for Other Indications in Europe, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.484 Autoinjectors Market for Other Indications in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.485 Autoinjectors Market for Other Indications in Rest of the World, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.486 Prefilled Syringes Price, 2020-2030: Conservative, Base and Optimistic Scenarios (USD per unit)
Table 19.487 Global Prefilled Syringes Market, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 19.488 Global Prefilled Syringes Market, Conservative, Base and Optimistic Scenario, 2020-2030 (Million, Units)
Table 19.489 Prefilled Syringes Market: Distribution by Type of Syringe Barrel Material, 2020, 2025 and 2030 (USD Million)
Table 19.490 Prefilled Syringes Market: Distribution by Type of Chamber System, 2020, 2025 and 2030 (USD Million)
Table 19.491 Prefilled Syringes Market: Distribution by Type of Pharmacological Molecule, 2020, 2025 and 2030 (USD Million)
Table 19.492 Prefilled Syringes Market: Distribution by Target Therapeutic Area, Conservative, Base and Optimistic Scenario, 2020-2030
Table 19.493 Global Needle-free Injection Systems Market, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 19.494 Global Needle-free Injection Systems Market: Distribution by Actuation Mechanism, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 19.495 Global Needle-free Injection Systems Market: Distribution by Target Therapeutic Area, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 19.496 Global Novel Drug Reconstitution Systems Market, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
Table 19.497 Global Dual Chamber Prefilled Syringes Market, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
Table 19.498 Dual Chamber Prefilled Syringes Market, 2021 and 2030: Distribution by Physical State of Drug
Table 19.499 Dual Chamber Prefilled Syringes Market for Liquid / Powder Drugs, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
Table 19.500 Dual Chamber Prefilled Syringes Market for Liquid / Liquid Drugs, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
Table 19.501 Dual Chamber Prefilled Syringes Market, 2021 and2030: Distribution by Type of Fabrication Material Used
Table 19.502 Glass Dual Chamber Prefilled Syringes Market, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
Table 19.503 Plastic Dual Chamber Prefilled Syringes Market, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
Table 19.504 Dual Chamber Prefilled Syringes Market, 2021-2030: Distribution by Volume
Table 19.505 Dual Chamber Prefilled Syringes Market for <1 mL Syringes, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
Table 19.506 Dual Chamber Prefilled Syringes Market for 1-2.5 mL Syringes, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
Table 19.507 Dual Chamber Prefilled Syringes Market for 2.5-5 mL Syringes, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
Table 19.508 Dual Chamber Prefilled Syringes Market for >5 mL Syringes, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
Table 19.509 Dual Chamber Prefilled Syringes Market, 2021 and 2030: Distribution by Geography
Table 19.510 Dual Chamber Prefilled Syringes Market in North America, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
Table 19.511 Dual Chamber Prefilled Syringes Market in Europe, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
Table 19.512 Dual Chamber Prefilled Syringes Market in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
Table 19.513 Dual Chamber Prefilled Syringes Market in Latin America, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
Table 19.514 Dual Chamber Prefilled Syringes Market in Middle East and Africa, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
Table 19.515 Global Dual Chamber Cartridges Market, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
Table 19.516 Dual Chamber Cartridges Market, 2021 and 2030: Distribution by Physical State of Drug
Table 19.517 Dual Chamber Cartridges Market for Liquid / Powder Drugs, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
Table 19.518 Dual Chamber Cartridges Market for Liquid / Liquid Drugs, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
Table 19.519 Dual Chamber Cartridges Market, 2021 and 2030: Distribution by Type of Fabrication Material Used
Table 19.520 Glass Dual Chamber Cartridges Market, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
Table 19.521 Plastic Dual Chamber Cartridges Market, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
Table 19.522 Dual Chamber Cartridges Market, 2021 and 2030: Distribution by Volume
Table 19.523 Dual Chamber Cartridges Market for <1 mL Cartridges, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
Table 19.524 Dual Chamber Cartridges Market for 1-2.5 mL Cartridges, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
Table 19.525 Dual Chamber Cartridges Market for 2.5-5 mL Cartridges, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
Table 19.526 Dual Chamber Cartridges Market for >5 mL Cartridges, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
Table 19.527 Dual Chamber Cartridges Market, 2021-2030: Distribution by Geography
Table 19.528 Dual Chamber Cartridges Market in North America, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
Table 19.529 Dual Chamber Cartridges Market in Europe, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
Table 19.530 Dual Chamber Cartridges Market in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
Table 19.531 Dual Chamber Cartridges Market in Latin America, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
Table 19.532 Dual Chamber Cartridges Market in Middle East and Africa, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
Table 19.533 Global Dual / Multi Chamber Infusion Bags Market, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
Table 19.534 Dual / Multi Chamber Infusion Bags Market, 2021-2030: Distribution by Physical State of Drug
Table 19.535 Dual / Multi Chamber Infusion Bags Market for Liquid Mixture, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
Table 19.536 Dual / Multi Chamber Infusion Bags Market for Frozen Mixture, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
Table 19.537 Dual / Multi Chamber Infusion Bags Market, 2021-2030: Distribution by Type of Plastic
Table 19.538 Dual / Multi Chamber Infusion Bags Market for Ethylene Vinyl Acetate Bags, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
Table 19.539 Dual / Multi Chamber Infusion Bags Market for Polypropylene Bags, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
Table 19.540 Dual / Multi Chamber Infusion Bags Market for Polyvinyl Chloride Bags, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
Table 19.541 Dual / Multi Chamber Infusion Bags Market for Other Plastic Materials Bags, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
Table 19.542 Dual / Multi Chamber Infusion Bags Market, 2021-2030: Distribution by Volume
Table 19.543 Dual / Multi Chamber Infusion Bags Market for <250 mL Infusion Bags, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
Table 19.544 Dual / Multi Chamber Infusion Bags Market for 250-500 mL Infusion Bags, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
Table 19.545 Dual / Multi Chamber Infusion Bags Market for 501-1,000 mL Infusion Bags, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
Table 19.546 Dual / Multi Chamber Infusion Bags Market for >1,000 mL Infusion Bags, Conservative, Base and Optimistic Scenario, 2021- 2030 (USD Billion)
Table 19.547 Dual / Multi Chamber Infusion Bags Market, 2021-2030: Distribution by Geography
Table 19.548 Dual / Multi Chamber Infusion Bags Market in North America, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
Table 19.549 Dual / Multi Chamber Infusion Bags Market in Europe, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
Table 19.550 Dual / Multi Chamber Infusion Bags Market in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
Table 19.551 Dual / Multi Chamber Infusion Bags Market in Latin America, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
Table 19.552 Dual / Multi Chamber Infusion Bags Market in Middle East and Africa, Conservative, Base and Optimistic Scenario, 2021-2030

List Of Companies

The following companies / institutes / government bodies and organizations have been mentioned in this report.

  1. 3D Medicines
  2. 89bio
  3. AB2 Bio
  4. Abbott Laboratories
  5. AbbVie
  6. Ablynx
  7. AC Immune
  8. Acceleron Pharma
  9. Accord Healthcare
  10. Acer Therapeutics
  11. ACG Management
  12. Activa Brand Products
  13. Adisave
  14. Adocia
  15. Affibody
  16. Affinivax
  17. Aguettant
  18. Aijex Pharma International
  19. Ajinomoto Bio-Pharma Services
  20. Akcea Therapeutics
  21. Akero Therapeutics
  22. Akeso
  23. Akeso Tiancheng
  24. AKRA DERMOJET
  25. AktiVax
  26. Alder BioPharmaceuticals
  27. Alexion
  28. Alexion Pharmaceuticals
  29. Alkermes
  30. Allakos
  31. Allergan
  32. Alnylam Pharmaceuticals
  33. Alopexx Oncology
  34. Alphamab
  35. Alteogen
  36. Altor BioScience
  37. ALTuCELL 
  38. Altus Pharmaceuticals
  39. Alvogen
  40. ALZA 
  41. AMAG Pharmaceuticals
  42. Amedra Pharmaceuticals 
  43. Amgen
  44. Amgen Astellas BioPharma
  45. AnaptysBio
  46. Andes Biotechnologies
  47. Androsystems
  48. Antares Pharma
  49. Anterogen
  50. Anthera Pharmaceuticals
  51. AOP Orphan Pharmaceuticals
  52. Apellis Pharmaceuticals
  53. Aphios
  54. Apobiologix 
  55. Apotex
  56. Araclon Biotech
  57. Arecor
  58. argenx
  59. ARMO BioSciences
  60. Arrowhead Pharmaceuticals
  61. Arsia Therapeutics
  62. ARTE 
  63. Arthritis Innovation Corporation (AIC)
  64. Asahi Kasei
  65. Ascendis Pharma
  66. ASIT Biotech
  67. ASLAN Pharmaceuticals
  68. Aspen Pharmacare
  69. Astellas Pharma
  70. AstraZeneca
  71. Athyrium Capital Management
  72. Atridia
  73. Avadel Pharmaceuticals
  74. Avant Medical Corporation
  75. Avid Bioservices
  76. Avillion
  77. Axxia Pharmaceuticals
  78. BASF 
  79. Bavarian Nordic
  80. Baxalta
  81. Bay City Capital
  82. Bayer
  83. Becton Dickinson
  84. Beijing Dongfang Biotech
  85. Beijing Northland Biotech
  86. Bespak
  87. Beta-Cell
  88. Beta-O2 Technologies 
  89. Bill & Melinda Gates Foundation
  90. Bill & Melinda Gates Foundation
  91. Bioam Gestion
  92. BioAtla
  93. BIOCAD
  94. Biocorp
  95. Biogen
  96. Bioject Medical Technologies
  97. BioMarin Pharmaceutical
  98. Biomay
  99. BioMimetix
  100. BioValve
  101. Bird Rock Bio
  102. BJ Bioscience
  103. Boehringer Ingelheim
  104. Boston Pharmaceuticals
  105. Braeburn Pharmaceuticals
  106. Bristol-Myers Squibb
  107. Britannia Pharmaceuticals
  108. Broadfin Capital
  109. Cadila Pharmaceuticals
  110. Calibr
  111. Cam Med
  112. Cambridge Antibody Technology
  113. Cambridge Consultants
  114. Camurus
  115. CAPRISA
  116. Carbion
  117. Catalyst Biosciences
  118. CDC Enterprises
  119. Celgene
  120. Celldex Therapeutics
  121. Cellnovo
  122. Centocor Ortho Biotech
  123. Central Texas Angel Network 
  124. CeQur
  125. Changchun BCHT Biotechnology
  126. Chondrial Therapeutics
  127. Chugai Pharmaceutical
  128. CinnaGen
  129. CiVi Biopharma
  130. Cleveland BioLabs
  131. Clinigen
  132. CM Biomaterials
  133. CM-CIC Innovation
  134. College Diabetes Network
  135. Companion Medical
  136. Complex Biosystems
  137. Copernicus
  138. Corbion
  139. Corvidia Therapeutics
  140. Creative Biolabs
  141. Creative BioMart
  142. Crescendo Pharmaceuticals
  143. Crossject
  144. CSL Behring
  145. CSPC Pharmaceutical 
  146. C-Tri
  147. Cumberland Pharmaceuticals
  148. CuraVac
  149. CytoDyn
  150. Cytori Therapeutics
  151. Daiichi Sankyo
  152. Daikyo Seiko
  153. DALI Medical Devices
  154. D'Antonio Consultants International
  155. Debiotech
  156. Deerfield Management
  157. Delpor
  158. DelSiTech
  159. Dermira
  160. Desentum
  161. DiaMedica Therapeutics
  162. Diamesco
  163. Diasome Pharmaceuticals
  164. Dicerna Pharmaceuticals
  165. Digital Medics
  166. Digna Biotech
  167. Dongbao
  168. Dr. Reddy's Laboratories
  169. DSM Venturing
  170. Duoject Medical Systems
  171. DURECT
  172. Dyax (acquired by Shire)
  173. Eagle Pharmaceuticals
  174. Eagle Pharmaceuticals
  175. Eddingpharm
  176. Eiger BioPharmaceuticals
  177. Eisai
  178. Elcam Medical
  179. Elektrofi
  180. Eli Lilly
  181. EMD Serono
  182. Emergent BioSolutions
  183. Emperra
  184. Enable Injections
  185. Endo Pharmaceuticals
  186. Enesi Pharma
  187. EOC Pharma
  188. Epilepsy Foundation
  189. Etubics 
  190. European Pharma Group
  191. Ever Supreme Bio Technology
  192. Evive Biotech
  193. Excelse Bio
  194. EyeTech
  195. Felton International
  196. Ferring Pharmaceuticals
  197. Finox Biotech
  198. Flamel Technologies
  199. Flowonix Medical
  200. FluGen
  201. Fresenius Kabi
  202. FUJIFILM Diosynth Biotechnologies
  203. Future Injection Technologies
  204. Fuze
  205. GALVmed
  206. GC Pharma
  207. GeneCure Biotechnologies
  208. Genentech
  209. Generon
  210. Genexine
  211. Genmab
  212. Genocea Biosciences
  213. Genor Biopharma
  214. GEROPHARM
  215. Gerresheimer
  216. Gilde Healthcare 
  217. Gilead Sciences
  218. GlaxoSmithKline
  219. Globe Medical Tech
  220. GlobeImmune
  221. Grifols
  222. Guangdong Xiangxue Precision Medical Technology
  223. HAL Allergy
  224. Halozyme Therapeutics
  225. Hanall Biopharma
  226. Hanmi Pharmaceutical
  227. Harbour BioMed
  228. Haselmeier
  229. Health Decisions
  230. Hengrui Therapeutics
  231. HengRui USA
  232. Hercules Capital
  233. Heron Therapeutics
  234. Hikma Pharmaceuticals
  235. Horizon Therapeutics
  236. Hospira
  237. Human Genome Sciences
  238. IDINVEST Partners
  239. ILTOO Pharma
  240. Il-Yang Pharmaceutical
  241. Immunex
  242. ImmunoForge
  243. Immunomedics
  244. ImmunoVaccine Technologies
  245. ImmuPharma
  246. ImmusanT
  247. Immutep
  248. Impax Laboratories
  249. Incepta Pharmaceuticals
  250. Indivior
  251. Inhibrx
  252. Injecto
  253. INJEX Pharma
  254. INmune Bio
  255. Inmunotek
  256. InnoCore Pharmaceuticals
  257. Innovare R&D
  258. Innovate UK
  259. Innovent Biologics
  260. Inolife Sciences
  261. Inovio Pharmaceuticals
  262. i-novion
  263. Insense
  264. Insulet 
  265. Insuline Medical
  266. Intarcia Therapeutics
  267. Intas Pharmaceuticals
  268. Integrity Bio
  269. Intrexon
  270. IO Biotech
  271. Ionis Pharmaceuticals
  272. Ipsen
  273. ISA Pharmaceuticals 
  274. ISU Abxis
  275. Izana Bioscience
  276. Janssen
  277. Janssen Biotech
  278. Janus Capital
  279. JCR Pharmaceuticals
  280. JDRF
  281. Jiangsu Delfu Medical Device
  282. Jiangsu Hengrui Medicine
  283. Jiangsu Wan Hai Medical Instruments
  284. JO Pharma 
  285. Johnson & Johnson
  286. Juvenile Diabetes Research Foundation
  287. Kaléo 
  288. Kangstem Biotech
  289. Kastle Therapeutics
  290. KBI Biopharma
  291. Kedrion Biopharma
  292. Kinevant Sciences
  293. King Pharmaceuticals
  294. Kingsbury Capital Partners
  295. Kiniksa Pharmaceuticals
  296. Kitasato Daiichi Sankyo Vaccine
  297. Knight Therapeutics
  298. Kolltan Pharmaceuticals
  299. Kymab
  300. Kyowa Hakko Kirin
  301. Kyowa Kirin 
  302. Laboratorios Liomont
  303. Lapeyronie Hospital
  304. Larimar Therapeutics
  305. Lenis Medical
  306. LEO Pharma
  307. Leukocare Biotechnology
  308. LIB Therapeutics
  309. Lindy Biosciences
  310. Lineage Therapeutics
  311. Lundbeck
  312. Lupin
  313. Luye Pharma
  314. Lynkogen
  315. Malvern Panalytical
  316. Manchester Institute of Biotechnology
  317. Maruho
  318. Maruishi Pharmaceutical
  319. Massachusetts Institute of Technology
  320. MaxiVAX
  321. McGill University
  322. McNair Group
  323. Medac Pharma
  324. Medical International Technology
  325. Medicalchain
  326. Medicines Patent Pool (MPP)
  327. Medicom Innovation Partner
  328. MedImmune
  329. MedinCell
  330. Medipacs
  331. Medison Pharma
  332. MedPro 
  333. Medtronic
  334. Medtrum
  335. Megapharm
  336. Merck
  337. Merck KGaA 
  338. Merck Serono
  339. Merieux Développement
  340. MGlas 
  341. MicroVAX
  342. Mika Medical
  343. MilliporeSigma
  344. Miracle Medical
  345. Mitsubishi Gas Chemical
  346. Mitsubishi Tanabe Pharma
  347. MJ Biopharm
  348. Momenta Pharmaceuticals
  349. Morphogenesis
  350. MorphoSys
  351. Mundipharma
  352. Mylan
  353. Nano Precision Medical
  354. NantCell
  355. National Cancer Institute
  356. National Institute of Allergy and Infectious Diseases
  357. National Institute of Diabetes and Digestive and Kidney Diseases 
  358. National Institute of Neurological Disorders and Stroke
  359. National Institutes of Health
  360. Nektar Therapeutics
  361. Nemera
  362. Neoleukin Therapeutics
  363. Neumedicines
  364. Neurimmune
  365. NeuroDerm
  366. NGM Biopharmaceuticals
  367. Ningbo Zhengli Pharmaceutical Packing
  368. Nippon Organon
  369. Nipro Medical 
  370. Nordic Group
  371. Novartis
  372. Novimmune
  373. Novo Nordisk
  374. NPS Pharmaceuticals
  375. Nuance Designs 
  376. Numab
  377. Nuova Ompi
  378. OBI Pharma
  379. OliPass
  380. OliX Pharmaceuticals
  381. Omeros 
  382. Ompi
  383. Oncolix
  384. Ono Pharmaceutical
  385. OPKO Health
  386. OrbiMed
  387. Orphan Technologies
  388. Orphan Technologies
  389. Otsuka Pharmaceutical
  390. Oval Medical Technologies
  391. Owen Mumford
  392. Oxford Finance 
  393. PA Consulting 
  394. Pacira BioSciences
  395. Palmetto Partners
  396. Par Pharmaceutical
  397. PaxVax
  398. Pendiq
  399. Penjet
  400. Pfizer
  401. PharmaJet
  402. Pharmakon Advisors
  403. PharmaSens
  404. Pharmstandard
  405. PhaseBio Pharmaceuticals
  406. PHC Injection Device Technologies
  407. Philogen
  408. Phoundry Pharmaceuticals
  409. Plas-Tech Engineering
  410. Polfa Tarchomin
  411. Population Council
  412. Portal Instruments
  413. Precision NanoSystems
  414. Primequal
  415. ProJect Pharmaceutics
  416. Prolynx
  417. Promius Pharma
  418. Protagonist Therapeutics
  419. ProteoThera
  420. Provenance Biopharmaceuticals
  421. Pulse NeedleFree Systems
  422. QS Medical Technology
  423. Qu Biologics
  424. RA Capital Management
  425. Ra Pharmaceuticals
  426. Radius Health
  427. Receptos
  428. Recon Therapeutics
  429. Redmile Group
  430. ReForm Biologics
  431. Regeneron Pharmaceuticals
  432. REMD Biotherapeutics
  433. RemeGen
  434. Rentschler Biotechnologie
  435. Revance Therapeutics
  436. Revolutions Medical
  437. Rhône-Poulenc Rorer
  438. Rhythm Pharmaceuticals
  439. RMS Medical Products
  440. Roche
  441. Rock Springs Capital
  442. Roselabs Bioscience
  443. ROXALL Medizin
  444. R-Pharm
  445. Sabby Management
  446. Safe Save Medical Cell Sciences & Technology
  447. Salix Pharmaceuticals
  448. Samsung Bioepis
  449. Sandoz
  450. Sanofi
  451. Sanofi Pasteur
  452. Santen Pharmaceutical 
  453. Schering-Plough 
  454. Schott
  455. Scripps Research Institute
  456. Sensile Medical
  457. Seqirus
  458. Serina Therapeutics
  459. Sernova
  460. Serum Institute of India
  461. Sewa Medicals
  462. Shandong Pharmaceutical Glass
  463. Shandong Weigao
  464. Shandong Zibo Minkang Pharmaceutical Packing
  465. Shanghai Dahua Pharmaceutical
  466. Shanghai JMT-Bio
  467. Shanghai Junshi Biosciences
  468. Shanghai Umitai Medical Technology 
  469. Shenzhen Geno-immune Medical Institute
  470. Shenzhen Salubris Pharmaceuticals
  471. Shin Yan Sheno Precision Industrial
  472. Shionogi
  473. Shire
  474. SHL Medical
  475. Shreya Life Sciences
  476. Silicon Valley Bank
  477. Sinocelltech
  478. SiO2 Medical Products
  479. SK Chemicals
  480. Société Générale Asset Management
  481. Sofinnova Partners
  482. Solteam Medical
  483. SOOIL Development
  484. Sosei Heptares
  485. SOTIO
  486. Spectrum Pharmaceuticals
  487. Square Pharmaceuticals
  488. STADA Arzneimittel
  489. Statera Biopharma
  490. SteadyMed Therapeutics
  491. Stemirna Therapeutics
  492. Strongbridge Biopharma
  493. Subcuject
  494. Sumitomo Dainippon Pharma
  495. Sun Pharmaceutical Industries
  496. Sun Yat-sen University
  497. Swedish Orphan Biovitrum
  498. Synermore Biologics
  499. Synthon Hispania
  500. Taisei Kako
  501. Taisho Pharmaceutical
  502. Takeda Pharmaceutical
  503. Talecris Biotherapeutics
  504. Tandem Diabetes Care
  505. Tasly Transgene Tianjin BioPharmaceutical
  506. Technical University of Munich
  507. Telegraph Hill Partners
  508. TerSera Therapeutics
  509. Terumo
  510. Tetris Pharma
  511. Teva Pharmaceuticals
  512. Texan Allergy & Sinus Center
  513. Texas Diabetes Institute
  514. Texas Emerging Technologies Fund
  515. The National Institute for Health and Care Excellence
  516. The National Medical Products
  517. The National Medical Products Administration
  518. The Wyss Institute at Harvard University
  519. TheraCyte
  520. Theralpha
  521. Tianjin SinoBiotech
  522. Titan Pharmaceuticals
  523. Tonghua Dongbao
  524. Torii Pharmaceutical
  525. Touche Medical
  526. TRACON Pharmaceuticals
  527. Transcoject
  528. Transgene
  529. Travere Therapeutics
  530. TREOS Bio
  531. TRIO Pharmaceuticals
  532. Tyfill Pharmapack
  533. TYME Technologies
  534. U.S. Medical Instruments
  535. UCB Pharma
  536. Ultragenyx Pharmaceutical
  537. Uman Pharma
  538. Uni-Bio Science Group
  539. Unilever
  540. Unilife 
  541. Union Medico
  542. United BioPharma
  543. United Therapeutics
  544. University of Colorado
  545. University of Texas Health Science Center
  546. US WorldMeds
  547. Vaccine Research Center (VRC)
  548. Valeant Pharmaceuticals 
  549. Valeritas
  550. VectivBio
  551. Venrock
  552. Ventana Medical Systems
  553. Vetter Pharma
  554. ViaCyte
  555. ViCentra
  556. Viela Bio
  557. ViiV Healthcare
  558. ViroMed
  559. ViroPharma
  560. Visus Therapeutics
  561. Vitaeris
  562. Vivo Capital
  563. Wanhai Medical
  564. West Pharmaceutical Services
  565. Wild Basin Investments
  566. XBiotech
  567. Xellia Pharmaceuticals
  568. XEME Biopharma
  569. Xencor
  570. Xeris Pharmaceuticals
  571. YangZhong Wealth Metal
  572. Youlyy Industrial
  573. Ypsomed
  574. Zensun
  575. Zogenix
  576. Zweite TechnoStart Ventures Fonds

PRICING DETAILS

USD 5,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com